---

Exhibit 99.1







ANGIOTECH PHARMACEUTICALS, INC.





ANNUAL INFORMATION FORM





FOR THE YEAR ENDED DECEMBER 31, 2007



DATED: MARCH 28, 2008





[exhibit991001.jpg]

1618 Station Street

Vancouver, BC, Canada.

V6A 1B6



---





TABLE OF CONTENTS





|                                                           |   
|---------------------------------------------------------- | --
|GLOSSARY OF TERMS                                          | 1 
|CORPORATE STRUCTURE                                        | 2 
|Incorporation                                              | 2 
|Intercorporate Relationships                               | 2 
|GENERAL DEVELOPMENT OF THE BUSINESS                        | 3 
|DESCRIPTION OF BUSINESS                                    | 10
|Overview                                                   | 10
|Business Strategy                                          | 11
|Angiotech History                                          | 12
|Technology Overview                                        | 13
|Products                                                   | 15
|Research and Product Development                           | 17
|Segmented Information                                      | 25
|Patents, Proprietary Rights and Licenses                   | 25
|Regulatory Environment                                     | 26
|Process Development, Manufacturing and Distribution        | 27
|Competitive Conditions                                     | 28
|Economic Dependence                                        | 28
|Employees                                                  | 28
|Facilities                                                 | 28
|Reimbursement                                              | 29
|Environmental Protection                                   | 30
|RISK FACTORS                                               | 31
|Risks Related to Our Business                              | 31
|DIVIDEND POLICY                                            | 49
|SELECTED CONSOLIDATED FINANCIAL INFORMATION                | 50
|CONSOLIDATED STATEMENTS OF INCOME                          | 50
|DIRECTORS AND EXECUTIVE OFFICERS                           | 54
|CORPORATE GOVERNANCE                                       | 56
|Audit Committee                                            | 57
|Governance and Nominating Committee                        | 59
|Compensation Committee                                     | 59
|DESCRIPTION OF CAPITAL STRUCTURE                           | 59
|Shares                                                     | 59
|INDEBTEDNESS                                               | 61
|RATINGS                                                    | 63
|MARKET FOR SECURITIES                                      | 64
|Trading Price and Volume                                   | 64
|Comparative Shareholder Return Performance Graph           | 67
|Quantitative and Qualitative Disclosures About Market Risk | 67
|LEGAL PROCEEDINGS                                          | 68
|MATERIAL CONTRACTS                                         | 70
|TRANSFER AGENT & REGISTRAR                                 | 71
|EXPERTS                                                    | 71
|FORWARD-LOOKING STATEMENTS                                 | 71
|ADDITIONAL INFORMATION                                     | 72
|Schedule A                                                 | i 



* * * * *









---





Unless otherwise indicated, the information presented in this Annual Information Form is presented as of December 31, 2007 and all currency amounts are stated in United States (U.S.) dollars.  As of March 26, 2008, the closing rate of exchange of the Bank of Canada was $1.00 U.S. dollar for each $1.0188Canadian. This Annual Information Form contains forward-looking statements which involve risks and uncertainties. See the section titled Forward-Looking Statements.



ANNUAL INFORMATION FORM

ANGIOTECH PHARMACEUTICALS, INC.

GLOSSARY OF TERMS



|                                       |                                                                                                                                                                                                                               
|-------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|angioplasty                            | The process of dilating a blood vessel, by various means, including insertion of a balloon-tipped catheter within the restricted region, then inflating the balloon (balloon angioplasty).                                    
|cardiovascular                         | A body system that includes the blood vessels that circulate blood to and from all parts of the body, the heart which keeps the blood in motion, and the lymphatic vessels, an ancillary set of vessels, that circulate lymph.
|catheter                               | A tube for insertion into a body cavity for introducing or removing a substance. A balloon-tipped catheter is a tube with a balloon at its tip that can be inflated or deflated.                                              
|device                                 | An item other than a drug that has application in medical therapy. Usually restricted to items used directly on or in the patient, not including diagnostic equipment or surgical instruments.                                
|ePTFE                                  | Expanded polytetrafluoroethylene is an inert material that does not break down in the body or interact with tissues.                                                                                                          
|hydrophilic/hydrophobic polymer matrix | A polymer combination that is capable of dissolving water-like and/or oil-like compounds within it.                                                                                                                           
|in vitro                               | An event that occurs outside a living organism, such as cell culture studies conducted in petri dishes.                                                                                                                       
|in vivo                                | An event that occurs within a living organism, such as testing the efficacy of a new drug in an animal.                                                                                                                       
|inflammation                           | The natural response of the body to irritation or injury, characterized by a cascade of immune events.                                                                                                                        
|perivascular                           | Relating to the outside of a blood vessel.                                                                                                                                                                                    
|pivotal study                          | A well-controlled study which meets the criteria of a health authority for approval/disapproval decisions. The study applies to drugs, medical devices and combination products.                                              
|polymer                                | A module which is composed of individual monomers or repeating units which are linked in a chain.                                                                                                                             
|restenosis                             | The re-narrowing of a blood vessel following angioplasty. The American Heart Association defines binary restenosis as 50% diameter closure or greater, of the treated (i.e., dilated) segment of the artery.                  
|stent                                  | A supportive cylindrical medical device, usually made of metal, inserted into a body duct or tube to open or prevent collapse of ducts or tubes.                                                                              



Page 1



---







CORPORATE STRUCTURE

Incorporation



Angiotech Pharmaceuticals, Inc. was incorporated in British Columbia in 1989 pursuant to the Company Act (British Columbia), the predecessor to the Business Corporations Act(British Columbia). Over the subsequent 19 years, we have amended our incorporating documents on several occasions to alter our share capital (for various financing and stock splits) and our corporate name.  In early 2004, the Business Corporations Act(British Columbia) was proclaimed and our shareholders adopted at the 2004 annual general meeting a new notice of articles and set of articles to reflect that significant legislative change.  The amendments made to previous incorporating documents were described in summary form in that annual general meeting information circular, none of which were material to our affairs.



Our head office and principal place of business is located at 1618 Station Street, Vancouver, BC, Canada, V6A 1B6. Our registered office is located at 1200 Waterfront Centre, 200 Burrard St., PO Box 48600, Vancouver, BC V7X 1T2.



Intercorporate Relationships



The table below sets out the Companys principal subsidiaries as at December 31, 2007, including the jurisdiction of incorporation and the percentage of voting securities currently held directly or indirectly by the Company.



|                                                             |                                |                                                               
|------------------------------------------------------------ | ------------------------------ | --------------------------------------------------------------
|Subsidiary                                                   | Incorporated under
the laws of | Percentage of voting
  securities held
  directlyor indirectly
|Angiotech Pharmaceuticals (US), Inc.                         | Washington                     | 100%                                                          
|Angiotech BioCoatings Corp.
(formerly STS Biopolymers, Inc.) | New York                       | 100%                                                          
|Angiotech America Inc.                                       | Illinois                       | 100%                                                          
|Angiotech Investment Partnership                             | British Columbia               | 100%                                                          
|0741693 B.C. Ltd.                                            | British Columbia               | 100%                                                          
|0761717 B.C. Ltd.                                            | British Columbia               | 100%                                                          
|3091796 Nova Scotia Company                                  | Nova Scotia                    | 100%                                                          
|3091797 Nova Scotia Company                                  | Nova Scotia                    | 100%                                                          
|3091798 Nova Scotia Company                                  | Nova Scotia                    | 100%                                                          
|3091799 Nova Scotia Company                                  | Nova Scotia                    | 100%                                                          
|3129537 Nova Scotia Company                                  | Nova Scotia                    | 100%                                                          
|3129538 Nova Scotia Company                                  | Nova Scotia                    | 100%                                                          
|3129539 Nova Scotia Company                                  | Nova Scotia                    | 100%                                                          
|3129540 Nova Scotia Company                                  | Nova Scotia                    | 100%                                                          
|3129541 Nova Scotia Company                                  | Nova Scotia                    | 100%                                                          
|3132933 Nova Scotia Company                                  | Nova Scotia                    | 100%                                                          
|3132934 Nova Scotia Company                                  | Nova Scotia                    | 100%                                                          
|3132935 Nova Scotia Company                                  | Nova Scotia                    | 100%                                                          
|3132936 Nova Scotia Company                                  | Nova Scotia                    | 100%                                                          
|Soldiers Field Liquidity Management LLC                      | Hungary                        | 100%                                                          
|Angiotech International AG                                   | Switzerland                    | 100%                                                          
|Angiodevice International GmbH                               | Switzerland                    | 100%                                                          
|Angiotech International Holdings, Corp.                      | Nova Scotia                    | 100%                                                          
|Angiotech Switzerland SA                                     | Switzerland                    | 100%                                                          
|Angiotech International Ventures AG                          | Switzerland                    | 100%                                                          
|Angiotech SARL                                               | France                         | 100%                                                          
|Angiotech UK Ltd                                             | England                        | 100%                                                          
|Angiotech Italy S.r.I.                                       | Italy                          | 100%                                                          



Page 2



---







|                                                                       |                 |     
|---------------------------------------------------------------------- | --------------- | ----
|Angiotech Denmark A/S                                                  | Denmark         | 100%
|Angiotech S.L.                                                         | Spain           | 100%
|Angiotech GmbH                                                         | Germany         | 100%
|Tercentenary Holdings, Corp.                                           | Nova Scotia     | 100%
|Afmedica, Inc.                                                         | Delaware        | 100%
|American Medical Instruments Holdings, Inc.                            | Delaware        | 100%
|Angiotech Delaware, Inc. (formerly American Medical Instruments, Inc.) | Delaware        | 100%
|Angiotech Capital, LLC                                                 | Nevada          | 100%
|B.G. Sulzle, Inc.                                                      | Delaware        | 100%
|Crimson Cardinal Capital, LLC                                          | Nevada          | 100%
|Manan Medical Products, Inc.                                           | Delaware        | 100%
|Medical Device Technologies, Inc.                                      | Delaware        | 100%
|NeuColl, Inc.                                                          | Delaware        | 100%
|Surgical Specialties Corporation                                       | Delaware        | 100%
|Quill Medical, Inc.                                                    | Delaware        | 100%
|Pearsalls Limited                                                      | England & Wales | 100%
|Pearsalls Development, Limited                                         | England & Wales | 100%
|PBN Medicals Denmark A/S                                               | Denmark         | 100%
|Bifos AB                                                               | Sweden          | 100%
|Angiotech Puerto Rico, Inc.                                            | Puerto Rico     | 100%
|Surgical Specialties Puerto Rico, Inc.                                 | Puerto Rico     | 100%
|Surgical Specialties UK Holdings Limited                               | England & Wales | 100%



In this Annual Information Form, references to the Company, Angiotech, us, or we are to Angiotech Pharmaceuticals, Inc. and all of its subsidiaries as a whole, except where it is clear that these terms only refer to Angiotech Pharmaceuticals, Inc.





GENERAL DEVELOPMENT OF THE BUSINESS



We are a specialty pharmaceutical and medical technology company that discovers, develops and markets technologies and products primarily to treat local diseases or to address complications associated with medical device implants, surgery or acute injury. Our business strategy is to develop and market proprietary, locally-delivered drug formulations or drug-device combination products, together with a portfolio of selected proprietary medical device products, that are designed to reduce surgical procedure side effects, improve surgical outcomes, shorten hospital stays, or are easier or safer for a physician to use. We target specialized medical markets that we believe can benefit from our technology and in which we can effectively market our products through our two specialized sales and marketing organizations, including selected general surgical markets and minimally invasive, or interventional, surgical markets. For the year ending December 31, 2007, our business generated revenue of $288 million.



Our research and development efforts focus on understanding and characterizing biological conditions that often occur concurrently with medical device implantation, surgery or acute injury. These conditions may include scar formation, inflammation, cell proliferation, infection or bleeding. Our product development approach involves screening known pharmaceutical agents for their usefulness in addressing these biological conditions. We then combine the pharmaceutical agents selected through our screening processes with our proprietary surgical drug delivery or medical device technologies to develop novel product candidates, including locally-delivered drug formulations or drug-eluting medical devices.



Our initial research and development efforts led to the development by Boston Scientific Corporation (BSC) of the TAXUS drug-eluting coronary stent system product line, which utilizes the drug paclitaxel and has been implanted in over 4 million patients to date. A stent is a small tube that is inserted permanently into a diseased section of a coronary artery or other blood vessel in the body. Some coronary stents, such as TAXUS, elute drugs after implantation and, as a result, have contributed to a significant reduction in the chance that arteries will become blocked again, based on data from several large human clinical studies. Due to the efficacy of drug-eluting stents, the market for stents has grown significantly. Prior to the launch in March 2004 of the TAXUS coronary stent, BSCs sales of bare metal coronary stents not incorporating our technology were $328 million for the year ended December 31, 2003. In the twelve-month period ended September 30, 2007, BSCs sales of TAXUS paclitaxel-eluting coronary stents were approximately $1.6 billion and in the year ended December 31, 2007, we recorded royalty revenue from BSC for those sales of $110.5 million. In the twelve-month period ended September 30, 2006, BSCs sales of TAXUS paclitaxel-eluting coronary stents were approximately $2.5 billion and in the year ended December 31, 2006, we recorded royalty revenue from BSC for those sales of $159.5 million.



Page 3



---







On March 23, 2006, we acquired 100% of the equity of privately-held American Medical Instruments Holdings, Inc. (AMI), a leading independent manufacturer of specialty, single-use medical devices primarily for the interventional radiology, biopsy, general surgery, aesthetic surgery and ophthalmology markets. We refer to our acquisition of AMI as the AMI acquisition. The AMI acquisition has significantly diversified our revenue base and provided us with commercial resources, including sales, marketing, and manufacturing. AMI has also provided us with a broad portfolio of medical device products to which we may apply our various proprietary technologies. Since the AMI acquisition, we generated a significant portion of our revenue from direct AMI product sales as a complement to our royalty revenue derived from sales of TAXUS coronary stents and other products. The AMI acquisition constituted a significant acquisition under National Instrument 51-102. In connection with the AMI acquisition we filed a business acquisition report on Form 51-102 F4.



The medical device product lines obtained through the AMI acquisition contain certain proprietary branded products that we believe offer technical advantages over competing products. Several of these medical device products may also provide opportunities to develop novel combination product candidates that utilize certain of our local drug delivery capabilities and technologies. We believe the potential technology advances represented by such combination product candidates may provide us the opportunity for increased market share, revenue and gross margins as compared to our traditional medical device product lines. We have patent protected, or have filed patent applications for, our technology and many of our products, product candidates and potential product candidates. Our portfolio of intellectual property developed, licensed or acquired to date includes over 250 issued U.S. patents and 230 pending U.S. patent applications and over 620 issued non-U.S. patents and 560 pending non-U.S. patent applications.



We operate in two segments: Pharmaceutical Technologies and Medical Products.





Pharmaceutical Technologies:



The Pharmaceutical Technologies segment develops, licenses and sells technologies that improve the performance of medical devices and the outcomes of surgical procedures. These technologies include various drug, drug delivery and surface modification materials and other medical biomaterials designed to be applied across a wide range of medical devices and technologies, surgical procedures and medical disciplines. This segment focuses primarily on establishing product development and marketing partnerships with major medical device, pharmaceutical or biomaterials companies and to date has derived the majority of its revenue from royalties due from partners that develop, market and sell products incorporating our technologies. Currently our principal revenues in this segment come from royalties derived from sales by BSC of TAXUS® coronary stent systems incorporating the drug paclitaxel.



Medical Products:



The Medical Products segment develops, manufactures and markets a wide range of single use, specialty medical devices, with products focused primarily on the interventional radiology, biopsy, general surgery, aesthetic surgery and ophthalmology markets. The Medical Products segment also manufactures finished medical devices and medical device components for third party medical device manufacturers and marketers. The Medical Products segment has specialized direct sales and distribution organizations in the U.S. and the European Union (E.U.), as well as significant manufacturing capabilities. This business segment derives the majority of its revenue from direct product sales to end users or various medical products distributors. Many of these products are made using our proprietary manufacturing processes, or are protected by intellectual property. The Medical Products segment may apply certain of its proprietary technologies to its products to create novel, next generation medical products to market directly to end users or medical products distributors.



Page 4



---







Acquisitions and Collaboration, License and Sales and Distribution Agreements



Acquisitions



Consistent with our strategy, we support our product development and commercialization activities with selective acquisitions of proprietary technologies and companies that complement our business. The following is a list of material acquisitions during the period from January 1, 2005 through December 31, 2007:



Quill Medical, Inc. (Quill)



On June 26, 2006, we completed the acquisition of 100% of the equity of Quill for approximately $40 million in cash plus potential future contingent payments of up to $160 million upon the achievement of certain revenue growth and development milestones. The potential additional payments are contingent on achievement of significant revenue growth of Quill products over a five year period, subject to certain conditions.  The launch of the Quill® Self-Retaining System (SRS) as described below triggered a development milestone payment of $10.0 million which was paid in cash in August of 2007, and is creditable against other future contingent payments. Through this acquisition, we now own the rights, in all fields of use, to develop and market applications of the Quill proprietary self-anchoring suture technology, including in a variety of general and specialty surgical and aesthetic surgery applications.



Unlike conventional sutures which are smooth, the Quill products have tiny teeth-like barbs along the surface. This self-anchoring suture technology may be used to close certain wounds or surgical incisions without the need for suture knots. Eliminating knot-tying can save surgical time, may reduce the risk of infection, and may reduce wound leakage. We are currently working to develop a broad portfolio of products using the Quill technology.  In January 2007, we launched the first of these new products, the Quill SRS for various wound closure and tissue approximation applications in general and aesthetic surgery. In the third and fourth quarters of 2007, we launched several new Quill SRS product lines.



The Quill acquisition was accounted for using the purchase method of accounting. The assets, liabilities, revenues and expenses of Quill were included in our consolidated financial statements from June 26, 2006, the date of acquisition. Total initial consideration of $40.3 million, including direct acquisition costs, was allocated to the assets acquired and liabilities assumed based on fair values at the date of acquisition, resulting in identifiable intangible assets of $50.0 million and goodwill of $7.0 million as of December 31, 2006. The additional $10.0 million paid in August 2007 was recorded as additional goodwill resulting in total goodwill of $17.0 million related to the Quill acquisition as of December 31, 2007. Goodwill is the excess of the purchase price over the net assets and liabilities which includes the tax basis of the assumed assets and liabilities.



American Medical Instruments Holdings, Inc.



On March 23, 2006, we completed the acquisition of 100% of the equity of AMI for approximately $787.9 million in cash.  Concurrently, we completed an offering of $250 million in aggregate principal amount of 7.75% senior subordinated notes due in 2014 in a private placement transaction, and entered into a $425 million senior secured credit facility consisting of a $350 million term facility maturing in 2013 and a $75 million revolving credit facility. The net proceeds from the sale of the $250 million 7.75% senior subordinated notes and the $350 million term loan, as well as cash on hand, were used to finance the AMI acquisition. We did not draw on the $75 million revolving credit facility.





Page 5



---





On December 11, 2006, the Company issued senior floating rate notes due in 2013 in the aggregate principal amount of $325 million, and repaid the outstanding principal amount of the term facility of $319.9 million with the net proceeds from the senior floating rate notes offering plus cash on hand and terminated the revolving credit facility.



The AMI acquisition was accounted for using the purchase method of accounting. The assets, liabilities, revenues and expenses of AMI were included in our consolidated financial statements from March 23, 2006, the date of acquisition.  Total consideration of $796.1 million, including acquisition costs, was allocated to the assets acquired and liabilities assumed based on fair values at the date of acquisition resulting in identifiable intangible assets of $191.6 million and goodwill of $586.2 million at the end of December 31, 2006.



In September 2006, we determined that certain operations acquired through the AMI acquisition were not aligned with our current business strategy. These operations were categorized as discontinued and include the following subsidiaries: American Medical Instruments, Inc., located in Dartmouth, Massachusetts; Point Technologies, Inc., located in Boulder, Colorado; and its subsidiary, Point Technologies S.A., located in Costa Rica. We reviewed the carrying value of the discontinued operations at the end of 2006 and the end of the first and second quarters of 2007. We recorded an impairment charge of $7.7 million at December 31, 2006 and a further impairment charge of $8.9 million at March 31, 2007. The impairment charges were determined based on our best estimate of net proceeds on ultimate disposition and were allocated proportionately to the long-term assets from discontinued operations. On July 31, 2007, we completed the sale of 100% of the issued and outstanding shares of Point Technologies, Inc. and its subsidiary Point Technologies S.A. for proceeds of $2.6 million. On August 30, 2007, we sold all of the assets and liabilities of American Medical Instruments, Inc. for proceeds of $2.2 million. Prior to the disposal of these operations, the assets and liabilities of these operations were shown separately on the consolidated balance sheets as current assets and current liabilities from discontinued operations and the net losses for these operations were shown separately on the consolidated statements of operations.



In the fourth quarter of 2006, we began the process of replacing the divisional structure of AMI with a centralized operational structure that is integrated into the other functions of Angiotech. As part of these activities, certain employees were terminated, which resulted in approximately $1.9 million in severance and related costs.  During the year ended December 31, 2007, the Company recorded charges of $5.2 million for plant closure and relocation activities associated with further capacity rationalization and integration of the Medical Products segment. The restructuring charges during the year ended December 31, 2007 included $3.2 million related to employee severance benefits at the Companys Syracuse location and $2.0 million related to various relocation activities at both the Companys Syracuse and Puerto Rico locations.



ePTFE Vascular Graft Business (Edwards)



In November 2005, we completed the acquisition of our ePTFE Vascular Graft Business, located in Laguna Hills, California, from Edwards Lifesciences Corporation (Edwards) for cash consideration of $14 million. The primary purpose of the acquisition was to obtain the ePTFE vascular graft product line to enhance the financial potential of our Vascular Wrap product development program. The acquisition was accounted for using the purchase method of accounting and resulted in goodwill of $12.7 million. The transaction also included a distribution agreement with Edwards.



Afmedica, Inc.



In October 2005, we completed the acquisition of 100% of the fully-diluted equity of Afmedica for cash consideration of $21.5 million. Afmedica was a private company developing perivascular technology using the drug rapamycin to treat peripheral vascular disease and coronary artery disease. The primary purpose of the acquisition was to obtain the intellectual property related to the use of the drug rapamycin in certain perivascular applications. Afmedicas equity holders will also be entitled to total contingent consideration of $10.0 million should we reach certain development and regulatory milestones with respect to any Afmedica product. As Afmedica was a development stage company consisting of primarily one asset, the transaction was accounted for as an asset acquisition and not as a business combination. The purchase price of $23.4 million, including transactions costs but excluding contingent consideration, was allocated to acquired IPR&D and was written-off at the time of acquisition because the perivascular technology, the only asset acquired, had not reached technological feasibility and had no alternative future use. The revenue and expenses of Afmedica have been included in our consolidated financial statements from October 7, 2005, the completion date of the acquisition.



Page 6



---







Collaboration, License and Sales and Distribution Agreements



In connection with our research and development efforts, we have entered into various arrangements with corporate and academic collaborators, licensors, licensees and others for the research, development, clinical testing, regulatory approval, manufacturing, marketing and commercialization of our product candidates. Terms of the various license agreements may require us, or our collaborators, to make milestone payments upon achievement of certain product development and commercialization objectives and pay royalties on future sales of commercial products, if any, resulting from the collaborations. Under appropriate circumstances, we may, from time to time, seek to amend, modify or terminate certain of these relationships.



The significant collaboration, license and sales and distribution agreements that we believe are the most critical in fully understanding and evaluating our business and reported financial results are described below:



Boston Scientific Corporation



In 1997, we entered into a License Agreement with BSC (the 1997 License Agreement), whereupon BSC became a co-exclusive licensee (together with Cook, Incorporated - Cook) of our proprietary paclitaxel technology for use in certain coronary and peripheral vascular fields of use.  This agreement provided for payment of certain product development milestones, as well as royalties to be derived from the sales of any products commercialized by BSC relating to the licensed technology. The technology licensed by BSC through this agreement is incorporated in BSCs proprietary TAXUS coronary vascular stent product line.



In November 2004, we amended the 1997 License Agreement upon BSCs election to become the exclusive worldwide licensee of our proprietary paclitaxel technology for use with coronary vascular stents. Pursuant to the terms of the amendment to the 1997 License Agreement, the royalty rates payable to us by BSC were increased by one percentage point (1%) across all royalty tiers as of November 23, 2004, for royalties payable to us in jurisdictions in which we have patent coverage. We also granted BSC the right to sublicense our paclitaxel-eluting coronary vascular stent technology to third parties for cash consideration of $13.9 million, which was recognized as license revenue in 2004. If BSC exercises its sublicensing rights in the future, we will receive a percentage of any sublicensing consideration paid to BSC and a royalty rate payable on any third party product sales.



Cook Group Incorporated



In 1997, we entered into the 1997 License Agreement with Cook, whereupon Cook became a co-exclusive licensee of our proprietary paclitaxel technology for use in certain coronary and peripheral vascular fields of use.  This agreement provided for payment of certain product development milestones, as well as royalties to be derived from the sales of any products commercialized by Cook relating to the licensed technology. The technology licensed by Cook through this agreement is incorporated in Cooks proprietary ZILVER PTX peripheral vascular stent product candidate, which is currently undergoing human clinical trials.



In September 2004, we amended the 1997 License Agreement to accommodate Cooks election to exit and return all licensed rights related to the coronary vascular field and to focus on the development of paclitaxel-eluting peripheral vascular and gastrointestinal stents. The 1997 License Agreement was amended to increase the royalty rate upon the commercial sale of paclitaxel-eluting peripheral vascular stent products; and to provide a multi-year extension to the 1997 License Agreement for Cook related to the peripheral vascular and gastrointestinal fields of use. In consideration for these amendments, we made a $25.0 million license payment to Cook upon execution of the amendment, which is being amortized over the estimated life of the future benefit of ten years.



Baxter Healthcare Corporation





Page 7



---





In April 2003, we entered into a Distribution and License Agreement and a Manufacturing and Supply Agreement with Baxter Healthcare Corporation (Baxter). These agreements gave Baxter the right to manufacture and distribute our surgical sealant product, CoSealTM, currently approved for sale in the U.S. and the E.U., and an option to license our non drug-loaded surgical adhesion prevention product, Adhibit, in the U.S., which is not currently approved for sale in the U.S. We received an upfront payment of $8.0 million in April 2003, of which $6.0 million is non-refundable and up to $2.0 million was potentially refundable if we terminated the agreement, at our option, upon the failure of Baxter to achieve certain minimum sales and we elected to continue distributing the product. In each of 2005 and 2006, we recognized $1.0 million of the potentially refundable amount as license fee revenue, as we did not terminate the agreement during the year. Our exposure to the remaining potential refund expired at the end of 2006. We received an additional $4.0 million in milestone payments in prior years upon the approved transfer of manufacturing of the CoSeal surgical sealant product to Baxter, and we may receive up to an additional $11.0 million if Baxter exercises options to obtain Adhibit rights in the U.S. and CoSeal rights in Japan and makes a milestone payment linked to achievement of regulatory approval for a certain indication in the U.S. The agreements, or portions thereof, may be terminated by Baxter at any time or by us if specified minimum sales are not achieved by Baxter. Unless otherwise terminated, the agreements expire upon the later of the expiration of the last issued patent or ten years.



CombinatoRx, Incorporated



In October 2005, we entered into a research and license agreement with CombinatoRx, Incorporated (CombinatoRx). The collaboration includes a joint research effort to combine CombinatoRxs combination drug discovery platform and capabilities with our expertise in local drug selection and delivery across a number of disease areas. As consideration for the license, we paid an upfront license payment to CombinatoRx of $27.0 million. In connection with this transaction, we also made a $15.0 million investment in CombinatoRx Series E Convertible Preferred shares. In November 2005, upon consummation of an initial public offering (IPO) by CombinatoRx, the Series E Convertible Preferred shares automatically converted to common shares at a 10% premium to the IPO price. CombinatoRx will also receive milestone payments and royalties for each combination pharmaceutical compound successfully developed and commercialized by us. For accounting purposes, the upfront license payment of $27.0 million and the premium paid on the common shares of $3.4 million were allocated to acquired in-process research and development and were written-off upon entering into the research and license agreement because the technology was at an early stage of development and had no alternative future use. The investment in common shares is being accounted for as a long-term available-for-sale security.  In June 2007, we executed an option to extend our collaboration with CombinatoRx based upon the successful advancement of certain selected product candidates into pre-clinical testing. The joint research being conducted under our research and license agreement has been extended beyond the initial two and a half year term to a total of five years. The extension resulted in a $7.0 million payment being made to CombinatoRx on October 2, 2007. We recorded this payment as an in-process research and development expense in the second quarter of 2007.



Genzyme Corporation



In May 2006, we entered into a Collaboration Agreement with Genzyme Corporation (Genzyme) to create novel, localized treatments for cancer patients that target the prevention of tumor re-growth after surgery through the direct application of a combined biomaterial / anti-cancer therapeutic at the site of tumor excision. These potential products may also be useful in treating inoperable tumors, reducing local tumor side-effects, and improving surgical outcomes while complementing existing systemic therapies. Under the agreement, the companies agreed to conduct research jointly, with both companies contributing key personnel, technology and intellectual property. Genzyme has primary responsibility for clinical development, manufacturing and worldwide commercialization of any collaboration products. We may participate in the development of products at our election, and we may have an ability to co-market any products eventually approved for sale. Collaboration costs and any eventual profits will be shared equally.



Athersys, Inc.





Page 8



---





In May 2006, we entered into a Strategic Alliance Agreement with Athersys, Inc. (Athersys) to co-develop and commercialize Athersys non-embryonic stem cell platform technology, MultiStem, for use in the indications of myocardial infarction and peripheral vascular disease. Athersys is a biopharmaceutical company engaged in the development of therapeutic products for the treatment of life threatening diseases, with development activities currently focused on drug discovery and pre-clinical research. We will share in the research and development costs and will be responsible for all commercialization related costs of MultiStem in the licensed indications. We will be entitled to 55% (subject to certain potential adjustments) of any future profits from any products approved for sale that result from the collaboration. Concurrent with the Strategic Alliance Agreement, we made a payment of $5.0 million to Athersys in exchange for a convertible promissory note, maturing in 6 years, with a coupon of 5% which will be convertible into Athersys stock upon Athersys obtaining additional future financing meeting certain conditions. Concurrent with Athersys fulfilling a milestone obligation, we made an additional payment of $5.0 million in January 2007, accrued as at December 31, 2006, which was in exchange for a convertible promissory note under substantially the same terms and conditions as the original note. This payment has been recorded as a long-term investment. In June 2007, Athersys completed a reverse merger with BTHC VI, Inc. and concurrently completed a $65 million private placement. As a result of Athersys transaction, our $10.0 million in convertible promissory notes plus accrued interest was converted into 1,883,848 common shares in Athersys. In March 2008, we notified Athersys of our intention to forego the payment of certain milestone payments due related to the initiation of human clinical trials for MultiStem, and as a result Athersys notified the Company of its election to increase its profit share component under the Strategic Alliance Agreement from 45% to 47.5%.



Orthovita, Inc.



In March 2006, we entered into a revised License Agreement with Orthovita, extending and expanding the terms of our June 2004 exclusive North American Sales and Distribution Agreement with respect to our VITAGELTM surgical haemostat product.  Upon completion of the sale of VITAGEL products in inventory, which Orthovita purchased from us in the fourth quarter of 2005, the original Sales and Distribution Agreement was terminated.



The key terms of the revised License Agreement include the completion of the contractual transfer of manufacturing responsibilities from us to Orthovita (which occurred in June 2006), the extension of the contract term from 2009 to 2014, the expansion of distribution rights to Orthovita for the rest of the world, the retention by Orthovita of worldwide exclusive rights in the field of orthopaedic indications through 2014 and co-exclusive rights outside the field of orthopedics beginning in 2007.  Under the terms of our revised License Agreement, from 2007 we may distribute our own brand of the VITAGEL surgical haemostat formulation on a co-exclusive basis outside the field of orthopedics. Under the revised agreement, we have continued to retain exclusive rights to develop and sell any drug-loaded version of the VITAGEL product.



In December 2006, we entered into a definitive agreement with Orthovita where Orthovita purchased the profit-sharing royalty rights for the VITAGEL surgical hemostat and CELLPAKER® Collection Device products under our License Agreement for $9.0 million in cash.  In connection with this agreement, we also entered into an amended and restated license agreement with Orthovita that, among other things, eliminates Orthovitas obligation to pay royalties to us and extends the term of the License Agreement from 2014 through July 2017, which covers the life of the licensed VITAGEL and CELLPAKER patent portfolio.  This amendment significantly changed the pattern over which economic benefits from the intellectual property were realized and in the fourth quarter of 2006, $9.0 million was recorded as royalty revenue and $2.6 million of remaining unamortized cost of the relevant intellectual property was fully amortized.



In connection with the License Agreement, in July 2004 we purchased approximately 5.7 million common shares of Orthovita for $25 million through a registered direct offering. On March 27, 2007, we sold all of these shares of Orthovita at $2.75 per share for gross proceeds of $15.6 million.



National Institutes of Health



In November 1997, we entered into an exclusive License Agreement with the NIH for the use of drug delivery systems to treat fibroproliferative vascular diseases, including restenosis, using local and systemic administration of paclitaxel and other microtubule stabilizing agents. This technology contributes to the overall technology package BSC uses to produce the TAXUS paclitaxel-eluting coronary stent. In consideration for the license, we pay a royalty to the NIH. The term of the License Agreement extends to the expiration of the last to expire of the patents licensed to us.



University of British Columbia





Page 9



---





Effective August 1997, we entered into a License Agreement with UBC for the use of their polymeric drug delivery methodologies incorporating paclitaxel and analogues and derivatives thereof. This technology contributes to the overall technology package BSC uses to produce the TAXUS paclitaxel-eluting coronary stent. In consideration for the license, we pay a royalty to UBC. The term of the license agreement is the longer of the expiration of the patent licensed under the agreement and 15 years.



During 2006 we modified and terminated the following significant agreement:



NuVasive, Inc.



In September 2006, we modified certain manufacturing and license agreements with NuVasive, Inc. (NuVasive”) with respect to NeoDiscTM, an implantable spinal disc technology, for which we received $20.0 million from NuVasive, consisting of $12.0 million in cash and $8.0 million in NuVasive common stock. As a result of this transaction, we were obligated to pay approximately $3.4 million of the consideration received from NuVasive to certain third parties for license fees and transaction costs. Of the $3.4 million we were obligated to pay, $2.9 million was paid in 2006 and the remaining $0.5 million was paid upon sale of the common stock in March 2007 (see below). The payment satisfies a $10.5 million milestone payment related to FDA approval of the Investigational Device Exemption application for NeoDisc, as well as future milestones, manufacturing services and all future royalties in respect to this product and other potential products based on the technology.  The contingent milestones related to the original agreement were included in the AMI purchase price allocation as other current receivables, and the estimated fair value of the manufacturing and royalty agreements were included in intangible assets at a value of $3.4 million. The common stock was sold in March 2007 for net proceeds of $9.4 million.





DESCRIPTION OF BUSINESS



Overview



We are a specialty pharmaceutical and medical technology company that discovers, develops and markets technologies and products primarily to treat local diseases or to address complications associated with medical device implants, surgery or acute injury. Our proprietary technologies include various device, drug, drug delivery, surface modification and other medical biomaterials technologies. Our research and development efforts focus on understanding and characterizing biological conditions that often occur concurrently with medical device implantation, surgery or acute trauma, including scar formation and inflammation, cell proliferation, infection and tumor tissue overgrowth. Our strategy is to apply these various technologies to create and commercialize novel, proprietary medical device, surgical implant and pharmaceutical products that reduce procedure side effects, improve surgical outcomes, shorten hospital stays, or are easier or safer for a physician to use.



We specialize in developing locally-delivered drug formulations or drug-device combination products to address unmet clinical needs. We use our drug-screening capabilities to identify new uses for known pharmaceutical compounds. We look for compounds that address the underlying biological causes of conditions that can occur concurrently with medical device implantation, surgery or acute trauma. Once appropriate drugs have been identified, we formulate the drug, or combination of drugs, with our portfolio of drug, drug delivery and surface modification and biomaterials technologies to develop a novel locally-delivered drug formulation or drug-eluting medical device or surgical implant. We have patent protected, or filed patent applications for, our technology and many of our products and product candidates, and our portfolio of intellectual property developed, licensed or acquired to date, includes over 250 issued U.S. patents and 230 pending U.S. patent applications, and over 620 issued non-U.S. patents and 560 pending non-U.S. patent applications.



The TAXUS® paclitaxel-eluting coronary stent is the initial commercial product to incorporate our technology and is sold by our partner BSC. As of December 31, 2007, over four million TAXUS coronary stents have been implanted in patients with coronary artery disease. A stent is a small tube that is inserted permanently into a diseased section of a coronary artery or other blood vessel in the body. Coronary stents such as TAXUS elute drugs after implantation and, as a result, have contributed to a significant reduction in the chance that arteries will become blocked again, based on data from several large human clinical studies. Due to the efficacy of drug-eluting stents, the market for stents has grown significantly. In the twelve-month period ended September 30, 2007, BSCs sales of TAXUS paclitaxel-eluting coronary stents were approximately $1.6 billion and in the year ended December 31, 2007, we recorded royalty revenue from BSC for those sales of $110.5 million representing approximately 34% of our total revenue from continuing operations. In the twelve-month period ended September 30, 2006, BSCs sales of TAXUS paclitaxel-eluting coronary stents were approximately $2.5 billion and in the year ended December 31, 2006, we recorded royalty revenue from BSC for those sales of $159.5 million. As per our accounting policy, we will not record royalty revenue from sales by BSC of the TAXUS paclitaxel-eluting coronary stent for the three months ended December 31, 2007 until the three-month period ending March 31, 2008.



Page 10



---







On March 23, 2006, we acquired 100% of the equity of privately-held AMI, a traditional medical device products business. The AMI business consists of a diverse portfolio of specialty single use medical device products primarily for the interventional radiology, biopsy, general surgery, aesthetic surgery and ophthalmology markets. The AMI acquisition significantly diversified our revenue base and provided us with commercial resources, including sales, marketing and manufacturing. AMI also provided us with a broad portfolio of medical device products to which we may apply our various proprietary technologies. Since the AMI acquisition, we have generated a significant portion of our revenue from direct product sales. For the year ending December 31, 2007, our direct sales of medical device products and components generated revenue of $170.2 million. For the year ending December 31, 2006, our direct sales of medical device products and components generated revenue of $138.6 million.



As a complement to our existing strategy of establishing product development and marketing partnerships, we are utilizing AMIs direct sales and distribution resources to market and sell certain of our existing approved products, as well as potentially certain of our product candidates currently undergoing human clinical trials. We intend to apply our various drug, drug delivery and surface modification technologies to certain of AMIs medical devices in order to potentially improve the performance, ease of use, safety, or the outcomes of the medical procedures in which they are used. We believe that applying our technologies to products and product candidates that are owned by us, in addition to providing technology to partners, may enhance returns on our research and development initiatives by enabling us to capture the substantial majority of the potential revenue from improvements in market share or market opportunity for these products and product candidates.



Our discovery approach has yielded a number of product candidates that are in various stages of research and clinical development. Our product pipeline includes our drug-eluting anti-microbial CVC, which is designed to reduce or prevent CVC-related infections in critical care patients, our paclitaxel-eluting Vascular Wrap product candidate, which is designed to treat complications associated with vascular graft implants, and our drug-eluting hydrogel product candidates, which are designed to manage pain, bleeding or infection in surgical patients.



Business Strategy



Our strategy is to apply our various technologies to develop and commercialize novel, proprietary medical device, surgical implant and pharmaceutical products that address the most frequent problems or complications observed in connection with medical device use or surgical procedures. Specific elements of our strategy include:





Identify and Prioritize Market Opportunities. We begin our product development process by identifying medical devices or surgical procedures where problems or complications arise soon after device implantation or the initial procedure, and where re-intervention is expensive, potentially harmful for patients or difficult to perform. We target areas where we have previously developed successful technologies, such as the treatment of scar formation and cell proliferation with paclitaxel and its analogues or derivatives, or where we have particular scientific focus or expertise. For example, numerous human trials have indicated that paclitaxel dramatically improves the clinical performance of stents used to treat patients with coronary artery disease, which has led to improved patient outcomes, premium pricing and growth of the stent market. We believe other medical devices and surgical implants could be similarly affected through the proprietary addition of locally-delivered therapeutics.



Develop Novel, Proprietary Product Candidates. After prioritizing opportunities, we identify the biology that may contribute to complications or failures of a device or procedure. We then screen and select a potential drug or drugs to combine with our biomaterial or drug delivery technologies to create  proprietary, locally-delivered drug formulation or drug-device combination product candidates. We continually assess and study applications of our technology, including analyzing the biology pertaining to the failure of certain medical devices and surgical implants, and determining the therapeutic drug selection, concentration, total dose and drug release characteristics required to enhance medical device and surgical implant performance. We believe this approach may allow us to create additional novel drug-eluting medical devices and surgical implants that achieve better clinical results than drugs, medical devices or surgical implants may achieve independently.



Page 11



---







Establish and Develop Intellectual Property Portfolio. After identifying potentially useful technologies or developing novel product candidates, we incorporate these elements into our new patent filings or our existing patent portfolio, and we attempt to develop and establish new intellectual property in jurisdictions throughout the world. We believe we are among the first companies to develop an extensive intellectual property portfolio of products combining approved pharmaceutical agents, such as paclitaxel, with medical devices and surgical implants. Recognizing the importance of intellectual property in our industry, we plan to continue to aggressively pursue patent protection in the U.S., the E.U. and other significant markets, as well as to protect trade secrets and know-how as our research and development activities uncover additional important medical product and therapeutic opportunities.



Select Commercialization Path. Once we reach a certain stage with a technology or product candidate, we select a development and commercialization path.  Where we have a distribution channel, we may elect to fully develop a product ourselves, or in selected cases where product opportunities may not fit our commercial capabilities, we will license certain of our products, technologies or product candidates to be developed, manufactured or commercialized by partners. We expect that we will focus on retaining commercial rights for those product candidates that are the best fit with the sales, marketing and manufacturing capabilities of AMI.



Pursue Selective Strategic Acquisitions and Licenses. To support our product development and commercialization activities, we have pursued, and will continue to selectively pursue, acquisitions or licenses to obtain proprietary pharmaceutical compounds or compound classes, formulation technologies, medical device technologies and intellectual property or other commercial assets. For example, the AMI acquisition enabled us to pursue the direct development and commercialization of certain of our product candidates in selected medical markets, including in interventional radiology and general surgery, and to potentially introduce new products incorporating our technology into the portfolio of products obtained through the AMI acquisition.





Angiotech History



We were founded in 1992. Our initial research focused on exploring new ways to use known pharmaceutical compounds to inhibit abnormal and/or rapid proliferation of cells in a variety of disease indications, either by inhibiting the formation of new blood vessels or exploiting other molecular mechanisms to inhibit cell replication. One of the initial applications of our research was in the use of known pharmaceutical classes for the treatment of complications that can occur after the minimally invasive treatment of coronary artery disease. Certain minimally invasive surgical treatments for coronary artery disease have experienced rapid growth over the past several decades as alternatives to open, invasive coronary artery bypass surgery. These surgical treatments include balloon angioplasty, where a balloon catheter is directed into a coronary artery through a small incision in the groin and inflated to clear a blockage, and coronary stenting, where small metal tubes are implanted in coronary arteries in conjunction with balloon angioplasty.



These treatments grew popularity despite the fact that many patients experienced a re-blockage of the treated artery, commonly referred to as restenosis, within six months of an initial angioplasty or stent implantation procedure. It is believed that the angioplasty or stent procedure causes an injury to the blood vessel wall, and thereby stimulates a biological healing response, including scar formation and tissue overgrowth. In selected patients this biological process may be overly aggressive and lead to restenosis, and the potential need for a repeat angioplasty, stent placement or other surgical procedure. Of all balloon angioplasty and non drug-eluting, or bare metal, stent procedures, it is estimated that between 20% and 40% of patients, as indicated by various studies, experience restenosis in the treated vessel, resulting in the need for additional treatment and significant additional risks for patients, as well as significant additional procedure and hospital costs.





Page 12



---





Our pioneering research led to the key discovery that paclitaxel blocks an important cellular pathway involved in the scar formation and tissue growth that can lead to restenosis. This early research indicated that paclitaxel or its analogues and derivatives could potentially be used in combination with balloon angioplasty and stents to reduce the complication rates of those procedures. As a result of our research, we established a co-exclusive, worldwide license agreement with BSC and Cook in July 1997, both international medical device manufacturers and distributors. That license agreement granted both BSC and Cook rights to develop and market paclitaxel-eluting coronary, peripheral and gastrointestinal stents using our technology. The 1997 License Agreement was amended in 2004, giving BSC exclusive rights for coronary applications of our technology.



Multiple human clinical trials, conducted primarily by BSC, have indicated that the use of paclitaxel-eluting stents significantly reduce observed rates of restenosis. For example, in BSCs pivotal TAXUS IV clinical trial, which enrolled a total of 1,326 patients, restenosis rates averaged 7.9% in the group treated with BSCs TAXUS paclitaxel-eluting stent, as compared to 26.6% in the control group in the study, where bare metal stents were used. Five year follow up and a meta analysis of  patients in the various TAXUS human clinical studies continues to show a significant clinical benefit for the TAXUS treated groups, with a target lesion restenosis rate of 12.1% as compared to 21.0% in the bare metal stent group (p<0.001). In addition, the overall death rate and Q-wave myocardial infarction rate at 5 years shows no difference between the two groups, suggesting similar safety in both arms of the studies.



In March 2004, BSC received FDA approval for and commenced sales in the U.S. of its paclitaxel-eluting coronary stent, the TAXUS Express. Under the terms of our license with BSC, we receive royalties derived from worldwide sales by BSC of paclitaxel-eluting stents. Due to the efficacy of drug-eluting stents, the market for stents has grown significantly. Prior to the launch in March 2004 of the TAXUS coronary stent, BSCs sales of bare-metal coronary stents not incorporating our technology were $328 million for the 12 months ended December 31, 2003. In the twelve-month period ended September 30, 2007, BSCs sales of TAXUS paclitaxel-eluting coronary stents were approximately $1.6 billion and in the year ended December 31, 2007, we recorded royalty revenue from BSC for those sales of $110.5 million. In the twelve-month period ended September 30, 2006, BSCs sales of TAXUS paclitaxel-eluting coronary stents were approximately $2.5 billion and in the year ended December 31, 2006, we recorded royalty revenue from BSC for those sales of $159.5 million.



On March 23, 2006, we acquired 100% of the equity of privately-held AMI, a leading independent manufacturer of specialty, single-use medical devices primarily for interventional radiology, tumor biopsy, vascular surgery, general surgery, aesthetic surgery and ophthalmology markets.  The AMI acquisition significantly diversified our revenue base and provided us with various commercial resources, including sales, marketing and manufacturing.  AMI also provided a broad portfolio of medical device products to which we may apply our various proprietary surface modification or drug technologies.  Since the AMI acquisition, we have recorded substantial revenue from sales of its broader product line and from selected products manufactured for other medical device company customers.



Industry Overview



The U.S. medical device industry recorded approximately $82 billion in product sales in 2007. There were also an estimated 34 million surgical procedures in various indications completed in the U.S. in 2007. Medical device products and procedures target a wide variety of medical markets and disease conditions.

Despite the long history of many medical technologies and the large numbers of surgical procedures completed annually, many of these treatments deliver sub-optimal outcomes, suffer from significant complication rates or do not completely address underlying medical problems. In addition, many medical devices can be dangerous or difficult for a physician to use, and as a result, require significant training and experience in order to achieve the desired procedural result. The most frequent problems or complications observed in connection with medical device use or surgical procedures can be categorized into four primary areas. These areas with selected examples of medical devices or procedures and complications include:



The Closing of Body Passageways Due to the Accumulation of Scar Tissue or Inflammation



Coronary vascular stents: re-occlusion of the treated vessel, or restenosis, at the treatment site, leading to the need for repeat surgical procedure.



Page 13



---







Sinus surgery: scarring and occlusion of the opening to the sinus cavity, resulting in failed procedure.



Synthetic hemodialysis access grafts: restenosis at the bypass graft attachment site, which can result in the need for a repeat surgical procedure.



Coronary artery bypass grafts: restenosis at the bypass graft attachment site, which can result in the need for a repeat surgical procedure.



Spine surgery: scarring, or adhesions, at the surgical site, which may lead to significant post-operative pain.



Myomectomy surgery for removal of uterine fibroids: adhesions at the surgical site, leading to potential fertility issues.



Pacemaker or implantable defibrillator leads: scar formation over leads can make removal of leads very difficult and may impair the transmission of electrical impulses.



Hydro-cephalic shunts: scar formation or cell proliferation may lead to occlusion of shunt.



Infusion pumps: occlusion of the pump channel due to overgrowth of excess scar may lead to pump failure.



Insufficient Healing of Adjacent Tissues, or Adjacent Tissue and a Device, Brought Together During Surgery



Abdominal aortic aneurysm stent grafts: inadequate vascular remodeling or other tissue formation between stent graft implant and adjacent vessel wall, which can lead to loosening or migration of the graft within the vessel and potential leakage of blood into aneurysm sac.



Neurological aneurysm coils or fillers: inadequate formation of fibrotic tissue in aneurysm space, which can lead to incomplete filling of space and the continued risk of rupture.



Artificial hip or knee implants: inadequate fit between joint space and prosthetic implant, which may lead to potential implant loosening.



Embolization therapy for treatment of fibroids or varicose veins: inconsistent treatment success due to failure to completely seal off blood supply or flow.



Surgical or Device-Related Infections



CVCs or peripherally inserted central catheter (PICC) lines: insertion site and bloodstream infection.



Pacemaker or implantable defibrillators: lead or implant pocket infection.



Artificial hip or knee implants: implant site infection.



Vascular access devices or trocars: insertion site and bloodstream infection.



Mechanical heart valves: site related valve cuff infections.



Implantable ear tubes: insertion site infections.



Complications Related to Surgical Procedures Designed to Eradicate Benign or Malignant Tumors



Liver or breast cancer tumor surgical resection: potential recurrence of cancer due to potential residual cells remaining around surgical margins.



Embolization agents for uterine fibroids: potential recurrence due to incomplete eradication of blood flow.



Implantable radioactive seeds for prostate cancer: potential recurrence due to incomplete eradication of cells using radiation alone.



Urological, respiratory or esophageal stents: potential proliferation of cells into stented area after tumor removal.

While medical device manufacturers have attempted to address many of the most common problems and procedure complications with new device designs, in many cases it may not be possible to address certain biology-related complications through device engineering or changes in surgical technique alone. In addition, pharmaceutical and biotechnology companies primarily focus on large chronic or primary care markets for oral, intravenous or other systemic therapies, and have in the majority of cases chosen not to pursue local therapies or opportunities for their products in medical device or surgical markets. As a result, a significant need and opportunity exists to combine pharmaceuticals and biomaterials science with engineering to address certain medical problems or procedure complications.





Page 14



---





Technology Overview



We have organized our research and development efforts into the following three key functional areas: (1) screening and evaluation of known pharmaceutically-active compounds; (2) development and testing of novel biomaterials, drug delivery and surface modification technologies; and (3) product engineering to design and manipulate medical devices. We then combine the capabilities and know-how of these research efforts to develop our portfolio of drug-eluting medical device, surgical implant and biomaterial products and product candidates.

We have devoted significant resources to our drug-screening efforts and technology. We have investigated disease mechanisms and the target cell-level biology, and, based on the results of those investigations, identified specific biological targets of interest. Through selective screening we have identified compounds of interest, and have developed panels of in vitro cell-based assays which focus on these targets. This proprietary technology enables us to discover new uses for known pharmaceutically active compounds. As of December 31, 2007, we have screened over 600 compounds using our approach, and have identified over 80 compounds of potential interest to our product discovery and development programs. Some of the initial discoveries of our drug screening activities related to the use of paclitaxel for the treatment of restenosis in vascular disease have formed the basis for our technology that is incorporated into the TAXUS paclitaxel-eluting coronary stents as well as several of our other key product candidates under development.

We have internally developed, acquired or licensed through our various business development activities a broad portfolio of device, drug, drug delivery and surface modification technologies and biomaterials. Our surgical implants and biomaterials are based on a platform of proprietary technologies.  We have specific formulations of polyethylene glycol-based, sprayable hydrophilic polymers that quickly react inside the body to bind tissue, as well as various formulations and proprietary combinations of bovine collagen. Collagen is a common connective tissue that can act as a scaffold for cell growth and migration as well as a drug delivery vehicle in a body space.



We also have several bioerodable surgical mesh and suture-related technologies, as well as biodegradable tissue adhesive technologies, all of which can be designed to degrade over desired time periods and which are suitable for drug delivery.

Our device and drug delivery surface modification technologies include patented, non-reactive hydrophilic and hydrophobic polymer matrices, which are chain-like structures that can be varied to optimize medical device performance characteristics such as lubricity, flexibility, hydration or device visibility under ultrasound.

In addition, our family of coating systems is designed to facilitate local delivery of bioactive pharmaceutical agents from medical devices. This technology consists of entrapping drugs in patented mixtures of hydrophilic and hydrophobic polymers, which are designed for controlled elution of a drug from an implantable object. Examples of classes of drugs that may be suitable for use with our technology include anti-infective, anti-thrombotic, anti-angiogenic, anti-proliferative, immune-modulating and scar-forming drugs. In addition, our patented primer system allows adhesion of various agents to metal substrates, with the flexibility to meet the potential requirements of many metal medical devices.

Further to the development of these technologies, we have invested significantly in engineering capabilities to facilitate the production and optimization of our medical device products. We have assembled a medical device design and engineering group to modify and optimize our medical devices to perform to specifications. We also have dedicated process engineers to optimize our manufacturing capabilities.



Products



Our product portfolio is grouped into two business segments: Pharmaceutical Technologies and Medical Products.



Our Pharmaceutical Technologies segment develops, licenses and sells technologies that improve the performance of medical devices and the outcomes of surgical procedures. This segment focuses primarily on establishing product development and marketing partnerships with major medical device, pharmaceutical or biomaterials companies and to date has derived the majority of its revenue from royalties due from partners that develop, market and sell products incorporating our technologies. Currently our principal revenues in this segment come from royalties derived from sales by BSC of TAXUS coronary stent systems incorporating the drug paclitaxel.



Page 15



---







Our Medical Products segment manufactures and markets a wide range of single use, specialty medical devices, with products focused primarily on interventional radiology, biopsy, general surgery, aesthetic surgery and ophthalmology. The Medical Products segment also manufactures finished medical devices and medical device components for third party medical device manufacturers and marketers. Our Medical Products segment has specialized direct sales and distribution capabilities, as well as significant manufacturing capabilities. This business segment derives the majority of its revenue from direct product sales to end users or various medical products distributors. Many of these products are made using our proprietary manufacturing processes, or are protected by intellectual property.

The Medical Products segment may apply certain of its proprietary technologies to its products to create novel, next generation medical products to market directly to end users or medical products distributors.

Pharmaceutical Technologies Business Segment

TAXUS Drug-Eluting Stents

The most significant commercial products containing technology developed and licensed by our Pharmaceutical Technologies segment are the TAXUS Express and TAXUS Liberté coronary stent systems. They are sold by BSC, our exclusive licensee in the coronary paclitaxel-eluting stent field. We derive royalty revenue from sales by BSC of TAXUS coronary stent systems. Royalty revenue received from BSC was $110.5 million for the year ended December 31, 2007.

BSC commenced sales of the TAXUS Express paclitaxel-eluting coronary stent system in January 2003 in the E.U. and other countries outside of the U.S., and in March 2004 in the U.S. As of December 31, 2007, over 4 million TAXUS paclitaxel-eluting coronary stents incorporating our technology have been implanted worldwide in patients with coronary artery disease.

BSC announced the completion of the initial launch of the TAXUS Liberté paclitaxel-eluting coronary stent system in 18 countries in January 2005 and in Europe in September 2005. The TAXUS Liberté stent system represents BSCs next generation product incorporating our research, technology and intellectual property related to the use of paclitaxel to treat restenosis and other local inflammatory diseases. The TAXUS Liberté stent has been designed by BSC to further enhance coronary stent deliverability and blood vessel conformability, particularly in challenging coronary lesions. BSC hopes to gain FDA approval to market and sell TAXUS Liberté in the U.S. in 2008.

BSC has concluded several clinical trials of paclitaxel-eluting coronary stents that have demonstrated positive results, including six separate clinical studies, with a total of over 31,000 patients studied over a 5 year period, designed to evaluate the near and long-term safety and efficacy of both the slow and moderate drug release versions of the TAXUS Express coronary stent system.  These various studies have universally indicated that paclitaxel-eluting coronary stents significantly reduce the incidence of restenosis and the need for repeat surgical procedures at the treated lesion site in coronary artery disease patients.

Certain clinicians have suggested that the use of drug-eluting stents may cause an increased rate of late thrombosis (the formation of blood clots in the stent long after the initial stent implantation) and in turn, potentially lead to an increased rate of myocardial infarctions (heart attacks) or deaths as compared to bare metal stents. This led to a decrease in the use of drug-eluting stents. Subsequently, the FDA held a meeting to look at the issue.  One of the points that was made was that the way thrombosis was being defined was less than optimal and may have been creating a bias against the drug-eluting stent.  This has led to the use of the Academic Research Consortium (ARC) definition for the purpose of defining a stent thrombosis. A meta-analysis of all the TAXUS studies (Boston Scientific Paclitaxel drug-eluting stent program) now has 5-year follow up data. The overall thrombosis rate at the end of 5 years is no different between the drug-eluting arm and the bare metal stent arm of the studies. Death rates and myocardial infarction rates also show no difference at the end of 5 years, while the target lesion revascularization rate continues to maintain a statistically significant benefit for the patients receiving the drug-eluting paclitaxel stent as compared to those patients who received a bare metal stent (TLR 12.1% vs 21.0%, p<0.001).



Page 16



---





Medical Products Business Segment

Interventional Radiology and Biopsy Products

We offer a variety of products targeted at the interventional radiology and biopsy markets. We currently sell the majority of these products in finished form, either directly to our various customers or to distributors. We also sell selected biopsy needles and related components to other third-party medical device suppliers that compete in various general surgery markets. Our most significant commercial products in this segment area include:



·

SKATER Drainage Catheters – the SKATER catheter line is used to facilitate drainage of fluid from wounds, infectious tissues or surgical sites, and features larger lumens and drainage holes, kink resistance, resistance to encrustation and high radiopacity. SKATER catheters also utilize our proprietary Slip-CoatTM lubricious coatings to facilitate placement.

·

EnSnare Retrieval Device –EnSnare is an intra-vascular device used for retrieving foreign bodies or devices from vascular structures, organs, or ducts. We believe EnSnare provides ease-of-use advantages for physicians due to its proprietary “four loop” design. We are the exclusive worldwide manufacturer and distributor of EnSnare.

·

V+Pad®Hemostatic Pad – the V+Pad product is a hydrophilic wound dressing that is intended for use in the local management of bleeding wounds such as vascular access sites (percutaneous catheters or tubes), surgical debridement and lacerations. The V+Pad promotes rapid control of bleeding in patients on anticoagulation therapy and in patients following hemodialysis. We are the exclusive distributor of V+Pad in the U.S.

·

Soft Tissue Biopsy Needles  we offer a wide range of soft tissue biopsy needles, both disposable and re-usable for use in different types of breast, lung, spinal and bone marrow biopsies. Some key features of our biopsy needles include: an echogenic tip for placement under ultrasound guidance, numerically ordered centimeter markings to facilitate precise depth placement, and adjustable needle stops allowing the restriction of forward movement and localizing the needle to the biopsy site.

·

BioPince® Full Core Biopsy Devices – BioPince is our biopsy instrument product line featuring a proprietary tri-axial “Cut and Trap” cannula system.  This system allows the device to deliver cylindrical, full-length biopsy specimens that are complete and largely undamaged, which we believe significantly improves the diagnostic value of the sample.

·

T-Lock Bone Marrow Biopsy Device – our bone marrow biopsy device, the T-Lock, has an ergonomically designed twist-lock handle, which improves a clinician’s ability to penetrate hard bone to obtain the biopsy sample. An adjustable needle stop to control the depth of penetration allows the clinician to safely aspirate at the sternum of the patient.

·

HemoStream® Dialysis Catheter –our HemoStream product (licensed from Rex Medical, LLC) is expected to be used for short-term vascular access for patients undergoing hemodialysis. HemoStream has a novel triple outflow lumen that is designed to prevent the common complication of sidewalling, which occurs when the catheter is drawn next to the vessel wall during dialysis. This is a common problem with dialysis catheters. We are the exclusive distributor of the HemoStream dialysis catheter line, and we expect to begin selling HemoStream in the U.S. during the second quarter of 2008.

·

BioSealLung Biopsy System – BioSeal is our biopsy system containing a proprietary hydrogel plug designed to prevent air leaks in patients having lung biopsies. On contact with moist tissue, the hydrogel plug absorbs fluids and expands to fill the void created by the biopsy needle puncture. The plug is absorbed into the body after healing of the puncture site has occurred. BioSeal is currently undergoing a human clinical trial in the U.S. designed to assess the safety and efficacy of BioSeal, with the primary endpoint being reduction in rates of pneumothorax in patients undergoing lung biopsy procedures. The clinical trial, which is expected to enroll a total of 330 patients in the U.S., is a prospective randomized multi-centered safety and efficacy evaluation. The trial enrolled its first patient in October 2005, and 299 patients were enrolled in the study as of March 1, 2008. The study is designed to provide a basis for U.S. approval for the commercialization of BioSeal. The product has already received CE Mark approval. We are the exclusive worldwide distributor of BioSeal, which has received CE Mark approval and is currently marketed and sold in the E.U.



Page 17



---





·

Other Selected Products – other selected products for the interventional radiology and biopsy markets include fixation pins, tunneling stylets and surgical tunnelers and isotope seed spacers and needles for prostate cancer treatment.

General Surgery Products

We offer a variety of products targeted at various surgical disciplines for wound closure, wound healing and general surgery. We currently sell the majority of these products in finished form, either directly or through distributors. We also sell selected surgical needles, suture products and wound closure product components to other third-party medical device suppliers that compete in various general surgery markets. Our most significant commercial products in this market area include:



·

Quill SRS – our Quill SRS self-anchoring sutures contain proprietary patterns of tiny teeth-like barbs, which can eliminate the need for surgeons to tie knots when closing certain wound types. We believe that use of Quill SRS sutures may lead to faster surgical times, improved wound cosmesis and lower wound infection and complication rates.

·

Sharpoint® Specialty Microsurgical Products – our Sharpoint microsurgical sutures include specialized suture configurations and materials that are complex to manufacture, as well as needles that are manufactured from specialty stainless steel wire that has been tempered to a specific balance of hardness and tensile strength, which allows a fine edge that resists bending as the surgeon applies pressure.

·

Silk and Polyester Braided and Monofilament Suture Materials – we manufacture a wide array of configurations of non-absorbable and absorbable sutures. Sutures configurations can vary in diameter size, length, and material.

·

Drilled End Needles – drilled end suture needles have a precisely drilled butt end for maximum suture holding strength and are adequately tempered for securing strong attachment of the suture. A smooth finished drill hole reduces the abrasive effect on the suture.

·

Channel Needles – channel needles have a channel with an underlying receptacle for attachment of the suture. Our needle franchise benefits from the reputation of our subsidiary manufacturer, B.G. Sulzle, Inc. which has been manufacturing needles for the medical industry for over 60 years.

·

LifespanTM ePTFE Vascular Grafts – we manufacture reinforced ePTFE synthetic vascular graft for use in bypass or reconstruction of diseased or occluded blood vessels or to provide arteriovenous shunts for blood access in hemodialysis patients. Our ePTFE product line has over 75 product iterations and includes vascular grafts of various sizes and lengths. The Lifespan graft products are currently being used in combination with our paclitaxel-eluting Vascular Wrap in on-going clinical trials.

·

Surgical Blades Used in Cataract Surgery  we have a wide range of surgical blades for cataract surgery including: clear corneal knives, standard implant knives, pilot tip implant knives, precision depth knives, sharptone crescent knives, spoon knives, stab knives, vitrectomy knives to create small, precise incisions, sub-2mm series knives, and a variety of slit and specialty knives.

CoSeal®Surgical Sealant

CoSeal surgical sealant is a commercially approved, non-drug-loaded biomaterial product and was obtained as part of our acquisition of Angiotech BioMaterials Corp. (formerly known as Cohesion Technologies, Inc.) in 2003. CoSeal is the first fully synthetic vascular sealing agent approved by the FDA, and has been sold in the U.S. since February 2002. CoSeal is approved for use in the U.S. and the E.U. to achieve adjunctive hemostasis in vascular reconstruction by mechanically sealing areas of leakage. CoSeal is designed to rapidly seal tissue surfaces, suture lines and synthetic grafts during surgery. A premixed configuration of CoSeal received both FDA and European CE Mark approval in February 2003 and April 2003 respectively, and received Health Canada approval in October 2003. The premixed configuration of CoSeal is simpler to use, can be stored at room temperature and has a two-hour lifespan once activated.



Page 18



---





On February 25, 2003, we entered into a strategic alliance with Baxter, which provides Baxter with worldwide (excluding Japan) sales, marketing and distribution rights of our CoSeal surgical sealant product. This alliance also gives Baxter an option for distribution rights in Japan. In April 2003, we broadened the strategic alliance to provide Baxter with worldwide manufacturing rights for CoSeal. As a result of these transactions, we receive royalties on the end-user sales of CoSeal by Baxter. We have retained all development and commercial rights for drug-loaded versions of CoSeal.



Page 19



---





Research and Product Development



We, or our partners, are evaluating several product candidates that explore the application of certain of our proprietary drug, drug delivery and surface modification technologies to create novel, next generation medical products. The following table outlines our most advanced product candidates and their stage of development:



|                                                         |                                                                   |                      |                                                                                                                                     |                                               |            
|-------------------------------------------------------- | ----------------------------------------------------------------- | -------------------- | ----------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------- | -----------
|Product                                                  | Indication                                                        | Stage of Development | Regulatory Status                                                                                                                   | Anticipated Product Launch                    | Partner    
|Stent Program                                            |                                                                   |                      |                                                                                                                                     |                                              
|TAXUS Liberté
(paclitaxel-eluting
coronary stent)        | Coronary artery disease                                           | Approved             | Pivotal study (ATLAS) designed for U.S. approval; commercially available in the E.U. and various other countries outside the U.S. | Launched (E.U. and rest of world)
2008 (U.S.) | BSC        
|ZILVER® PTX paclitaxel-eluting peripheral vascular stent | Peripheral vascular disease                                       | Late Stage Clinical  | E.U. and U.S. first-in-man studies in femoral-popliteal indications currently enrolling                                             | 2011                                          | Cook       
|Vascular / Anti-Scarring Program                         |                                                                   |                      |                                                                                                                                     |                                              
|Vascular Wrap
(paclitaxel-eluting mesh)                  | Peripheral vascular disease
(Europe)                              | Awaiting Approval    | Filed for CE Mark in November 2006                                                                                                  | Q4 2008                                       | None       
|                                                         | Arteriovenous access
(U.S.)                                       | Late Stage Clinical  | Pivotal study initiated in March 2007; actively enrolling patients                                                                  | 2011                                          | None       
|                                                         | Arteriovenous access (Europe)                                     | Late Stage Clinical  | Pivotal study initiated in May 2007; actively enrolling patients                                                                    | 2011                                          | None       
|MultiStem Stem Cell                                      | Acute Myocardial Infarction                                       | Phase I              | IND approved by FDA December 2007                                                                                                   | 2011                                          | Athersys   
|Anti-Infective Program                                   |                                                                   |                      |                                                                                                                                     |                                              
|5-FU Anti-Infective Central Venous Catheter              | Prevention of bacteria colonization on a CV catheter
(U.S.)       | Awaiting Approval    | Filed 510K December 2007                                                                                                            | Q4 2008                                       | None       
|5-FU Anti-Infective Dialysis Catheter                    | Prevention of bacteria colonization on a Dialysis catheter
(U.S.) | Development          | NA                                                                                                                                  | 2009                                          | Rex Medical
|Drug-eluting Hydrogel Program                            |                                                                   |                      |                                                                                                                                    
|Drug-eluting Biomaterial                                 | Ovarian Cancer                                                    | Pre-clinical         | NA                                                                                                                                  | 2014                                          | Genzyme    
|                                                         | Pain management                                                   | Pre-clinical         | NA                                                                                                                                  | 2014                                          | None       
|                                                         | Hemostasis                                                        | Pre-clinical         | NA                                                                                                                                  | 2014                                          | None       
|                                                         | Anti-infection                                                    | Pre-clinical         | NA                                                                                                                                  | 2014                                          | None       







Page 20



---





Stent Program

·

TAXUS Liberté Paclitaxel-eluting Coronary Stent System – the TAXUS Liberté coronary stent system, which was developed by our partner BSC, represents BSC’s next generation product incorporating our research, technology and intellectual property related to the use of paclitaxel to prevent restenosis and other local inflammatory diseases. It has been designed to further enhance coronary stent deliverability and blood vessel conformability, particularly in challenging coronary lesions. BSC has to date commenced sales of the TAXUS Liberté only in countries outside of the U.S. On August 24, 2004, BSC initiated the ATLAS trial, a pivotal study to collect data to support regulatory filings in the U.S. for product commercialization of TAXUS Liberté. The ATLAS trial is a global, multicenter pivotal study designed to support the FDA approval of the TAXUS Liberté stent system. The trial is assessing the safety and efficacy of a slow-release dose formulation paclitaxel-eluting TAXUS Liberté stent system. On February 22, 2005, BSC completed enrolment of 872 patients at 72 sites in the U.S., Canada, Australia, New Zealand, Singapore and Hong Kong. In addition to the ATLAS trial, the TAXUS Liberté clinical development program includes several expansion studies for long lesion stenting, small vessel stenting and direct stenting of coronary lesions. In October 2006, BSC announced 12-month follow up data from the ATLAS trial. The data demonstrated that the safety and efficacy benefits with the TAXUS Liberté stent were maintained at 12 months. These data are currently being reviewed by the FDA, and BSC expects to begin marketing the TAXUS Liberté stent in the U.S. in 2008.

·

ZILVER® PTX Paclitaxel-eluting Peripheral Vascular Stent– the ZILVER PTX peripheral vascular stent, which was developed and is under evaluation in clinical trials being conducted by our partner Cook, is a specialized stent product incorporating our proprietary paclitaxel technology and is designed for placement in diseased arteries in the limbs to restore blood flow. In January 2007, Cook released nine-month data from its E.U. clinical study. The preliminary data presented by Cook on the first 60 patients in the randomized trial, which is examining the safety of using Cook's ZILVER PTX paclitaxel-eluting stent to treat blockages, or lesions, of the superficial femoral artery (SFA) above the knee, indicated that the ZILVER PTX showed an equal adverse event rate to conventional angioplasty for treating SFA lesions. The ZILVER PTX stent also displayed a zero percent fracture rate for 41 lesions at six months and 18 lesions at one year. Efficacy of the device in treating peripheral vascular disease lesions is being evaluated in multiple pivotal clinical trials in the U.S. and Japan, The U.S. study is planned to enroll a total of 480 patients at 28 investigative sites.

Vascular/Anti-Scarring Program

·

Vascular Wrap – our Vascular Wrap product candidate utilizes the same proprietary paclitaxel technology that led to the development of BSC’s TAXUS coronary stent product line. The Vascular Wrap is a paclitaxel-eluting mesh surgical implant designed to treat complications in patients who undergo vascular graft or bypass surgery. The Vascular Wrap is designed to reduce scar or intimal hyperplasia formation at the site where a graft is sewn into native vessel (the anastamosis site), which can often lead to complications, including repeat surgical procedures.

Patients with end-stage renal disease (ESRD) are highly dependent on vascular access to facilitate hemodialysis, a method of filtering out toxins in the blood using a dialysis machine. The incidence of ESRD in the U.S. is approximately 100,000 patients per year, and approximately 330,000 patients currently require routine hemodialysis. These patients require vascular access via the placement of arteriovenous grafts or via the creation of arteriovenous fistulae. In the U.S., synthetic grafts, such as ePTFE, are implanted in approximately 42 percent of hemodialysis access surgeries. Patients with end-stage renal disease today face approximately a 50 percent probability that their AV graft will fail within the first year of use. The principal cause of this failure is the development of restenosis (or neointimal hyperpasia) at the vascular anastomosis site. This high failure rate is a substantive cause of morbidity and may necessitate medical and surgical intervention in order to maintain graft patency.



Page 21



---





In March 2007, we launched a pivotal human clinical trial in the U.S. designed to evaluate the safety and efficacy of the Vascular Wrap after surgical implantation with an ePTFE vascular graft in the upper extremity for AV access. The pivotal trial is a multi-center, randomized, single-blind study and will involve approximately 628 patients at 50 centers in the U.S. The primary objective of the study is to demonstrate that the patency of the Vascular Wrap Paclitaxel-Eluting Mesh and the ePTFE graft is superior to the patency of the ePTFE graft alone within one year following vascular access surgery. Subjects will also be followed over a four-year period to confirm the long-term safety of this product candidate, although we anticipate filing for U.S. regulatory approval after completion of the primary one year follow up period.

In May 2007, we launched a pivotal trial in Europe designed to assess the safety and effectiveness of the Vascular Wrap after surgical implantation with an ePTFE vascular graft in the upper extremity for hemodialysis vascular (AV) access, as an adjunct to our U.S. pivotal clinical trial. The study is a multi-center, randomized, single-blind study and will involve approximately 198 patients at 20 centers in Europe. Within one year following vascular access surgery, the patency of the Vascular Wrap combined with an ePTFE vascular graft will be compared to a control group of patients who receive the standard of care, which is an ePTFE vascular graft alone.

Peripheral arterial disease (PAD) is an significant cause of morbidity and mortality among the aging population worldwide. Artery stenosis or occlusion causes reduced blood flow, decreased mobility, and limb loss in the later disease stages. Population surveys in Europe and the U.S. estimate that PAD prevails in 10 to 25% of the population. The major cause of PAD is atherosclerosis, in which deposits narrow and eventually occlude the arteries. The disease progresses in the lower extremities to critical limb ischemia (CLI), characterized by leg pain at rest, skin ulceration and gangrene, and may ultimately lead to amputation. Among patients diagnosed with CLI, approximately 25% may require amputation within a year. Limb salvage depends on restoring and maintaining blood flow. Surgical interventions include endovascular therapy (angioplasty and stenting). However, in patients with severe occlusion and stenosis, small vessel occlusion, calcified lesions, as well as those with diabetes, surgical bypass provides a final option to manage the occlusion(s) prior to amputation. The success of grafting to restore blood flow depends on inflow and outflow of the graft.

In November 2006, we reported results from our European first-in-man study examining the safety and clinical performance of the Vascular Wrap when used to treat patients suffering from advanced PAD in their lower limbs. The trial produced evidence that the Vascular Wrap reduced the overall incidence of leg amputation, and prolonged limb retention time for patients in the treatment arm relative to the control group. For the patients that underwent an amputation during the study period, the mean interval to amputation for patients treated with the Vascular Wrap was 156 days, as compared to the mean interval to amputation for the control group of 76 days. The Vascular Wrap also proved to be well tolerated, with no adverse events attributed to the use of the product. Upon the completion of this clinical trial, we submitted an application for a CE Mark for our Vascular Wrap for the PAD indication. We are currently still under review by the European regulatory body for a CE Mark. Upon receipt of a CE Mark, we would commence commercialization of our Vascular Wrap product in the E.U. and certain other countries outside of the United States.

·

MultiStem Stem Cell –  MultiStem is a biologic product that consists of undifferentiated human stem cells obtained from adult bone marrow or other non-embryonic tissue sources. The cells may be produced on a large scale for future clinical use and stored in frozen form until needed. Material from a single qualified donor may be used to produce hundreds of thousands or even millions of clinical doses of MultiStem, which are extensively characterized to ensure product consistency and safety.

Despite recent advances in cardiovascular care, myocardial infarction remains one of the leading causes of death and disability in the United States. Myocardial infarction is caused by the blockage of one or more arteries that supply blood to the heart, resulting in significant injury to the heart muscle that severely affects the patient's quality of life or causes death. Such blockages can be caused, for example, by the rupture of an atherosclerotic plaque. According to the American Heart Association 2007 Statistical Update, there were approximately 865,000 cases of myocardial infarction that occurred in the United States in 2004 and approximately 7.9 million individuals living in the United States that had previously suffered a heart attack. In addition, there were more than 452,000 deaths that occurred from various forms of ischemic heart disease, and 156,000 deaths due directly to myocardial infarction in 2004. A variety of risk factors are associated with an elevated risk of myocardial infarction or atherosclerosis, including age, high blood pressure, smoking, sedentary lifestyle, and genetics. While advances in the diagnosis, prevention, and treatment of heart disease have had a positive impact, myocardial infarction remains a leading cause of death and disability in the United States and the rest of the world.



Page 22



---





MultiStem has been studied in validated animal models of acute myocardial infarction at both the Cleveland Clinic and the University of Minnesota. Investigators demonstrated that the administration of allogeneic MultiStem into the hearts of animals damaged by experimentally induced heart attacks resulted in significant functional improvement in cardiac output and other functional parameters compared with animals that received placebo or no treatment. Further, the administration of immunosuppressive drug was not required and provided no additional benefit, and supports the concept of potentially using MultiStem as an allogeneic product.

In May 2006, we established a collaboration with our partner Athersys to co-develop the MultiStem technology for the treatment of acute myocardial infarction. Athersys has completed pre-clinical studies in established pig models of acute myocardial infarction, examining various factors such as the route and method of MultiStem administration, dose ranging, and timing of treatment. In January 2008, Athersys filed an IND for the use of MultiStem for the treatment of acute myocardial infarction and is planning to initiate a phase I study in Q1 2008.

Anti-Infective Program

·

Anti-Infective CVC – we are developing 5-FU, an approved compound, as a preventative of catheter-related infections. Our drug screening efforts have indicated that 5-FU may effectively interrupt the colonization of an implanted medical device by micro-organisms that typically gain entrance to the bloodstream via local skin penetration of implanted catheters. This reduction in colonization by bacteria may also have a net effect of reducing biofilm burden on the implanted catheters, making them less likely to serve as reservoirs for additional infection.

CVCs are usually inserted into critically ill patients to administer fluids, drugs, and nutrition, as well as to facilitate frequent blood draws. One of the complications associated with CVC implantation is infection, which can occur when bacteria contaminate the catheter. CVC infections that progress to bloodstream infections, or septicemia, can become life threatening. Approximately 3.5 million CVCs are used in the U.S. annually, leading to approximately 250,000 CVC-related infections and an estimated 40,000 deaths. In the U.S., the cost per catheter-related infection can range from $3,700 to $29,000. In addition, the Centers for Disease Control and Prevention (CDC) has raised concerns about the overuse of traditional antibiotics, which can contribute to an increase in the antibiotic resistance of bacteria.

In September 2007, the Centers for Medicare and Medicaid Services (CMS) announced that beginning October 1, 2008, it will no longer provide reimbursement over and above the typical Inpatient Prospective Payment System (IPPS) rate for care required to treat several types of hospital acquired infection (HAI). CMS collaborated with the CDC and other groups to identify a number of hospital-acquired conditions that were high volume, high cost, or both and could reasonably have been prevented through the application of evidence-based guidelines. The final rule states that hospitals will not receive additional payment for cases in which one of the selected conditions was not present on admission. These selected conditions include, among others, vascular catheter-associated infections.

In July 2007, we completed enrollment of a pivotal human clinical trial to compare our 5-FU CVC to a leading anti-infective catheter with respect to preventing bacterial colonization. The study was a randomized, single-blind, multi-center clinical study that enrolled 960 patients at 25 centers in the U.S. In October 2007, we announced that the study met its primary endpoint of non-inferiority as compared to the market leading anti-infective CVC and indicated an excellent safety profile. Specifically, our 5-FU CVC showed a 47% reduction in infection rate versus the standard of care. The rate of colonization of our 5-FU catheters was 2.9% (n=12) compared to 5.3% (n=21) in the comparator group, implying a relative reduction in bacteria colonization with 5-FU coating of 46% (p=0.052). Our 5-FU catheter also had zero percent occurrence of catheter-related bloodstream infections, compared to 2.8% for the comparator group. There also was no evidence of acquired resistance to 5-FU in clinical isolates exposed to the drug for a second time. In December 2007, we filed for our pre-notification 510(k) with the FDA to seek U.S. market approval based on this clinical data.



Page 23



---





·

Anti-Infective Dialysis Catheter – We have a FDA-approved dialysis catheter, HemoStream, that we sell through our direct sales force. A dialysis catheter is used for exchanging blood between a hemodialysis machine and a patient. Some common malfunctions of dialysis catheters include clotting, infection, and kinking. We are currently developing our 5-FU anti-infective technology for our HemoStream dialysis catheter line, and we currently anticipate filing for a 510(k) approval to market this product candidate in the U.S. in 2009.

Drug-Eluting Hydrogel Program

We have a polyethylene glycol-based tissue sealant technology that is FDA approved and commercially available in the U.S. and the E.U. under the trade name CoSeal. Common uses for this biomaterial include rapidly sealing tissue surfaces, suture lines and synthetic grafts during surgery. CoSeal has many benefits as a sealant technology, including: (1) no immunogenicity; (2) fully biodegradeable; (3) sprayable delivery method that allows for use in minimally invasive surgical procedures; (4) two-hour lifespan once biomaterial mixture becomes activated; and (5) longer shelf-life due to the ability to be stored at room temperature. Approved as the first fully synthetic vascular sealing agent by the FDA, CoSeal received both FDA and European CE Mark approval in February 2003 and April 2003 respectively.



·

Anti-Cancer Drug-Eluting Hydrogel– according to the American Cancer Society (ACS), ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. The ACS estimates that during 2007 there were approximately 15,280 deaths from ovarian cancer in the United States. Since there is no true test for ovarian cancer, an exploratory surgical procedure called laparotomy is generally required for the definitive diagnosis of ovarian cancer. During this procedure, cysts or other suspicious areas must be removed and biopsied. After the incision is made, the surgeon assesses the fluid and cells in the abdominal cavity. If the lesion is cancerous, the surgeon continues with a process called surgical staging to ascertain how far the cancer has spread. Surgical treatment may be sufficient for malignant tumors that are well-differentiated and confined to the ovary. Addition of systemic chemotherapy is often prescribed for more aggressive tumors that are confined to the ovary. For patients with advanced disease, a combination of surgical reduction with a chemotherapy regimen is standard. Patients that undergo treatment for ovarian cancer, however, still have an incidence of cancer recurrence of between 70% to 90%. Current approved drugs to treat patients with ovarian cancer include carboplatin, cisplatin, and combination of cisplatin with paclitaxel. We are currently in preclinical stage development with our anti-cancer drug-eluting hydrogel product candidates for ovarian and other potential cancer surgery indications. We have entered into a joint development collaboration with our partner Genzyme for this program.

·

Anti-Pain Drug-Eluting Hydrogel– surgeons often manage local pain patients feel as a result of undergoing surgery with systemic narcotics such as morphine or codeine.  Systemic administration of narcotic drugs, however, can result in unfavorable side effects including difficulty breathing, sedation, nausea and vomiting, falls and prolonged hospitalization, and can affect patients recovery. A key feature of our tissue sealant pain product candidate is the ability to apply the sealant directly at the wound site and in the different layers within the wound. This may enable effective, localized treatment of both the incisional and deep, visceral pain components associated with moderate and major surgery. In addition to pain relief, the tissue sealant may also provide hemostasis and may prevent the formation of adhesions after surgery. We are currently in preclinical stage development with our anti-pain drug-eluting hydrogel product candidates.

·

Hemostatic Drug-Eluting Hydrogel topical hemostats and tissue sealants are routinely utilized to prevent excess blood loss during surgery. Topical hemostats are generally less expensive and more reliable than tissue sealants, and provide an established clinical record. However, concerns have been raised regarding the animal source products used in hemostats, and topical hemostats also have limited utility in certain minimally invasive and other surgical procedures. As a result, clinicians are increasingly choosing tissue sealants and other alternative products over topical hemostats. A thrombin-eluting tissue sealant can be delivered through a minimally invasive laparascopic port, which is a limitation of the topical hemostats available today. We are currently in preclinical stage development with our hemostatic drug-eluting hydrogel product candidates.



Page 24



---





·

Anti-Infective Drug-Eluting Hydrogel – in spite of the use of prophylactic antibiotics, surgical site infections (SSI) still present a significant risk and can substantially burden patients and health care services with increased morbidity, mortality and economic cost. The goals of antibiotic prophylaxis are to achieve inhibitory antibiotic levels at incision and throughout the procedure. Animal studies have shown that antibiotic prophylaxis is most effective in preventing post-surgical infections when administered before the start of surgery and pharmacokinetic data suggest administration as near the time of incision as possible. Especially high infection rates are associated with certain procedures including operations on the mid-chest or stomach, intestinal surgery in patients with inflammatory bowel disease, colorectal surgery involving resection, surgeries on patients with a perforated gangrenous appendix or pelvic operations.

Additionally, during the year ended December 31, 2007, we completed the following clinical program:

·

Non Drug Loaded Sprayable Biomaterial Adhesion Barrier (AdhibitTM) – our non drug-loaded Adhibit sprayable barrier product is designed to provide for the reduction of surgery-induced adhesions that can occur after a surgical procedure. In April 2006, we announced data from our 71 patient human clinical study conducted in the E.U., designed to assess the safety and efficacy of Adhibit sprayable barrier in preventing adhesions in patients undergoing a procedure to remove fibroids from the uterus (myomectomy surgery). The data indicated that the use of Adhibit sprayable barrier reduced post-operative adhesion formation as measured by the modified American Fertility Society (mAFS) score, a scoring system that factors in both the extent and tenacity of adhesions. Patients in the group that were treated with Adhibit sprayable barrier experienced a statistically significant reduction in their mAFS score when compared with those in the control group.  We are currently evaluating, together with our partner Baxter Healthcare Corporation (Baxter), the timing and form of any regulatory submission for approval of this indication in the E.U. We granted Baxter exclusive worldwide marketing and distribution rights to our non-drug loaded Adhibit sprayable barrier product, except in the U.S., where Baxter has an option to obtain those rights.



Segmented Information



The company operates in two reportable segments: (i) Pharmaceutical Technologies and (ii) Medical Products.  Prior to the AMI acquisition the Company reported its operations under one segment, drug-eluting medical devices and biomaterials.



Patents, Proprietary Rights and Licenses



Patents and other proprietary rights are essential to our business. We file patent applications to protect technology, inventions and improvements to inventions that are considered important to our business. We also rely upon trade secrets, continuing technological innovations and licensing opportunities to develop and maintain our competitive position. Furthermore, we endeavor to extend our intellectual property portfolio by exclusively licensing patents and patent applications from others and initiating research collaborations with outside sources.

Our patents and patent applications relate to, among other things:



the use of paclitaxel and other agents for the treatment of chronic inflammatory diseases, such as restenosis (including as a stent component), rheumatoid arthritis and psoriasis;



compositions of and use of pharmacologic agents as medical device coatings and drug-eluting biomaterials;



hybrid polymer systems designed for localized delivery of bioactive agents and controlled elution of drugs from medical device surfaces;



non-reactive hydrophilic/hydrophobic polymer matrix, which can be varied to optimize performance characteristics such as lubricity, flexibility and hydration;



biocompatible surface treatments used in ultrasound imaging technology to cause medical devices to shine brightly in ultrasound images providing greater echogenicity, or visibility;



Page 25



---







hemostatic and sealant compositions, as well as broad intellectual property rights relating to collagen;



drug delivery compositions, such as our proprietary systemic formulation, medical device coatings and other local drug delivery systems; and



methods of administration.

As part of our patent strategy, we have filed a variety of patent applications internationally, including in the E.U. and Japan. Pursuant to the review of patents in these countries, an opposition can be filed by a third party after the granting of a patent.  At the European Patent Office (EPO), various patents either owned or licensed by or to the Company are in opposition proceedings. In EP0809515 (which the Company licenses from (and to) BSC), the EPO held an oral hearing on January 30, 2008, and thereafter revoked this patent.  This decision of the opposition board may be appealed.  Oppositions against European Patent Nos. EP0876165 (which relates to our CoSealTM product), EP1429664 (which relates to our Quill SRS products), EP0975340, EP1118325, EP1155689 and EP1407786 are in progress, with briefs being exchanged. The grant of European Patent No. EP0830100, which relates to our ePTFE vascular graft products, was opposed with an oral hearing conducted on September 28, 2006. At the end of the hearing, the EPO determined that an amended form of the patent was valid. The opponent appealed this decision On March 1, 2006, the Board of Appeals of the Japanese Patent Office issued a final order of revocation regarding certain claims of our Japanese Patent No. 3423317, directed to a stent coated with paclitaxel. Angiotech appealed this decision to Japans Intellectual Property High Court, and after holding several hearings, the court ruled in November 2007 in favor of the Japanese Patent Office.  Angiotech has appealed this decision to the Japanese Supreme Court.  An adverse decision by an Opposition Division in any country, or subsequently, by a Board of Appeal could result in revocation of our patent or a narrowing of the scope of protection afforded by the patent. The ultimate outcomes of the pending Japanese and European Oppositions, including appeals, are uncertain at this time. We do not know whether the patents that we have received or licensed, or those we may be able to obtain or license in the future, would be held valid or enforceable by a court or whether our patents would be found to infringe a competitors patents related to its technology or product. Further, we have no assurance that third parties will not (whether pursuant to or in breach of the terms) modify or terminate any license they have granted to us.



Regulatory Environment



The research and development, manufacture labeling, advertising, sale and marketing of our drug and medical device products and those of our collaborators are subject to extensive regulation by the FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries. Since we focus on combining pharmaceutical compounds with medical devices and biomaterials, we are subject to both drug and device regulations depending upon the categorization of the commercial product or potential product candidate.

Drug and device licensing laws require registration of manufacturing facilities, carefully controlled research and testing of products, government review and approval or clearance of results prior to marketing of products, adherence to current good manufacturing practices (cGMPs), during production and processing of products, and compliance with comprehensive post-marketing requirements including restrictions on advertising and promotion and requirements for reporting adverse events to the FDA in the U.S. and other regulatory authorities abroad. In the U.S., these activities are subject to rigorous regulation by the FDA. Similar regulations apply in the E.U. and other markets.

Our success is ultimately dependent upon our and our collaborators obtaining marketing approval or clearance for potential product candidates currently under development and will depend on our and our collaborators ability to comply with FDA and other market regulations governing the manufacturing, quality control, pre-clinical evaluation, and clinical testing of those candidates. If we or our present or future collaborators are not able to comply with the continuing FDA regulations that accompany FDA approval, the FDA may halt our clinical trials, require us to recall a drug from distribution, or withdraw approval of the new drug application for that drug or the 510(k) or Premarket Approval for the device. Depending on the circumstances surrounding the clinical evaluation of a product, we may sponsor clinical trials, contract clinical trial activities to contract research organizations, or CROs, or rely upon our corporate collaborators to sponsor such clinical development. There can be no assurance that any of our and our collaborators clinical trials or product development activities will provide favorable data or that the data will be acceptable to any government regulatory agency to provide us with approval to market and sell our products or product candidates. Moreover, even if we and our collaborators believe the results of our product development activities are favorable, regulatory authorities may interpret the results differently than we do.



Page 26



---





We have significant medical device component engineering and manufacturing, as well as finished goods and packaging manufacturing operations. The manufacturing processes used in the production of finished medical devices are subject to FDA regulatory inspection, and must comply with FDA regulations, including its Quality Systems Regulation, (QSR), which sets forth the cGMP requirements for medical devices. The QSR requires manufacturers of finished medical devices to follow elaborate design, testing, control, documentation and other quality assurance procedures during the finished device manufacturing process. Our FDA registered facilities are subject to FDA inspection at any time for compliance with the QSR and other FDA regulatory requirements. Failure to comply with these regulatory requirements and similar foreign requirements may result in civil and criminal enforcement actions, including financial penalties, seizures, injunctions or other measures. In some cases, failure to comply with the QSR could prevent us or our customers from marketing products or gaining clearance to market additional products. Our products must also comply with state and foreign regulatory requirements.



Process Development, Manufacturing and Distribution



We have significant manufacturing capabilities for our medical devices. Our medical device manufacturing capabilities include core competencies in each of the following areas: sutures, metals, plastics, textiles and assembly. Our sutures manufacturing capabilities include the ability to make our Quill barbed suture with various approved polymer materials. Our metal manufacturing capabilities include bending, grinding, drilling, polishing, chemical etching, thermal curing and wire winding. Our plastics manufacturing capabilities include injection molding, insert molding and wire coating. Our textiles manufacturing capabilities include braiding and embroidery of sutures. Our assembly capabilities include small lot assembly, suture attachment, kit assembly and packaging.

We also have significant manufacturing capabilities for our biomaterials and coating technologies. We have the capability to manufacture ePTFE vascular grafts. We also have the capability to manufacture surgical meshes for our Vascular Wrap product. In addition, we have a dedicated coating facility to process and manufacture our various drug-coated devices.

We devote considerable resources to develop procedures and process controls for our product candidates to ensure successful technology transfer for commercial scale manufacturing. We expect that process and assay development performed during preclinical and clinical stages of manufacturing will result in products with the desired ease of use and stability. These activities include scaling up production methods, developing quality control systems, optimizing batch-to-batch reproducibility, testing sterilization methods and establishing reliable sources of raw materials for synthesizing proprietary products.

Sales and Marketing

We market and sell various medical device products through two surgeon-focused specialty sales organizations.

Because of the nature of our combination drug-devices, we believe that our sales representatives must understand the underlying biology of how our combination drug-devices work in order to effectively convert surgeons to the use of our products. We believe that the typical sale cycle of our combination drug-devices will require evidence-based data which will require our sales representatives to have a strict understanding of conclusions from prospective clinical trials that demonstrate statistically why one approach is superior to another using comparative data.

We have a sales team comprised of over 140 individuals focused primarily on selling product lines to interventional radiologists, interventional cardiologists, vascular surgeons, general surgeons and aesthetic surgeons and ophthalmologists. This sales team is supplemented by a network of over 160 independent distributors.

These sales forces target physician customers directly, as well as alternate site health care providers such as ambulatory surgery centers or urgent care centers. The primary goal of our sales teams is to increase market share of our highest margin products into markets that we believe are not well served by our larger competitors. These competitors sell their products primarily to larger hospitals or large group purchasing organizations based on contracts for a range of products and do not employ direct sales professionals targeting our key market segments.





Page 27



---





Competitive Conditions



We expect to face competition from technologies targeting the same diseases and clinical indications that our technologies target. Some of the companies developing these technologies have substantially greater product development capabilities and financial, scientific, manufacturing, sales and marketing resources and experience than we do.

The medical device, biotechnology and pharmaceutical industries are subject to rapid and substantial technological change. There can be no assurance that developments by others will not render obsolete our products or technologies or that we will be able to keep pace with technological developments. Some competitive products have an entirely different approach or means to accomplish the desired therapeutic effect than our product candidates. These competitive products, including enhancements or modifications made to such products in the future, could be more effective and less costly than our products, technologies or our product candidates.

There are a number of companies developing competing drug-eluting coronary stents or other treatments for restenosis that may be considered to be directly competitive with our technology. In particular, Johnson & Johnson (JNJ) has developed and commercialized a coronary drug- eluting stent using the drug rapamycin, which has been approved for use in the U.S., E.U., Japan and various other countries throughout the world. In addition Abbott Laboratories, Medtronic, Inc. and several other competitors are developing drug-eluting stents, and have commercially launched these competing products in the E.U. and other countries throughout the world.  Medtronic recently received approval and launched its drug-eluting stent product in the U.S., and Abbott Laboratories is expected to launch its drug-eluting stent product in the U.S. in 2008. Successful clinical results, regulatory review and commercialization of any of these or other technologies to treat restenosis following angioplasty or stent placement could have a material adverse impact on our business. In addition, other companies are developing various other technologies for the reduction of restenosis which may compete with our approach should these products be approved.

We compete with a number of additional large companies across various of our product lines. These competitors have substantially greater business and financial resources than us. These competitors include JNJ and the U.S. Surgical division of Covidien in surgical sutures and wound closure devices; C.R. Bard Inc., the Allegiance division of Cardinal Health, Inc. and the Sherwood, Davis & Geck division of Tyco International Ltd. in biopsy needle devices; and Alcon, Inc., Allergan, Inc. and the Allegiance division of Cardinal Health, Inc. in ophthalmology products.



Economic Dependence



We are dependent upon the 1997 license agreement with BSC as 38% of our gross revenue from continuing operations for the year ended December 31, 2007 was generated from this contractual relationship (2006  51%). We are dependent upon BSC in regards to our future revenues and the commercial success of our lead product, the paclitaxel-eluting coronary stent systems.  We also anticipate that a substantial amount of our revenue for the next few years will be derived from BSC.  The royalty revenue that we received from BSC is in U.S. dollars, while the royalties are calculated on sales generated by BSC on a world-wide basis which are subject to foreign market, currency and regulatory risks.   See the section entitled Risk Factors  Risks Related to Our Business for further discussion on this topic.



Employees



As of December 31, 2007, on a worldwide basis, we have 1,613 employees, including 1,036 in manufacturing, 131 in R&D, 202 in sales and marketing and 244 in administration. In addition, we have contractual arrangements with scientists at various research and academic institutions. All personnel or their management companies execute confidentiality agreements with us. While we will continue to seek to hire highly qualified employees, we believe that we have employed sufficiently qualified personnel.



Facilities





Page 28



---





We have 18 facilities located in five different countries, which include Canada, the U.S., the United Kingdom, Denmark and Switzerland. Of the 18 facilities, 12 are primarily used to manufacture and distribute medical devices or materials for medical device products. Our other six facilities are primarily used for research, development and administrative activities and with respect to our Henrietta, New York facility, a combination of research, development, administration and a limited amount of manufacturing. Collectively, these facilities have over 650,000 square feet of modern technical manufacturing, research and administrative operations. The following chart summarizes the facilities where our domestic and international operations occur:



|                                   |                                          |                  
|---------------------------------- | ---------------------------------------- | -----------------
|                                   |                                          |                  
|Location                           | Primary Purpose                          | Owned or Leased  
|Chicago, IL                        | Administration                           | Leased           
|Lausanne, Switzerland              | Administration                           | Leased           
|Gainesville, FL                    | Manufacturing                            | Owned            
|Henrietta, NY                      | Manufacturing and Research & Development | Leased           
|Herndon, VA                        | Research & Development Manufacturing     | Leased           
|Laguna Hills, CA                   | Manufacturing                            | Leased           
|North Bend, WA                     | Administration                           | Leased           
|Reading, PA                        | Manufacturing                            | Owned            
|Rincon, Puerto Rico (2 facilities) | Manufacturing                            | 1 Leased, 1 Owned
|Stenlose, Denmark (3 facilities)   | Manufacturing                            | Owned            
|Syracuse, NY(1)                    | Manufacturing                            | Owned            
|Taunton, United Kingdom            | Manufacturing                            | Owned            
|Vancouver, B.C. (2 facilities).    | Administration and Research              | Leased           
|Wheeling, IL                       | Manufacturing                            | Owned            



_______________________________________________________

(1)

In process of shutting down.



We have several important, and in some cases proprietary, manufacturing capabilities and processes. These include specific capabilities in the areas of various metal bending, grinding and chemical etching, electroplating and electropolishing, plastic injection molding, wire coating, braiding and weaving of surgical textiles and kit assembly and packaging.



Reimbursement



In the U.S., healthcare providers generally rely on third-party payers, including both private health insurance plans and governmental payers, such as Medicare and Medicaid, to cover and reimburse all or part of the cost of a medical device and the procedures in medical devices that are used. Our ability to commercialize human therapeutic products and product candidates successfully will depend in part on the extent to which coverage and reimbursement for such products and related treatments will be available from government health administration authorities, private health insurers and other third-party payers or supported by the market for these products. Third-party payers are increasingly challenging the price of medical products and services and instituting cost containment measures to control or significantly influence the purchase of medical products and services. These cost containment measures, if instituted in a manner affecting the coverage for or payment of our products, could have a material adverse effect on our ability to operate profitably.



There can be no assurance that third-party payers coverage and reimbursement will be available or sufficient for our current products or the products we might develop. We believe that recommendations and endorsements by physicians will be essential for market acceptance of our products, and we do not know whether these recommendations or endorsements will be obtained. We also believe that surgeons will not use these products unless they determine, based on clinical data and other factors, that the clinical benefits to patients and cost savings achieved through use of these products outweigh their cost. Acceptance among physicians may also depend upon the ability to train surgeons and other potential users of our products and the willingness of such users to learn these relatively new techniques.





Page 29



---





In the U.S., there have been and we expect there will continue to be a number of legislative and regulatory proposals to change the healthcare system in ways that could significantly affect our business. Efforts by governmental and third-party payers to reduce healthcare costs or the announcement of legislative proposals or reforms to implement government controls could cause a reduction in sales or in the selling price of our products, which could seriously harm our business. We cannot predict the impact on our business of any legislation or regulations related to the healthcare system that may be enacted or adopted in the future.



Environmental Protection



Our business is subject to a broad range of governmental regulation and requirements, including federal, state, local and foreign environmental laws and regulations governing, among other matters, air emissions, wastewater discharges, workplace health and safety as well as the use, handling, storage and disposal of hazardous materials and remediation of contamination associated with the release of these materials at or from our facilities or off-site disposal locations. Some of these laws can impose liability for remediation costs on a party regardless of fault or the lawfulness of its conduct. Many of our manufacturing processes involve the use and subsequent regulated disposal of hazardous materials. To date, such matters have not had a material adverse impact on our business or financial condition. We cannot assure you, however, that such matters will not have such an effect in the future.







Page 30



---





RISK FACTORS



You should consider carefully the following information about these risks, together with all of the other information contained in this annual information form. Additional risks and uncertainties not currently known to us or that we currently deem immaterial may impair our business operations. If any of the following risks actually occur, our business, results of operations and financial condition could be harmed.



Risks Related to Our Business



We were not profitable for the year ended December 31, 2007 and may not be able to regain and maintain profitability.



We began operations in 1992 and have incurred a loss from operations in each of the years of our existence except for fiscal 2004 and 2006.  As of December 31, 2007, our accumulated deficit was $102.5 million.  Our ability to become profitable again will depend on, among other things, the successful commercialization of new technologies, and the successful expansion of our direct sales force, particularly in Europe, while maintaining good relationships with our distributors.



While we believe that our available cash and cash equivalents, working capital and cash generated from operations should be sufficient to meet our operating and capital needs for the year ending December 31, 2008, our funding needs may vary depending upon a number of factors including: progress of our research and development programs; costs associated with completing clinical studies and the regulatory process; collaborative and license arrangements with third parties; opportunities to in-license complementary technologies; cost of filing, prosecuting and enforcing our patent claims and other intellectual property rights; expenses associated with litigation; and potential acquisitions and technological and market developments. Consequently, we may need to raise additional funds to satisfy the funding of our current research and development programs, to repay or refinance our indebtedness, to commence or to continue the preclinical studies and clinical studies necessary to obtain marketing approval contractual obligations, to meet other operating and capital requirements, or for potential acquisitions and in-licensing of technologies. Additional financing may not be available, and even if available, may not be on acceptable terms. We may seek to raise additional capital through an offering of equity or debt.



We depend on BSC for a significant amount of our future revenues and development of TAXUS.



Although the acquisition of our Medical Products segment has diversified our revenue, we anticipate that a significant amount of our revenue for the next few years will be derived from and dependent upon royalty revenues from BSC. We do not have control over the sales and marketing efforts, stent pricing, production volumes, distribution or regulatory environment related to BSCs paclitaxel-eluting coronary stent program. Our involvement is limited to the terms of our 1997 license agreement, (as amended) with BSC and Cook, which provides for the receipt of royalty revenue based on the net sales of TAXUS and specifies the applicable royalty rates.



Royalty revenue from BSC for the year ended December 31, 2007 decreased by 31% from 2006, which BSC has attributed to a decline in the number of angioplasty procedures in the U.S.  If BSC is impaired in its ability to market and distribute TAXUS, whether for this reason or due to a failure to comply with applicable regulatory requirements, discovery of a defect in the device, increased incidence of adverse events or identification of other safety issues, or previously-unknown problems with the manufacturing operations for TAXUS (any of which could, under certain circumstances, result in a manufacturing injunction), our revenues could be further significantly reduced. BSCs failure to resolve these issues in a timely manner and to the satisfaction of the FDA and other regulatory authorities, or the occurrence of similar problems in the future, could delay the launch of TAXUS Liberté in the United States and could have a significant impact on our royalty revenue from sales of TAXUS. Additionally, BSC may terminate our 1997 license agreement under certain circumstances, including, if BSC is unable to acquire a supply of paclitaxel at a commercially reasonable price, if BSC reasonably determines that the paclitaxel-eluting coronary stent is no longer commercially viable, or if our license agreement with the National Institutes of Health (NIH), certain of which rights are sublicensed to BSC, terminates. During the year ended December 31, 2007, revenue from BSC represented approximately 38% of our total revenue from continuing operations, compared to 51% for the year ended December 31, 2006.



Page 31



---





The amounts payable by BSC to us vary from 1% to 9% of net sales depending on various factors, including volume of sales from time to time and patent protection laws in the country of sale. From these amounts, we must pay certain royalties to our licensors, including the NIH and the University of British Columbia (UBC), under license agreements. The average gross royalty rate earned in the year ended December 31, 2007 on BSCs net sales for the period October 1, 2006 to September 30, 2007 was 7.6% for sales in the United States (as compared to 7.9% for the same period of the prior year) and 5.6% for sales in other countries (as compared to 6.0% for the same period of the prior year). There is no guarantee that royalty payments under our 1997 license agreement with BSC will continue, and demand for BSCs paclitaxel-eluting coronary stent products could continue to decline as a result of the factors stated above, as well as competition, technological change, reimbursement or other factors.  Also, the royalty rate payable by BSC could decline if and when patent protection expires, or no longer exists as defined by our license agreement with BSC, in certain jurisdictions.



Boston Scientific may be enjoined from the selling, or otherwise become subject to limitations applicable to its ability to sell, TAXUS in the U.S.



Our royalty revenue derived from the sale of paclitaxel-eluting coronary stents depends on BSC’s ability to continue to sell its TAXUS Express 2TM stent and to launch next generation paclitaxel-eluting stents including the TAXUS LibertéTM stent, in the U.S.  Historically, stent manufacture and sale is the subject of a substantial amount of U.S. patent litigation, and we anticipate that our licensees, including BSC and others, may be involved in material legal proceedings related to paclitaxel-eluting stents.



Many of the products we are counting on to grow our business are not yet ready for sale or have only recently been introduced for sale.



Many of the products we are counting on to drive future growth are not yet ready for sale or have only recently been introduced for sale. For example, Vascular Wrap and 5-FU CVC have not yet been approved for sale, our HemoStream Dialysis Catheter has been approved for sale but has not yet been commercially launched, and our Quill SRS product has only recently become available for sale. If any of these or our other products are not approved for sale or do not achieve market acceptance, our ability to generate revenues will be adversely affected



If our products are alleged to be harmful, we may not be able to sell them, we may be subject to product liability claims not covered by insurance and our reputation could be damaged.



The nature of our business exposes us to potential liability risks inherent in the testing, manufacturing and marketing of pharmaceutical products and medical devices. Using our drug candidates or devices in clinical trials may expose us to product liability claims. These risks will expand with respect to drugs or devices, if any, that receive regulatory approval for commercial sale. In addition, some of the products we manufacture and sell are designed to be implanted in the human body for varying periods of time. Even if a drug or device were approved for commercial use by an appropriate governmental agency, there can be no assurance that users will not claim that effects other than those intended may have resulted from our products. Component failures, manufacturing flaws, quality system failures, design defects, inadequate disclosure of product-related risks or product-related information or other safety issues with respect to these or other products we manufacture or sell could result in an unsafe condition or injury to, or death of, a patient.



In the event that anyone alleges that any of our products are harmful, we may experience reduced consumer demand for our products or our products may be recalled from the market. In addition, we may be forced to defend individual or class action lawsuits and, if unsuccessful, to pay a substantial amount in damages. A recall of some of our products could result in exposure to additional product liability claims, lost sales and significant expense to perform the recall. The outcome of litigation, particularly class action lawsuits, is difficult to assess or quantify. Plaintiffs in these types of lawsuits often seek recovery of very large or indeterminate amounts, including not only actual damages, but also punitive damages. The magnitude of the potential loss relating to these types of lawsuits may remain unknown for substantial periods of time. In addition, the cost to defend against any future litigation may be significant.





Page 32



---





We do not have insurance covering our costs and losses as a result of any recall of products or devices incorporating our technologies whether such recall is instituted by a device manufacturer or us as required by a regulatory agency.  Insurance to cover costs and losses associated with product recalls is expensive.  If we seek insurance covering product recalls in the future it may not be available on acceptable terms.  Even if obtained, insurance may not fully protect us against potential liability or cover our losses. Some manufacturers that suffered such claims in the past have been forced to cease operations or even to declare bankruptcy.



We do have insurance covering product liability.  However, our insurance may not fully protect us from potential product liability claims.  If a product liability claim or a series of claims is brought against us in excess of our insurance coverage, our business could suffer.  Some manufacturers that suffered such claims in the past have been forced to cease operations or even to declare bankruptcy.



Our success depends on the successful commercialization of our technology.



The successful commercialization of our technology is crucial for our success. Successful product development in the pharmaceutical industry is highly uncertain and very few research and development projects produce a commercial product. Medical devices, pharmaceutical applications and surgical implants utilizing our technology are in various stages of clinical and commercial development and face a variety of risks and uncertainties. Principally, these risks and uncertainties include the following:



o

Future clinical trial results may show that some or all of our technology, or the technology of our strategic collaborators that incorporate our technology, is not safe or effective.



o

Even if our technology is shown to be safe and effective, we and our strategic collaborators may face significant or unforeseen difficulties in manufacturing our medical devices or the medical devices and surgical implants that use our technology. These difficulties may become apparent when we or our strategic collaborators manufacture the medical devices or surgical implants on a small scale for clinical trials and regulatory approval or may only become apparent when scaling-up the manufacturing to commercial scale.



o

Even if our technology-based products are successfully developed, receive all necessary regulatory approvals and are commercially produced, there is no guarantee that there will be market acceptance of them or that they will not cause unanticipated side effects in patients. For example, if drug-eluting stents are found to cause, or are perceived to be the cause of, blood clots in patients, then sales of our drug-eluting stent products may be adversely affected.  Royalty revenue from BSC for the year ended December 31, 2007 decreased by 31% from 2006, which BSC has attributed to a decline in the number of angioplasty procedures in the U.S.  During the year ended December 31, 2007, revenue from BSC represented approximately 38% of our total revenue from continuing operations, compared to 51% for the year ended December 31, 2006.   In addition, there is no guarantee that there will be market acceptance of our products. Our ability to achieve market acceptance for any of our products will depend on a number of factors, including whether or not competitors may develop technologies which are superior to or less costly than our technology-based products, and whether governmental and private third-party payers provide adequate coverage and reimbursement for our products, with the result that our technology-based products, even if they are successfully developed, manufactured and approved, may not generate significant revenues.



If we are unsuccessful in dealing with any of these risks, or if we are unable to successfully commercialize our technology for some other reason, it would likely seriously harm our ability to generate revenue.



We depend on our strategic collaborators for the development, regulatory approval, testing, manufacturing and the potential commercialization of our products.



Historically, our strategy has been to enter into various arrangements with corporate and academic collaborators, licensors, licensees and others for the research, development, clinical testing, regulatory approval, manufacturing, marketing and commercialization of our product candidates. For instance, we collaborate with BSC and Cook to develop and market paclitaxel-eluting coronary and peripheral stents, and with Baxter to manufacture and market our CoSeal® product for use as both a sealant and adhesion prevention product. Strategic collaborators, both existing (particularly BSC) and those that we may collaborate with in the future, are or may be essential to the development of our technology and potential revenue and we have little control over or access to information regarding our collaborators activities with respect to our products.



Page 33



---







Our strategic collaborators may fail to successfully develop or commercialize our technology to which they have rights for a number of reasons, including:



o

failure of a strategic collaborator to continue, or delays in, its funding, research, development and commercialization activities;



o

the pursuit or development by a strategic collaborator of alternative technologies, either on its own or with others, including our competitors, as a means for developing treatments for the diseases targeted by our programs;



o

the preclusion of a strategic collaborator from developing or commercializing any product, through, for example, litigation or other legal action; and



o

the failure of a strategic collaborator to make required milestone payments, meet contractual milestone obligations or exercise options which may result in our terminating applicable licensing arrangements.



We have and we expect that we will continue to enter into licensing agreements with third parties to give us access to technologies that we may use to develop products through our strategic collaboration and partnership arrangements. The technologies governed by these license agreements may be critical to our ability to maintain our competitive advantage in our existing products and to develop future products. For example, through licenses with NIH and UBC, we have been granted access to technologies that have contributed to the development of the TAXUS paclitaxel-eluting coronary stent.



Pursuant to terms of existing license agreements, licensors will have the ability under certain specified circumstances to terminate the license. Events which may allow licensors to exercise these termination provisions include our bankruptcy, sub-licensing without the licensors consent, a transaction which results in our change of control, our failure to use the required level of diligence efforts to develop, market and sell products based on the licensed technology, our inability to maintain adequate levels of insurance with respect to the licensed technologies or other acts or omissions that may constitute a breach by us of our license agreement. In addition, any failure to continue to have access to these technologies may materially affect the benefits that we currently derive from the collaboration and partnership arrangements and may negatively impact our results and operations.



If our process related to product development does not result in an approved and commercially successful product, our business could be adversely affected.



We focus our research and development activities on areas in which we have particular strengths. The outcome of any development program is highly uncertain, notwithstanding how promising a particular program may seem. Success in preclinical and early-stage clinical trials may not necessarily translate into success in large scale clinical trials. Further, to be successful in clinical trials, increased investment will be necessary, which will adversely affect our short-term profitability.



In addition, we will need to obtain and maintain regulatory approval in order to market new products. Notwithstanding the outcome of clinical trials for new products, regulatory approval may not be achieved. The results of clinical trials are susceptible to varying interpretations that may delay, limit or prevent approval or result in the need for post-marketing studies. In addition, changes in regulatory policy for product approval during the period of product development and review by regulators of a new application may cause delays or rejection. Even if we receive regulatory approval, this approval may include limitations on the indications for which we can market the product. There is no guarantee that we will be able to satisfy the applicable regulatory requirements, and we may suffer a significant variation from planned revenue as a result.



Our current and planned clinical trials may not begin on time, or at all, and may not be completed on schedule, or at all.





Page 34



---





The commencement or completion of any of our clinical trials may be delayed or halted for numerous reasons, including, but not limited to, the following:



o

the FDA or other regulatory authorities do not approve a clinical trial protocol or a clinical trial, or place a clinical trial on hold;

o

the data and safety monitoring committee of a clinical trial recommends that a trial be placed on hold or suspended;

o

patients do not enroll in clinical trials at the rate we expect;

o

patients are not followed-up at the rate we expect;

o

patients experience adverse side effects or events related to our products;

o

patients die or suffer adverse medical effects during a clinical trial for a variety of reasons, including the advanced stage of their disease and medical problems, which may or may not be related to our product candidates;

o

regulatory inspections of our clinical trials or manufacturing facilities, which may, among other things, require us to undertake corrective action or suspend or terminate our clinical trials if investigators find us not to be in compliance with regulatory requirements;

o

the failure of our manufacturing process to produce finished products which conform to design and performance specifications;

o

changes in governmental regulations or administrative actions;

o

the interim results of the clinical trial are inconclusive or negative;

o

pre-clinical or clinical data is interpreted by third parties in different ways; or

o

our trial design, although approved, is inadequate to demonstrate safety and/or efficacy.



Clinical trials may require the enrolment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Patient enrolment in clinical trials and completion of patient follow-up in clinical trials depend on many factors, including the size of the patient population, the nature of the trial protocol, the proximity of patients to clinical sites and the eligibility criteria for the study and patient compliance. For example, patients may be discouraged from enrolling in our clinical trials if the trial protocol requires them to undergo extensive post-treatment procedures to assess the safety and effectiveness of our stents, or they may be persuaded to participate in contemporaneous trials of competitive products. Delays in patient enrolment or failure of patients to continue to participate in a study may cause an increase in costs and delays or result in the failure of the trial.



Our clinical trial costs will increase if we have material delays in our clinical trials or if we need to perform more or larger clinical trials than planned. Adverse events during a clinical trial could cause us to repeat a trial, terminate a trial or cancel the entire program.



Pre-clinical development is a long, expensive and uncertain process, and we may terminate one or more of our pre-clinical development programs.



We may determine that certain pre-clinical product candidates or programs do not have sufficient potential to warrant the allocation of resources. Accordingly, we may elect to terminate our programs for such product candidates. If we terminate a pre-clinical program in which we have invested significant resources, our prospects will suffer, as we will have expended resources on a program that will not provide a return on our investment and will have missed the opportunity to have allocated those resources to potentially more productive uses.



We may not be able to protect our intellectual property or obtain necessary intellectual property rights from third parties, which could adversely affect our business.



Our success depends, in part, on ensuring that our intellectual property rights are covered by valid and enforceable patents or effectively maintained as trade secrets and our ability to detect violations of our intellectual property rights and enforce such rights against others.





Page 35



---





The validity of our patent claims depends, in part, on whether prior art references described or rendered obvious our inventions as of the filing date of our patent applications. We may not have identified all prior art, such as U.S. and foreign patents or published applications or published scientific literature, that could adversely affect the validity of our issued patents or the patentability of our pending patent applications. For example, patent applications in the United States are maintained in confidence for up to 18 months after their filing. In some cases, however, patent applications remain confidential in the U.S. Patent and Trademark Office, which we refer to as the U.S. Patent Office, for the entire time prior to issuance as a U.S. patent. Patent applications filed in countries outside the United States are not typically published until at least 18 months from their first filing date. Similarly, publication of discoveries in scientific or patent literature often lags behind actual discoveries. Therefore, we cannot be certain that we were the first to invent, or the first to file patent applications related to, our technology. In the event that a third party has also filed a U.S. patent application covering a similar invention, we may have to participate in an adversarial proceeding, known as an interference, declared by the U.S. Patent Office to determine priority of invention in the United States. It is possible that we may be unsuccessful in the interference, resulting in a loss of some portion or all of our U.S. patent positions. The laws in some foreign jurisdictions do not protect intellectual property rights to the same extent as in the United States, and many companies have encountered significant difficulties in protecting and defending such rights in foreign jurisdictions. If we encounter such difficulties or we are otherwise precluded from effectively protecting our intellectual property rights in foreign jurisdictions, our business prospects could be substantially harmed.



We have filed and are pursuing patent applications in Canada, the United States and other jurisdictions. Through either direct ownership or licence, we hold more than 250 U.S. patents and have over 230 pending U.S. patent applications and over 620 issued non-U.S. patents and 560 pending non-U.S. patent applications that cover various aspects of our technology, where many of these patents and applications have foreign counterparts.  We may not be able to obtain patent protection for key elements of our technology, as the patent positions of pharmaceutical, biotechnology and medical device companies are uncertain and involve complex legal and factual questions for which important legal issues are largely unresolved. For example, no consistent policy has emerged regarding the scope of health-related patent claims that are granted by the U.S. Patent Office or enforced by the U.S. federal courts. Rights under any of our issued patents may not provide us with commercially meaningful protection for our products or afford us a commercial advantage against our competitors or their competitive products or processes. In addition, even if a patent is issued, the coverage claimed in a patent application may be significantly reduced in the patent as granted.



There can be no assurance that:



o

patent applications will result in the issuance of patents;

o

additional proprietary products developed will be patentable;

o

licenses we have obtained from third parties that we use in connection with our technology will not be terminated;

o

patents issued will provide adequate protection or any competitive advantages;

o

patents will not be successfully challenged by any third parties; or

o

the patents of others will not impede our or our collaborators ability to commercialize our technology.



For example, the drug paclitaxel is itself not covered by composition of matter patents. Therefore, although we are developing an intellectual property portfolio around the use of paclitaxel for intended commercial applications, others may be able to engage in off-label use of paclitaxel for the same indications, causing us to lose potential revenue. Furthermore, others may independently develop similar products or technologies or, if patents are issued to us, design around any patented technology developed by us, which could affect our potential to generate revenues and harm our results of operations.



Patent protection for our technology may not be available based on prior art. The publication of discoveries in scientific or patent literature often lags behind actual discoveries. As a consequence, there may be uncertainty as to whether we or a third party were the first creator of inventions covered by issued patents or pending patent applications or that we or a third party were the first to file patent applications for such inventions. Moreover, we might have to participate in interference proceedings declared by the U.S. Patent Office, or other proceedings outside the United States, including oppositions, to determine priority of invention or patentability, which could result in substantial cost to us even if the outcome were favorable. An unfavorable outcome in an interference or opposition proceeding could preclude us, our collaborators and our licensees from making, using or selling products using the technology or require us to obtain license rights from prevailing third parties. We do not know whether any prevailing party would offer us a license on commercially acceptable terms, if at all. We may also be forced to pay damages or royalties for our past use of such intellectual property rights, as well as royalties for any continued usage.



Page 36



---







As part of our patent strategy, we have filed a variety of patent applications internationally. Oppositions have been filed against various granted patents that we either own or license and which are related to certain of our technologies.  For example, at the EPO, various patents either owned or licensed by or to the Company are in opposition proceedings. In EP0809515 (which the Company licenses from (and to) BSC), the EPO held an oral hearing on January 30, 2008, and thereafter revoked this patent.  This decision of the opposition board may be appealed.  Oppositions against European Patent Nos. EP0876165 (which relates to our Co-SealTM product), EP1429664 (which relates to our Quill SRS products), EP0975340, EP1118325, EP1155689 and EP1407786 are in progress, with briefs being exchanged. The grant of European Patent No. EP0830100, which relates to our ePTFE vascular graft products, was opposed with an oral hearing conducted on September 28, 2006. At the end of the hearing, the EPO determined that an amended form of the patent was valid. The opponent appealed this decision On March 1, 2006, the Board of Appeals of the Japanese Patent Office issued a final order of revocation regarding certain claims of our Japanese Patent No. 3423317, directed to a stent coated with paclitaxel. Angiotech appealed this decision to Japans Intellectual Property High Court, and after holding several hearings, the court ruled in November 2007 in favor of the Japanese Patent Office.  Angiotech has appealed this decision to the Japanese Supreme Court.   The ultimate outcomes of these oppositions, including possible appeals, are uncertain at this time.



Our future success and competitive position depend in part on our ability to obtain and maintain certain proprietary intellectual property rights used in our approved products and principal product candidates. Any such success depends in part on effectively prosecuting claims against others who we believe are infringing our rights and by effectively defending claims of intellectual property infringement brought by our competitors and others. The stent-related markets have experienced rapid technological change and obsolescence in the recent past, and our competitors have strong incentives to stop or delay us from introducing new products and technologies. See We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.



We do not know whether the patents that we have received or licensed, or may be able to obtain or license in the future, would be held valid or enforceable by a court or whether a competitors technology or product would be found to infringe such patents. Further, we have no assurance that third parties will not properly or improperly modify or terminate any license they have granted to us.



We have obtained licenses from third parties with respect to their intellectual property that we use in connection with our technology. However, we may need to obtain additional licenses for the development of our current or future products. Licenses may not be available on satisfactory terms or at all. If available, these licenses may obligate us to exercise diligence in bringing our technology to market and may obligate us to make minimum guarantee or milestone payments. These diligence and milestone payments may be costly and could seriously harm our business. We may also be obligated to make royalty payments on the sales, if any, of products resulting from licensed technology and may be responsible for the costs of filing and prosecuting patent applications. These costs could affect our results of operations and decrease our earnings.



Certain of our key technology includes trade secrets and know-how that may not be protected by patents. There can be no assurance that we will be able to protect our trade secrets. To help protect our rights, we undertake to require employees, consultants, advisors and collaborators to enter into confidentiality agreements. We cannot assure you that all employees, consultants, advisors and collaborators have signed such agreements, or that these agreements will adequately protect our trade secrets, know-how or other proprietary information in the event of any unauthorized use or disclosure. Furthermore, any confidentiality agreements in existence may be breached and we may not have adequate remedies for any such breach. Any disclosure of confidential data into the public domain or to third parties could allow our competitors to learn our trade secrets and use the information in competition against us.



We have significantly increased our levels of research and development and the size of our sales force in anticipation of the growth of our business, resulting in increased expenses. Therefore, if sales fail to grow according to our plans, we will have a mismatch between our revenues and these increased expenses.



Page 37



---





We have recently increased our levels of research and development and the size of our sales force in the U.S., Europe and other parts of the world in order to further develop our product pipeline and to better commercialize our existing and future products. As a result, we have incurred significant expenses related to these cost centers of our business, which we expect to continue at their new higher levels in the future. If our development efforts fail to generate new products or we are unable to effectively commercialize our existing and future products, the revenues generated by our products may not offset these costs, which could adversely affect our financial condition or results of operations.

If certain single-source suppliers fail to deliver key product components in a timely manner, our manufacturing ability would be impaired and our product sales could suffer.



We depend on certain single-source suppliers that supply components used in the manufacture of certain of our products, including our Vascular Wrap and Quill SRS products. If we need alternative sources for key component parts for any reason, these component parts may not be immediately available to us. If alternative suppliers are not immediately available, we will have to identify and qualify alternative suppliers, and production of these components may be delayed. We may not be able to find an adequate alternative supplier in a reasonable time period or on commercially acceptable terms, if at all. Shipments of affected products have been limited or delayed as a result of such problems in the past, and similar problems could occur in the future. Our inability to obtain our key source supplies for the manufacture of our products may require us to delay shipments of products, harm customer relationships or force us to curtail or cease operations.

If physicians do not recommend and endorse our products or products that use our technology, or if our working relationships with physicians deteriorate, our products or products that use our technology may not be accepted in the marketplace, which could adversely affect our sales and royalty revenues.



In order for us to sell our products or continue to receive royalty revenues from the sale of products that use our technologies, physicians must recommend and endorse them. We believe that recommendations and endorsements by physicians will be essential for market acceptance of our products, and we do not know whether we will obtain the necessary recommendations or endorsements from physicians. Acceptance of our products or of products that use our technology depends on educating the medical community as to the distinctive characteristics, perceived benefits, safety, clinical efficacy and cost-effectiveness of these products compared to products of competitors, and on training physicians in the proper application of these products. If we are not successful in obtaining the recommendations or endorsements of physicians for our products or our collaborators are not successful in doing the same for their products that use our technology, our sales and royalty revenues may not increase or may decline.

In addition, if we fail to maintain our working relationships with physicians, many of our products may not be developed and marketed in line with the needs and expectations of professionals who use and support our products. The research, development, marketing and sales of many of our new and improved products is dependent upon our maintaining working relationships with physicians. We rely on these professionals to provide us with considerable knowledge and experience regarding our products and the marketing of our products. Physicians assist us as researchers, marketing consultants, product consultants, inventors and as public speakers. If we are unable to maintain our strong relationships with these professionals and continue to receive their advice and input, the development and marketing of our products could suffer, which could adversely affect the acceptance of our products in the marketplace and our sales.

If we are unable to license new technologies to utilize in the development of products, our ability to maintain our competitive advantage in our existing products and to develop future products may be adversely affected.



We have entered into, and we expect that we will continue to enter into, licensing agreements with third parties to give us access to technologies that we may use to develop products through our strategic collaboration and partnership arrangements. The technologies governed by these license agreements may be critical to our ability to maintain our competitive advantage in our existing products and to develop future products. For example, through a license with Harvard University and through sublicenses with the National Institutes of Health and University of British Columbia we have been granted access to technologies that have contributed to the developments of the Vascular Wrap component of our VaxSys SynergyTM product.



Page 38



---





Pursuant to terms of our existing license agreements, licensors have the right under certain specified circumstances to terminate their respective licenses. Events that may allow licensors to exercise these termination provisions include:

o

our bankruptcy;

o

sub-licensing without the licensors consent;

o

a transaction which results in a change of control of us;

o

our failure to use the required level of diligence to develop, market and sell products based on the licensed technology;

o

our failure to maintain adequate levels of insurance with respect to the licensed technologies; or

o

other acts or omissions that may constitute a breach by us of our license agreement.



In addition, any failure to continue to have access to these technologies may materially adversely affect the benefits that we currently derive from our collaboration and partnership arrangements and may adversely affect our results and operations.

Compulsory licensing and/or generic competition may affect our business in certain countries.



In a number of countries governmental authorities and other groups have suggested that companies which manufacture medical products (i.e., pharmaceuticals and medical devices) should make products available at a low cost. In some cases, governmental authorities have held that where a pharmaceutical or medical device company does not do so, their patents might not be enforceable to prevent generic competition. Alternatively, some governmental authorities could require that we grant compulsory licenses to allow competitors to manufacture and sell their own versions of our products, thereby reducing our sales or the sales of our licensee(s). In all of these situations, the results of our operations in these countries could be adversely affected.



We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.



In connection with maintaining the value of our various intellectual property and exclusivity rights, we regularly evaluate the activities of others worldwide. Our success will depend, in part, on our ability to obtain patents, or licenses to patents, maintain trade secret protection and enforce our rights against others. Should it become necessary to protect those rights, we intend to pursue all cost-efficient strategies, including, when appropriate, negotiation or litigation in any relevant jurisdiction.



For example, we have been involved in several litigation and opposition proceedings against Conor MedSystems (Conor) in connection with Conors CoStar paclitaxel eluting stent, where the Cordis division of JNJ purchased Conor in the first quarter of 2007.  On July 5, 2007, JNJ announced by press release and filing with the SEC, that they were withdrawing CoStar stent from Europe, Asia, and Latin America where it had already obtained regulatory approval, and were discontinuing efforts to obtain FDA approval for CoStar stent in the U.S.  Thereafter, Conor withdrew from its opposition to the grant of our New Zealand patent, and along with BSC filed a letter with the U.S. District Court of Delaware announcing a stipulated dismissal of BSCs infringement action against CoStar.  In September 2007, we reached a settlement agreement with Conor and its parent company JNJ whereby Conor agreed to discontinue its participation in all paclitaxel stent related litigation and opposition proceedings against Angiotech.  Thus, litigation with Conor in the Netherlands, Australia, and the U.K. has ended, with the caveat that Angiotech is continuing with its appeal in the U.K. House of Lords, of the decision of the U.K. Patents Court finding EP (U.K.) 0 706 376 invalid, however Conor is not participating in the House of Lords proceedings.  Litigation against other parties is still ongoing.  On April 4, 2005, we and BSC commenced legal action in the Netherlands against Sahajanand Medical Technologies Pvt. Ltd. (SMT) for patent infringement of the Netherlands-equivalent of EP0706376. A hearing was held on March 10, 2006, and the court issued a decision on May 3, 2006, finding the patent valid and the activity of SMT to be an infringement of the patent. SMT appealed this decision and a hearing was held on March 13, 2008, with the court indicating that their judgment will issue on May 29, 2008. In December 2005, we and BSC initiated a Preliminary Proceedings action against Occam International BV and its parent company Biosensors BV requesting a preliminary injunction for infringement of the Netherlands-equivalent of EP0706376. A hearing was held on January 13, 2006, and the court issued a judgment on January 27, 2006, denying the relief requested by us. We and BSC filed an appeal to this judgment on February 24, 2006, and the court is expected to set a date sometime after September 2008 for hearing the appeal.  The ultimate outcomes of these legal proceedings are uncertain at this time.



Page 39



---







On September 9, 2005, DePuy Mitek, Inc., filed suit against Arthrex Inc. and Pearsalls Limited (Pearsalls), one of our subsidiaries, for infringement of DePuy Miteks patent which relates to certain sutures (U.S. Patent No. 5,314,446).  Following a trial in August 2007, the court issued a judgment in favor of Arthrex; DePuy Mitek appealed this judgment to the Court of Appeals.  Arthrex has indemnified Pearsalls against any potential damages regarding sale of FiberWire products, and will pay for the cost of this defense. On July 2, 2004, Dr. Gregory W. Baran filed a complaint for willful patent infringement against one of our subsidiaries, Medical Device Technologies, Inc. A Markman hearing to construe the claims of the asserted patents (U.S. Patent No. 5,025,797 and U.S. Patent No. 5,400,798) was held in December 2005, and a decision was issued on September 25, 2007.  This litigation is currently proceeding and is in the discovery stage. No hearing date has yet been set by the court.



We intend to pursue and to defend vigorously any and all actions of third parties related to our extensive patent portfolio and pioneering technology. Any failure to obtain and protect intellectual property could adversely affect our business and our ability to operate could be hindered by the proprietary rights of others.



Our involvement in intellectual property litigation could result in significant expense, adversely affecting the development of product candidates or sales of the challenged product or intellectual property and diverting the efforts of our technical and management personnel, whether or not such litigation is resolved in our favor. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources and intellectual property litigation may be used against us as a means of gaining a competitive advantage. Competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. Uncertainties resulting from the initiation and continuation of any litigation could affect our ability to continue our operations. In the event of an adverse outcome as a defendant in any such litigation, we may, among other things, be required to:



o

pay substantial damages or back royalties;

o

cease the development, manufacture, use or sale of product candidates or products that infringe upon the intellectual property of others;

o

expend significant resources to design around a patent or to develop or acquire non-infringing intellectual property;

o

discontinue processes incorporating infringing technology; or

o

obtain licenses to the infringed intellectual property.



We cannot assure you that we will be successful in developing or acquiring non-infringing intellectual property or that necessary licenses will be available upon reasonable terms, if at all. Any such development, acquisition or license could require the expenditure of substantial time and other resources and could have a material adverse effect on our business and financial results. If we cannot develop or acquire such intellectual property or obtain such licenses, we could encounter delays in any introduction of products or could find that the development, manufacture or sale of products requiring such licenses could be prohibited.



If third parties file patent applications, or are issued patents claiming technology also claimed by us in pending applications, we may be required to participate in interference proceedings with the U.S. Patent Office, or other proceedings outside the United States, including oppositions, to determine priority of invention or patentability, which could result in substantial cost to us even if the eventual outcome were favorable.



Our ability to operate could be hindered by the proprietary rights of others.



A number of pharmaceutical, biotechnology and medical device companies as well as research and academic institutions have developed technologies, filed patent applications or received patents on various technologies that may be related to our business. Some of these technologies, applications or patents may conflict with or adversely affect our technologies or intellectual property rights, including those that we license from others. We are aware of other parties holding intellectual property rights that may represent prior art or other potentially conflicting intellectual property, including stents coated with agents intended to reduce restenosis. Any conflicts with the intellectual property of others could limit the scope of the patents, if any, that we may be able to obtain or result in the denial of our current or future patent applications altogether.



Page 40



---







If patents that cover our activities are issued to other persons or companies, we could be charged with infringement. In the event that other parties patents cover any portion of our activities, we may be forced to develop alternatives or negotiate a license for such technology. We do not know whether we would be successful in either developing alternative technologies or acquiring licenses upon reasonable terms, if at all. Obtaining any such licenses could require the expenditure of substantial time and other resources and could harm our business and decrease our earnings. If we do not obtain such licenses, we could encounter delays in the introduction of our products or could find that the development, manufacture or sale of products requiring such licenses is prohibited.



Technological advances and evolving industry standards could reduce our future product sales, which could cause our revenues to grow more slowly or decline.



The markets for our products are characterized by rapidly changing technology, changing customer needs, evolving industry standards and frequent new product introductions and enhancements. The emergence of new industry standards in related fields may adversely affect the demand for our products. This could happen, for example, if new standards and technologies emerged that were incompatible with customer deployments of our applications. In addition, any compounds, products or processes that we develop may become obsolete or uneconomical before we recover any of the expenses incurred in connection with their development. We cannot assure you that we will succeed in developing and marketing product enhancements or new products that respond to technological change, new industry standards, changed customer requirements or competitive products on a timely and cost-effective basis. Additionally, even if we are able to develop new products and product enhancements, we cannot assure you that they will achieve market acceptance.



We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of their former employers.



Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no such claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. If we fail in defending such claims, in addition to paying money claims, we may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper or prevent our ability to commercialize certain product candidates, which could severely harm our business.



We may incur significant costs complying with environmental laws and regulations.



Our research and development processes and manufacturing operations involve the use of hazardous materials. We are subject to federal, state, provincial, local and other laws and regulations in the countries in which we operate or sell our products, which govern the use, manufacture, storage, handling and disposal of such materials and certain waste products. The risk of accidental contamination or injury from these materials cannot be completely eliminated. In the event of an accident or the discovery of pre-existing contamination at one or more of our facilities, we could be held liable for any damages that result and any such liability could exceed our resources. We may not be specifically insured with respect to this liability, and we do not know whether we will be required to incur significant costs to comply with environmental laws and regulations in the future, or whether our operations, business or assets will be harmed by current or future environmental laws or regulations.



We face and will continue to face significant competition.



Competition from pharmaceutical companies, medical device companies, biotechnology companies and academic and research institutions is intense and is expected to increase. Many of our competitors and potential competitors have substantially greater product development capabilities, experience conducting clinical trials and financial, scientific, manufacturing, sales and marketing resources and experience than our company. Some of these competitors include JNJ, Guidant Corporation, Genzyme Corporation, Baxter, Abbott Laboratories, BSC, Medtronic, Inc., Wyeth, Inc., Novartis AG, C.R. Bard, the Allegiance division of Cardinal Health, Inc., Bausch & Lomb, and Tyco Ltd., among others. We also face competition from non-medical device companies, such as pharmaceutical companies, which may offer non-surgical alternative therapies for disease states which are currently or intended to be treated using our products. Other companies may:



Page 41



---







o

develop and obtain patent protection for products earlier than us;

o

design around patented technology developed by us;

o

obtain regulatory approvals for such products more rapidly;

o

have greater manufacturing capabilities and other resources;

o

have larger or more experienced sales forces;

o

develop more effective or less expensive products; or

o

have greater success in obtaining adequate third-party payer coverage and reimbursement for their competing products.



While we intend to expand our technological capabilities in order to remain competitive, there is a risk that:



o

research and development by others will render our technology or product candidates obsolete or non-competitive;

o

treatments or cures developed by others will be superior to any therapy developed by us; and

o

any therapy developed by us will not be preferred to any existing or newly-developed technologies.



The commercial potential of our products and product candidates will be significantly limited if we are not able to obtain adequate levels of reimbursement or market acceptance for them.



Our ability to commercialize human therapeutic products and product candidates successfully will depend in part on the extent to which coverage and reimbursement for such products and related treatments will be available from government health administration authorities, private health insurers and other third-party payers or supported by the market for these products. There can be no assurance that third-party payers coverage and reimbursement will be available or sufficient for the products we might develop.



Third party payers are increasingly challenging the price of medical products and services and instituting cost containment measures to control or significantly influence the purchase of medical products and services. These cost containment measures, if instituted in a manner affecting the coverage of or payment for our products, could have a material adverse effect on our ability to operate profitably. In some countries in the E.U. and in the U.S., significant uncertainty exists as to the reimbursement status of newly-approved healthcare products, and we do not know whether adequate third-party coverage and reimbursement will be available for us to realize an appropriate return on our investment in product development, which could seriously harm our business. In the U.S., while reimbursement amounts previously approved appear to have provided a reasonable rate of return, there can be no assurance that our products will continue to be reimbursed at current rates or that third party payers will continue to consider our products cost-effective and provide coverage and reimbursement for our products, in whole or in part.



We cannot be certain that our products will gain commercial acceptance among physicians, patients and third party payers, even if necessary international and U.S. marketing approvals are maintained. We believe that recommendations and endorsements by physicians will be essential for market acceptance of our products, and we do not know whether these recommendations or endorsements will be obtained. We also believe that surgeons will not use these products unless they determine, based on clinical data and other factors, that the clinical benefits to patients and cost savings achieved through use of these products outweigh their cost. Acceptance among physicians may also depend upon the ability to train surgeons and other potential users of our products and the willingness of such users to learn these relatively new techniques.



Future legislation or regulatory changes to, or consolidation in, the healthcare system may affect our ability to sell our product profitably.





Page 42



---





There have been, and we expect there will continue to be, a number of legislative and regulatory proposals to change the healthcare system, and some could involve changes that could significantly affect our business. Efforts by governmental and third-party payers to reduce health care costs or the announcement of legislative proposals or reforms to implement government controls could cause a reduction in sales or in the selling price of our products, which would seriously harm our business. Additionally, initiatives to reduce the cost of healthcare have resulted in a consolidation trend in the healthcare industry, including hospitals. This in turn has resulted in greater pricing pressures and the exclusion of certain suppliers from certain market segments as consolidated groups such as group purchasing organizations, independent delivery networks and large single accounts continue to consolidate purchasing decisions for some of our hospital customers. We expect that market demand, government regulation, and third-party reimbursement policies will continue to change the worldwide healthcare industry, resulting in further business consolidations and alliances among our customers and competitors, which may reduce competition, exert further downward pressure on the prices of our products and may adversely impact our business, financial condition or results of operations.



We must receive regulatory approval for each of our product candidates before they can be sold commercially in Canada, the U.S. or internationally, which can take significant time and be very costly.



The development, manufacture and sale of medical devices and human therapeutic products in Canada, the U.S. and internationally is governed by a variety of statutes and regulations. These laws require, among other things:



o

regulatory approval of manufacturing facilities and practices;

o

adequate and well-controlled research and testing of products in pre-clinical and clinical trials;

o

review and approval of submissions containing manufacturing, pre-clinical and clinical data in order to obtain marketing approval based on establishing the safety and efficacy of the product for each use sought, including adherence to good manufacturing practices during production and storage; and

o

control of marketing activities, including advertising and labeling.



The product candidates currently under development by us or our collaborators will require significant research, development, pre-clinical and clinical testing, pre-market review and approval, and investment of significant funds prior to their commercialization. We are dependent on our collaborators for regulatory approval and compliance, and have little or no control over these matters. The process of completing clinical testing and obtaining such approvals is likely to take many years and require the expenditure of substantial resources, and we do not know whether any clinical studies by us or our collaborators will be successful, that regulatory approvals will be received, or that regulatory approvals will be obtained in a timely manner. Despite the time and resources expended by us, regulatory approval is never guaranteed. Even if regulatory approval is obtained, regulatory agencies may limit the approval to certain diseases, conditions or categories of patients who can use them.



If any of our development programs are not successfully completed in a timely fashion, required regulatory approvals are not obtained in a timely fashion, or products for which approvals are obtained are not commercially successful, it could seriously harm our business.



Our products and manufacturing facilities that have, or may receive, regulatory approval, are or will be subject to ongoing regulation. In addition, we have little or no control over the manufacturing facilities of our collaborators in which our products are manufactured.



Our products and manufacturing operations are subject to extensive regulation in the U.S. by the FDA and by similar regulatory agencies abroad. Ongoing regulation includes compliance with an array of manufacturing and design controls and testing, quality control, storage and documentation procedures. Regulatory agencies may also require expensive post-approval studies. Any adverse events associated with our products must also be reported to regulatory authorities. If deficiencies in our or our collaborators manufacturing and laboratory facilities are discovered, or we or our collaborators fail to comply with applicable post-market regulatory requirements, a regulatory agency may close the facility or suspend manufacturing.



Page 43



---





With respect to products manufactured by third-party contractors, we are, and we expect to continue to be, dependent on our collaborators for continuing regulatory compliance and we may have little or no control over these matters. Our ability to control third-party compliance with FDA and other regulatory requirements will be limited to contractual remedies and rights of inspection. Our failure or the failure of third-party manufacturers to comply with regulatory requirements applicable to our products may result in legal or regulatory action by those regulatory authorities. There can be no assurance that our or our collaborators manufacturing processes will satisfy regulatory, cGMP or International Standards Organization (ISO) requirements.

In addition, there may be uncertainty as to whether or not we or others who are involved in the manufacturing process will be able to make the transition to commercial production of some of our newly developed products. A failure to achieve regulatory approval for manufacturing facilities or a failure to make the transition to commercial production for our products will adversely affect our prospects, business, financial condition and results of operations.



If we are unable to fully comply with federal and state fraud and abuse laws, we could face substantial penalties, which may adversely affect our business, financial condition and results of operations.



We are subject to various laws pertaining to health care fraud and abuse, including the federal Anti-Kickback Statute, physician self-referral laws, the federal False Claims Act, the federal Health Insurance Portability and Accountability Act of 1996, the federal False Statements Statute, and state law equivalents to these federal laws, which may not be limited to government-reimbursed items and may not contain identical exceptions. Violations of these laws are punishable by criminal and civil sanctions, including, in some instances, civil and criminal penalties, damages, fines, exclusion from participation in federal and state healthcare programs, including Medicare and Medicaid, and the curtailment or restructuring of operations. Any action against us for violation of these laws could have a significant impact on our business.  In addition, we are subject to the U.S. Foreign Corrupt Practices Act.  We have a network of approximately 160 distributors.  Any action against us for violation by us or our distributors of this act could have a significant impact on our business.



We may be unsuccessful in marketing, selling and distributing certain of our products.



We distribute a number of our products worldwide. In order to achieve commercial success for our approved products, we have been expanding our sales and marketing force in the U.S., Europe and other parts of the world.  If our distribution personnel or methods are not sufficient to ensure we have supply to meet demand for our products or if there is a quality control failure with our products, it could harm our prospects, business, financial condition and results of operations.



To the extent that we enter into co-promotion or other marketing and sales arrangements with other companies, any revenues received will be dependent on the efforts of others, and we do not know whether these efforts will be successful. Failure to develop a direct sales and marketing force or enter into appropriate arrangements with other companies to market and sell our products will reduce our ability to generate revenues.



We may encounter unanticipated costs or loss of business associated with terminating or relocating facilities and operations



We are currently consolidating our Syracuse, NY and existing Puerto Rico manufacturing facilities into a single location in Puerto Rico. There is a risk that the costs associated with this consolidation may be greater than anticipated, particularly if the process takes longer than planned. There is also a risk that during the consolidation of plants, we may be unable to meet customer demand on a time line that is suitable to them or that the quality of the product we produce fails to meet customer standards which could have a negative impact on our business.



Consolidation in the healthcare industry could have an adverse effect on our revenues and results of operations.



Many healthcare industry companies, including medical device companies, are consolidating to create new companies with greater market power. As the healthcare industry consolidates, competition to provide goods and services to industry participants will become more intense. These industry participants may try to use their market power to negotiate price concessions or reductions for medical devices that incorporate components produced by us. If we are forced to reduce our prices because of consolidation in the healthcare industry, our revenues would decrease and our consolidated earnings, financial condition or cash flows would suffer.





Page 44



---





We may incur losses associated with foreign currency fluctuations.



Effective January 1, 2004, we commenced reporting our operating results and financial position in U.S. dollars in order to more accurately represent the currency of the economic environment in which we operate.



Our operations are in some instances conducted in currencies other than the U.S. dollar and fluctuations in the value of foreign currencies relative to the U.S. dollar could cause us to incur currency exchange losses. In addition to the U.S. dollar, we currently conduct operations in Canadian dollars, Euro, Swiss francs, Danish krone, and U.K. pound sterling. Exchange rate fluctuations may reduce our future operating results.  In the year ended December 31, 2007, we reported $0.3 million of foreign exchange losses due to foreign currency fluctuations compared to $0.5 million of foreign exchange gains for the year ended December 31, 2006 and $1.1 million of foreign exchange gains for the year ended December 31, 2005.



We have not entered into any forward currency contracts or other financial derivatives to hedge foreign exchange risk, and therefore we are subject to foreign currency transaction and translation gains and losses. We purchase goods and services in U.S. and Canadian dollars, Swiss francs, Danish krone, and U.K. pound sterling, and earn a significant portion of our license and milestone revenues in U.S. dollars. Foreign exchange risk is managed primarily by satisfying foreign denominated expenditures with cash flows or assets denominated in the same currency.



Acquisition of companies or technologies may result in disruptions to our business.



As part of our business strategy, we may acquire additional assets and businesses principally relating to or complementary to our current operations. Any acquisitions or mergers by us will be accompanied by the risks commonly encountered in acquisitions of companies. These risks include, among other things, higher than anticipated acquisition costs and expenses, the difficulty and expense of integrating the operations and personnel of the companies and the loss of key employees and customers as a result of changes in management.



In addition, geographic distances may make integration of acquired businesses more difficult. We may not be successful in overcoming these risks or any other problems encountered in connection with any acquisitions.



If significant acquisitions are made for cash consideration, we may be required to use a substantial portion of our available cash, cash equivalents and short-term investments. Future acquisitions by us may cause large one-time expenses or create goodwill or other intangible assets that could result in significant asset impairment charges in the future. Acquisition financing may not be available on acceptable terms, if at all.



We may not generate sufficient cash flow from any of our future permitted acquisitions to service our indebtedness.



In any acquisition, we expect to benefit from cost savings through, for example, the reduction of overhead or the acquisition of products and from revenue enhancements resulting from the acquisition. However, there can be no assurance that we will be able to generate sufficient cash flow from any future permitted acquisitions to service any indebtedness incurred to finance such acquisitions or realize any other anticipated benefits. Nor can there be any assurance that our profitability will be improved by any one or more acquisitions. Any acquisition may involve operating risks, such as:



o

the difficulty of assimilating and integrating the acquired operations and personnel into our current business;

o

the potential disruption of our ongoing business;

o

the diversion of managements attention and other resources;

o

the possible inability of management to maintain uniform standards, controls, procedures and policies;

o

the risks of entering markets in which we have little or no experience;

o

the potential impairment of relationships with employees;

o

the possibility that any liabilities we may incur or assume may prove to be more burdensome than anticipated; and

o

the possibility that the acquired business or products do not perform as expected.



Page 45



---







If we fail to hire and retain key management, scientific and technical personnel, we may be unable to successfully implement our business plan.



We are highly dependent on our senior management and scientific and technical personnel. The competition for qualified personnel in the healthcare field is intense, and we rely heavily on our ability to attract and retain qualified managerial, scientific and technical personnel. Our ability to manage growth effectively will require continued implementation and improvement of our management systems and the ability to recruit and train new employees. We may not be able to successfully attract and retain skilled and experienced personnel, which could harm our ability to develop our product candidates and generate revenues.



Risks Relating to our Indebtedness, Shares, and Organization and Structure



Our existing and future permitted debt could adversely affect our operations.



As of December 31, 2007, we had outstanding $575 million of indebtedness, excluding accrued interest. We are currently considering other facilities to replace the revolving portion of the credit facility that was terminated in connection with the issuance of the Senior Floating Rate Notes due 2013 (the Floating Rate Notes), but there can be no assurance that we will be able to obtain such a facility.  Excluding intercompany transactions, our subsidiaries that are not guarantors of the Floating Rate Notes or Subordinated Notes (defined herein) accounted for approximately $53 million or 18% of our total revenues from continuing operations for the year ended December 31, 2007, and approximately $488 million or 42% of our total assets and approximately $116 million or 16% of our total liabilities as of December 31, 2007.  The Floating Rate Notes and 7.75% Senior Subordinated Notes due 2014 (the Subordinated Notes) are guaranteed by the same group of our subsidiaries.



The amount and terms of our indebtedness and other financial obligations could have important consequences for our operations. For example, it:



o

could increase our vulnerability to general adverse economic and industry conditions;

o

could limit our ability to obtain additional financing in the future for working capital, capital expenditures, acquisitions, general corporate purposes or other purposes;

o

will require us to dedicate a substantial portion of our cash flow from operations to the payment of principal and interest on our indebtedness, thereby reducing the funds available to us for operations and any future business opportunities, including acquisitions permitted by our Subordinated Notes and Floating Rate Notes;

o

will limit our planning flexibility for, or ability to react to, changes in our business and the industry; and

o

could place us at a competitive disadvantage with competitors who may have less indebtedness and other obligations or greater access to financing.



The Floating Rate Notes bear interest at rates that fluctuate with changes in certain prevailing benchmarks. If interest rates increase, we may be unable to meet our debt service obligations under the Floating Rate Notes and Subordinated Notes and other indebtedness.



We and our subsidiaries are permitted to incur substantially more debt, which could further exacerbate the risks associated with our leverage.



The terms of the indentures governing the Floating Rate Notes and Subordinated Notes expressly permit the incurrence of additional amounts of debt for specified purposes. For example, if we decide to seek and are successful in obtaining commitments for a new revolving credit facility, all borrowings under that facility will rank senior to the Floating Rate Notes and Subordinated Notes and the guarantees, to the extent of the value of the assets securing such borrowings.  Moreover, the indentures governing the Floating Rate Notes and Subordinated Notes do not impose any limitation on our incurrence of liabilities that are not defined as Indebtedness under such indentures (such as trade payables). If new debt or other liabilities are added to our and our subsidiaries current levels of debt, the related risks that we and they now face could be exacerbated.





Page 46



---





If our cash flows prove inadequate to service our debt and provide for our other obligations, we may be required to refinance all or a portion of our existing debt or future debt at terms unfavorable to us.



Our ability to make payments on and refinance our debt, including the Floating Rate Notes, the Subordinated Notes and other financial obligations, and to fund our capital expenditures and acquisitions will depend on our ability to generate substantial operating cash flow. This will depend on our future performance, which will be subject to prevailing economic conditions and to financial, business and other factors beyond our control. If our cash flows were to prove inadequate to meet our debt service and other obligations in the future, we may be required to refinance all or a portion of our existing or future debt, including the Floating Rate Notes and Subordinated Notes, on or before maturity, to sell assets or to obtain additional financing. We cannot assure you that we will be able to refinance any of our indebtedness, including the Floating Rate Notes and Subordinated Notes, sell any such assets or obtain such additional financing on commercially reasonable terms or at all. Additionally, because the indentures governing the Floating Rate Notes and Subordinated Notes require that, upon the occurrence of a change of control, as defined in the indentures, we must make an offer to repurchase the Floating Rate Notes and Subordinated Notes, respectively, at a price equal to 101% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of repurchase.  In the event that we were required to repurchase the Floating Rate Notes and Subordinated Notes pursuant to our offer, such repurchase could result in the use of a significant amount of our available cash.



The indentures governing the Floating Rate Notes and Subordinated Notes contain covenants that may limit our ability to take advantage of certain business opportunities advantageous to us that may arise.



The indentures governing the Floating Rate Notes and Subordinated Notes contain certain covenants that, among other things, limit our ability and the ability of certain of our subsidiaries to:



o

incur, assume or guarantee additional indebtedness or issue preferred stock;

o

pay dividends or make other equity distributions to our shareholders;

o

purchase or redeem our capital stock;

o

make certain investments;

o

create liens;

o

sell or otherwise dispose of assets;

o

engage in transactions with our affiliates; and

o

merge or consolidate with another entity or transfer all or substantially all of our assets.



These restrictions could limit our ability to obtain future financing, make acquisitions or needed capital expenditures, withstand economic downturns in our business, industry or the economy in general, conduct operations or otherwise take advantage of business opportunities that may arise.



Although the indentures for the Floating Rate Notes and Subordinated Notes contain a fixed charge coverage test that limits our ability to incur indebtedness, this limitation is subject to a number of significant exceptions and qualifications. Moreover, the indentures do not impose any limitation on our incurrence of liabilities that are not considered Indebtedness under the indentures (such as operating leases), nor do they impose any limitation on the amount of liabilities incurred by subsidiaries, if any, that might be designated as Unrestricted Subsidiaries under the indentures. Despite current indebtedness levels, we and our subsidiaries may still be able to incur substantially more debt. This could further exacerbate the risks associated with our leverage. Also, although the indentures limit our ability to make restricted payments, these restrictions are subject to significant exceptions and qualifications.



Our stock price has been volatile, is likely to continue to be volatile and could decline substantially.



Our common shares have been, and are likely to continue to be, highly volatile. For example, in the twelve months ending December 31, 2007, shares of our common stock traded on the NASDAQ and the Toronto Stock Exchange have closed at a high of $9.18 and CDN$10.81, respectively, and at a low of $3.10 and CDN$3.12, respectively.   Our share price could fluctuate significantly in the future for various reasons, including the following:



o

future announcements concerning us or our competitors;



Page 47



---





o

quarterly variations in operating results;

o

the introduction of new products or changes in product pricing policies by us or our competitors;

o

an acquisition or loss of significant customers, distributors and suppliers;

o

changes in earnings estimates by analysts;

o

changes in third-party reimbursement practices;

o

regulatory developments;

o

intellectual property developments;

o

reports of results of clinical trials;

o

the commencement of material litigation against us or our collaborators; or

o

fluctuations in the economy or general market conditions.



In addition, stock markets in general, and the market for shares of biopharmaceutical and life science companies in particular, have experienced extreme price and volume fluctuations in recent years that may be unrelated to the operating performance of the affected companies. These broad market fluctuations may cause the market price for our common shares to decline. The market price of our common shares could decline below its current price and may fluctuate significantly in the future. These fluctuations may or may not be related to our performance or prospects.



In the past, market investors have often instituted securities class action litigation after periods of volatility in the market price of a companys securities. If one of our shareholders files a securities class action suit, we could incur substantial legal fees and our managements attention and resources could be diverted from operating our business in order to respond to the litigation.



U.S. investors may not be able to obtain enforcement of civil liabilities against us.



We were formed under the laws of British Columbia, Canada. A substantial portion of our assets are located outside the U.S. In addition, a majority of the members of our board of directors and our officers are residents of countries other than the U.S. As a result, it may be impossible for U.S. investors to affect service of process within the U.S. upon us or these persons or to enforce against us or these persons any judgments in civil and commercial matters, including judgments under U.S. federal or state securities laws. In addition, a Canadian court may not permit U.S. investors to bring an original action in Canada or to enforce in Canada a judgment of a state or federal court in the U.S.



Laws and provisions in our notice of articles and articles and shareholder rights plan could delay or deter a change in control.



Our notice of articles and articles allow for the issuance of preference shares. The board of directors may set the rights and preferences of any series of preference shares in its sole discretion without the approval of the holders of our common shares. The rights and preferences of the preference shares may be superior to those of the common shares. Accordingly, the issuance of preference shares also could have the effect of delaying or preventing a change of control of our company. In addition, under the Business Corporations Act (British Columbia), some business combinations, including a merger or reorganization or the sale, lease or other disposition of all or a substantial part of our assets, must be approved by at least three-quarters of the votes cast by our shareholders in aggregate or, in some cases, approved by at least three-quarters of the votes cast by holders of each class of shares.  In some cases, a business combination must be approved by a court. Shareholders may also have a right to dissent from the transaction, in which case, we would be required to pay dissenting shareholders the fair value of their common shares provided they have followed the required procedures. There are, at present, no preference shares outstanding.



In addition, our shareholders adopted a shareholder rights plan which provides for substantial dilution to an acquiror unless either the acquiror makes a bid to all shareholders, which, among other things, is held open for at least 60 days and is accepted by independent shareholders holding at least 50% of the outstanding common shares, or the bid is otherwise approved by our board of directors.  This shareholder rights plan was amended and restated on June 9, 2005, and has a term of nine years, subject to reconfirmation by the shareholders at the annual general meetings in 2008 and 2011.





Page 48



---





Furthermore, all of our executive officers have contractual rights under employment agreements to have their stock options vest immediately and obtain 12 to 24 months severance pay in the event of a change of control of our company.



Limitations on the ability to acquire and hold our common shares may be imposed by the Competition Act (Canada). This legislation permits the Commissioner of Competition to review any acquisition of a significant interest in our company. This legislation grants the Commissioner jurisdiction to challenge such an acquisition before the Competition Tribunal if the Commissioner believes that it would, or would be likely to, result in a substantial lessening or prevention of competition in any market in Canada. The Investment Canada Act (Canada) subjects an acquisition of control of a company by a non-Canadian to government review if the value of our assets as calculated pursuant to the legislation exceeds a threshold amount which, for an investor from a World Trade Organization member country, was CDN$281 million in 2007 and is CDN$295 million in 2008. A reviewable acquisition may not proceed unless the relevant minister is satisfied or is deemed to be satisfied that there is likely to be a net benefit to Canada from the transaction.



Each of these matters could delay or deter a change in control that would be attractive to, and provide liquidity for, shareholders, and could limit the price that investors are willing to pay in the future for our common shares.







DIVIDEND POLICY



We have never declared or paid any cash or share dividends on our common shares. We currently intend to retain any future earnings to fund the development and growth of our business and we do not anticipate paying any cash or share dividends in the foreseeable future.





Page 49



---





SELECTED CONSOLIDATED FINANCIAL INFORMATION



The following table sets forth selected consolidated financial information for each of our five most recently completed financial years. This data should be read in conjunction with our audited consolidated financial statements, including the notes to the financial statements, and the risk factors set out in this annual information form.

CONSOLIDATED STATEMENTS OF INCOME



|                                                    |   | Year ended   |   |   | Year ended   |   |   | Year ended   |   |   | Year ended   |   |   | Year ended   |  
|--------------------------------------------------- | - | ------------ | - | - | ------------ | - | - | ------------ | - | - | ------------ | - | - | ------------ | -
|                                                    |   | December 31, |   |   | December 31, |   |   | December 31, |   |   | December 31, |   |   | December 31, |  
|                                                    |   | 2007         |   |   | 2006         |   |   | 2005         |   |   | 2004         |   |   | 2003         |  
|(in thousands of U.S. $)                            |   |              |   |   | (restated)   |   |   |              |   |   |              |   |   |              |  
|REVENUE                                             |   |              |   |   |              |   |   |              |   |   |              |   |   |              |  
|Royalty revenue                                     | $ | 116,659      |   | $ | 175,254      |   | $ | 189,203      |   | $ | 100,638      |   | $ | 4,297        |  
|Product sales, net                                  |   | 170,193      |   |   | 138,590      |   |   | 5,334        |   |   | 8,281        |   |   | 7,859        |  
|License fees                                        |   | 842          |   |   | 1,231        |   |   | 5,111        |   |   | 17,312       |   |   | 8,069        |  
|                                                   
|                                                    |   | 287,694      |   |   | 315,075      |   |   | 199,648      |   |   | 126,231      |   |   | 20,225       |  
|                                                   
|EXPENSES                                            |   |              |   |   |              |   |   |              |   |   |              |   |   |              |  
|License and royalty fees                            |   | 18,652       |   |   | 25,986       |   |   | 28,345       |   |   | 18,072       |   |   | 1,850        |  
|Cost of products sold                               |   | 94,949       |   |   | 69,543       |   |   | 5,653        |   |   | 5,632        |   |   | 4,660        |  
|Research and development                            |   | 53,963       |   |   | 45,393       |   |   | 31,988       |   |   | 26,659       |   |   | 15,126       |  
|Selling, general and administration                 |   | 99,315       |   |   | 78,933       |   |   | 37,837       |   |   | 21,180       |   |   | 18,519       |  
|Depreciation and amortization                       |   | 33,429       |   |   | 36,014       |   |   | 9,540        |   |   | 9,235        |   |   | 8,751        |  
|In-process research and development                 |   | 8,125        |   |   | 1,042        |   |   | 54,957       |   |   | 6,375        |   |   | 6,639        |  
|                                                   
|                                                    |   | 308,433      |   |   | 256,911      |   |   | 168,320      |   |   | 87,153       |   |   | 55,545       |  
|                                                   
|Operating (loss) income                             |   | (20,739      | ) |   | 58,164       |   |   | 31,328       |   |   | 39,078       |   |   | (35,320      | )
|Other (expenses) income:                            |   |              |   |   |              |   |   |              |   |   |              |   |   |              |  
|Foreign exchange (loss) gain                        |   | (341         | ) |   | 515          |   |   | 1,092        |   |   | 2,050        |   |   | (20,208      | )
|Investment and other income                         |   | 10,393       |   |   | 6,235        |   |   | 10,006       |   |   | 5,668        |   |   | 2,590        |  
|Interest expense on long-term debt                  |   | (51,748      | ) |   | (35,502      | ) |   | -            |   |   | -            |   |   | -            |  
|Write-down of deferred financing costs              |   | -            |   |   | (9,297       | ) |   | -            |   |   | -            |   |   | -            |  
|Write-down of investment                            |   | -            |   |   | -            |   |   | (5,967       | ) |   | -            |   |   | -            |  
|Loss on redemption of available for-sale securities |   | (8,157       | ) |   | -            |   |   | -            |   |   | -            |   |   | -            |  
|                                                   
|Total other (expenses) income                       |   | (49,853      | ) |   | (38,049      | ) |   | 5,131        |   |   | 7,718        |   |   | (17,618      | )
|(Loss) income from continuing operations before     |   |              |   |   |              |   |   |              |   |   |              |   |   |              |  
|income taxes and cumulative effect of change in     |   |              |   |   |              |   |   |              |   |   |              |   |   |              |  
|accounting policy                                   |   | (70,592      | ) |   | 20,115       |   |   | 36,459       |   |   | 46,796       |   |   | (52,938      | )
|                                                   
|Income tax (recovery) expense                       |   | (14,545      | ) |   | 2,092        |   |   | 28,055       |   |   | (6,183       | ) |   | -            |  
|(Loss) income from continuing operations before     |   |              |   |   |              |   |   |              |   |   |              |   |   |              |  
|cumulative effect of change in accounting policy    |   | (56,047      | ) |   | 18,023       |   |   | 8,404        |   |   | 52,979       |   |   | (52,938      | )
|                                                   
|Loss from discontinued operations, net of income    |   | (9,893       | ) |   | (7,708       | ) |   | (9,591       | ) |   | (527         | ) |   | 52           |  
|taxes                                               |   |              |   |   |              |   |   |              |   |   |              |   |   |              |  
|Cumulative effect of change in accounting policy    |   | -            |   |   | 399          |   |   | -            |   |   | -            |   |   | -            |  
|                                                   
|Net (loss) income                                   | $ | (65,940      | ) | $ | 10,714       |   | $ | (1,187       | ) | $ | 52,452       |   | $ | (52,886      | )
|                                                   
|Basic net income (loss) per common share:           |   |              |   |   |              |   |   |              |   |   |              |   |   |              |  
|Continuing operations                               | $ | (0.66        | ) | $ | 0.21         |   | $ | 0.10         |   | $ | 0.63         |   | $ | (0.75        | )
|Discontinued operations                             |   | (0.12        | ) |   | (0.09        | ) |   | (0.11        | ) |   | -            |   |   | -            |  
|Total                                               | $ | (0.78        | ) | $ | 0.12         |   | $ | (0.01        | ) | $ | 0.63         |   | $ | (0.75        | )
|Diluted net income (loss) per common share:         |   |              |   |   |              |   |   |              |   |   |              |   |   | -            |  
|Continuing operations                               | $ | (0.66        | ) | $ | 0.21         |   | $ | 0.10         |   | $ | 0.62         |   | $ | (0.75        | )
|Discontinued operations                             |   | (0.12        | ) |   | (0.09        | ) |   | (0.11        | ) |   | (0.01        | ) |   | -            |  
|Total                                               | $ | (0.78        | ) | $ | 0.12         |   | $ | (0.01        | ) | $ | 0.61         |   | $ | (0.75        | )



Page 50



---







|Basic weighted average number of common   |        |        |        |        |       
|----------------------------------------- | ------ | ------ | ------ | ------ | ------
|shares outstanding (in thousands)         | 85,015 | 84,752 | 84,121 | 83,678 | 70,580
|Diluted weighted average number of common |        |        |        |        |       
|shares outstanding (in thousands)         | 85,015 | 85,437 | 85,724 | 85,697 | 70,580

BALANCE SHEET INFORMATION

|As at                             |   |           |   |   |            |   |   | December 31, |   |   |         |   |   |         |  
|--------------------------------- | - | --------- | - | - | ---------- | - | - | ------------ | - | - | ------- | - | - | ------- | -
|                                  |   | 2007      |   |   | 2006       |   |   | 2005         |   |   | 2004    |   |   | 2003    |  
|(in thousands of U.S.$)           |   |           |   |   | (restated) |   |   |              |   |   |         |   |   |         |  
|Cash, cash equivalents and short- |   |           |   |   |            |   |   |              |   |   |         |   |   |         |  
|term investments                  | $ | 91,326    |   | $ | 108,617    |   | $ | 195,442      |   | $ | 271,484 |   | $ | 296,794 |  
|Working capital                   |   | 97,745    |   |   | 115,892    |   |   | 181,317      |   |   | 268,300 |   |   | 296,087 |  
|Total assets                      |   | 1,150,108 |   |   | 1,224,624  |   |   | 494,694      |   |   | 479,077 |   |   | 395,722 |  
|Total long-term obligations       |   | 645,096   |   |   | 658,366    |   |   | 4,459        |   |   | 12,882  |   |   | 6,808   |  
|Deficit                           |   | (102,497  | ) |   | (34,893    | ) |   | (45,607      | ) |   | (44,420 | ) |   | (96,872 | )
|Total shareholders equity        |   | 442,072   |   |   | 498,692    |   |   | 462,680      |   |   | 441,826 |   |   | 377,371 |  



QUARTERLY RESULTS

The following tables present our unaudited consolidated quarterly results of operations for each of our last eight quarters:

|                                               |   |              |   |   | Quarter ended |   |   |          |  
|---------------------------------------------- | - | ------------ | - | - | ------------- | - | - | -------- | -
|(in thousands of U.S.$, except per share data) |   | December 31, |   |   | September 30, |   |   | June 30, |  
|                                               |   | 2007         |   |   | 2007          |   |   | 2007     |  
|                                              
|Royalty and license revenue                    | $ | 27,423       |   | $ | 26,674        |   | $ | 29,932   |  
|Product sales                                  |   | 43,935       |   |   | 41,352        |   |   | 42,420   |  
|Total revenues                                 |   | 71,358       |   |   | 68,026        |   |   | 72,352   |  
|Operating (loss) income                        |   | (6,034       | ) |   | (5,907        | ) |   | (11,150  | )
|Net (loss) income from continuing operations   |   | (23,498      | ) |   | (10,832       | ) |   | (15,045  | )
|Net (loss) income                              |   | (26,444      | ) |   | (11,988       | ) |   | (15,215  | )
|                                              
|Basic (loss) income per share:                 |   |              |   |   |               |   |   |          |  
|Continuing operations                          | $ | (0.28        | ) | $ | (0.13         | ) | $ | (0.18    | )
|Discontinued operations                        |   | (0.03        | ) |   | (0.01         | ) |   | -        |  
|Total                                          | $ | (0.31        | ) | $ | (0.14         | ) | $ | (0.18    | )
|                                              
|Diluted (loss) income per share:               |   |              |   |   |               |   |   |          |  
|Continuing operations                          | $ | (0.28        | ) | $ | (0.13         | ) | $ | (0.18    | )
|Discontinued operations                        |   | (0.03        | ) |   | (0.01         | ) |   | -        |  
|Total                                          | $ | (0.31        | ) | $ | (0.14         | ) | $ | (0.18    | )





Page 51



---







|                                               |   |              |   |   | Quarter ended |   |  
|---------------------------------------------- | - | ------------ | - | - | ------------- | - | -
|(in thousands of U.S.$, except per share data) |   | December 31, |   |   | September 30, |   |  
|                                               |   | 2006         |   |   | 2006          |   |  
|                                               |   | (restated)   |   |   |               |   |  
|                                              
|Royalty and license revenue                    | $ | 48,527       |   | $ | 43,762        |   | $
|Product sales                                  |   | 44,726       |   |   | 42,509        |   |  
|Total revenues                                 |   | 93,253       |   |   | 86,271        |   |  
|Operating income (loss)                        |   | 13,082       |   |   | 16,478        |   |  
|Net income (loss) from continuing operations   |   | (3,860       | ) |   | 7,404         |   |  
|Net income (loss)                              |   | (10,303      | ) |   | 6,926         |   |  
|                                              
|Basic income (loss) per share:                 |   |              |   |   |               |   |  
|Continuing operations                          | $ | (0.05        | ) | $ | 0.09          |   | $
|Discontinued operations                        |   | (0.08        | ) |   | (0.01         | ) |  
|Total                                          | $ | (0.13        | ) | $ | 0.08          |   | $
|Diluted income (loss) per share:               |   |              |   |   |               |   |  
|Continuing operations                          | $ | (0.05        | ) | $ | 0.09          |   | $
|Discontinued operations                        |   | (0.08        | ) |   | (0.01         | ) |  
|Total                                          | $ | (0.13        | ) | $ | 0.08          |   | $



As per note 1(b) to the Companys 2007 audited consolidated financial statements, the Company restated its financial statements as at and for the year ended December 31, 2006 to correct errors in accounting for income taxes.  These errors arose from using incorrect tax rates for determining certain deferred tax balances, incorrect calculations of certain tax credits and incorrect adjustments of changes in estimates between the 2005 income tax provision and the 2005 income tax returns.  Years prior to 2006 were not affected by these errors.  In addition, the Company corrected certain other amounts disclosed in the income tax rate reconciliation for 2006 and the composition of deferred income tax balances as at December 31, 2006.  These errors aggregated to adjustments to the income tax provision of $7,298,000, deferred income tax balances of $1,900,000 and current taxes payable of $5,398,000 resulting in an increase in net income for 2006 of $7,298,000.
The Company also recorded certain other adjustments related to 2006 unadjusted differences that were considered not to be material at the time the 2006 consolidated financial statements were prepared. These include increased expense for: i) certain capitalized inventory variances of $580,000; ii) adjustments of $700,000 to the fair value of inventory acquired in the AMI acquisition (note 5(a)(ii); and (iii)) internal travel costs of $380,000 related to the AMI acquisition and a litigation expense accrual of $680,000 for the resolution of a loss contingency, affecting selling, general and administration expense.  The increased expense is partially offset by a reduction in stock based compensation expense of $282,000 resulting from a calculation error.  The Company also reclassified fees of $577,000 to royalty expense that had previously been recorded in selling, general and administration, offset partially by a reclassification of a $196,000 reduction in license costs that had previously been recorded in cost of products sold.  Adjusting these items results in an increase in license and royalty fees of $381,000, an increase in cost of products sold of $1,476,000, an increase in selling, general and administration of $201,000, a decrease in income from continuing operations before income taxes of $2,058,000 and a decrease in net income of $1,169,000 (net of income taxes of $889,000).



In addition, the Company reclassified $7,811,000 from deferred income taxes to prepaid expenses and other assets, and $2,065,000 to other liabilities; $2,200,000 from additional paid in capital to share capital to reflect stock option exercises; and increased the cumulative translation adjustment by $10,012,000 to record certain amounts related to foreign operations that have a functional currency which differs from the parents reporting currency



Page 52



---





The following tables present the impact of the restatement:



|For the year ended December 31, 2006            |   | As Previously |   |   |          |  
|----------------------------------------------- | - | ------------- | - | - | -------- | -
|                                                |   | Reported      |   |   | Restated |  
|Statement of Operations                         |   |               |   |   |          |  
|License and royalty fees                        | $ | 25,605        |   | $ | 25,986   |  
|Cost of products sold                           |   | 68,067        |   |   | 69,543   |  
|Selling, general and administration             |   | 78,732        |   |   | 78,933   |  
|Operating Income                                |   | 60,222        |   |   | 58,164   |  
|Income from continuing operations before income |   | 22,173        |   |   | 20,115   |  
|taxes                                           |   |               |   |   |          |  
|Income tax expense                              |   | 10,279        |   |   | 2,092    |  
|Net income                                      |   | 4,585         |   |   | 10,714   |  
|Basic net income per common share               |   | 0.05          |   |   | 0.12     |  
|Diluted net income per common share             |   | 0.05          |   |   | 0.12     |  
|                                               
|Statement of Cash Flows                         |   |               |   |   |          |  
|Net income                                      |   | 4,585         |   |   | 10,714   |  
|Deferred income taxes                           |   | (21,204       | ) |   | (17,989  | )
|Stock-based compensation                        |   | 6,100         |   |   | 5,818    |  
|Other                                           |   | (772          | ) |   | 1,713    |  
|Net change in working capital                   |   | 9,416         |   |   | (2,791   | )
|Acquisition of businesses, net of cash acquired |   | (822,033      | ) |   | (820,953 | )
|                                               
|As at December 31, 2006                         |   | As Previously |   |   |          |  
|                                                |   | Reported      |   |   | Restated |  
|                                               
|Balance Sheet                                   |   |               |   |   |          |  
|Inventory                                       |   | 33,619        |   |   | 33,039   |  
|Deferred income taxes, current portion          |   | 5,372         |   |   | 7,061    |  
|Prepaid expenses and other current assets       |   | 6,303         |   |   | 7,145    |  
|Intangible assets                               |   | 244,954       |   |   | 247,199  |  
|Goodwill                                        |   | 630,770       |   |   | 638,355  |  
|Other assets                                    |   | 255           |   |   | 7,224    |  
|Accounts payable and accrued liabilities        |   | 48,982        |   |   | 49,662   |  
|Income taxes payable                            |   | 11,724        |   |   | 6,068    |  
|Deferred income tax liability                   |   | 69,215        |   |   | 75,017   |  
|Other liabilities                               |   | -             |   |   | 2,065    |  
|Share capital                                   |   | 470,190       |   |   | 472,390  |  
|Additional paid-in capital                      |   | 27,564        |   |   | 25,082   |  
|Accumulated deficit                             |   | (41,022       | ) |   | (34,893  | )
|Accumulated other comprehensive income          |   | 26,101        |   |   | 36,113   |  







Page 53



---





DIRECTORS AND EXECUTIVE OFFICERS

The following table sets forth the name, residence, office and principal occupation for the past five years of each of our directors and executive officers as of December 31, 2007.  Each director is elected by the shareholders at the annual general meeting and holds office until our first annual general meeting following the directors election or appointment, unless his or her office is earlier vacated.  Each executive officer holds office at the pleasure of the Board of Directors.



|                                                |                             |                                                                                                                                                                                                                                                                                                                                           
|----------------------------------------------- | --------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|Name and
Residence                              | Position with the
  Company | Principal Occupations Within the Past Five Years                                                                                                                                                                                                                                                                                          
|Directors:                                      |                             |                                                                                                                                                                                                                                                                                                                                           
|David Howard (1)(2)(3)
British Columbia, Canada | Director                    | Sept/02 to present  Chair, Angiotech;
Mar/00 to present  Director, Angiotech;
Aug/03 to July/05  Chairperson, SCOLR, Inc.;
May/00 to Aug/03  President & CEO, SCOLR, Inc.                                                                                                                                                             
|                                                |                             |                                                                                                                                                                                                                                                                                                                                           
|Laura Brege
California, U.S.A.                  | Director                    | Aug/07 to present  Director, Angiotech;
2006-Present  Executive Vice President & Chief Business Officer, Onyx Pharmaceuticals, Inc. (drug development company);
1999-2007  General Partner, Red Rock Management                                                                                                                        
|                                                |                             |                                                                                                                                                                                                                                                                                                                                           
|Edward Brown(2)(3)
California, U.S.A.           | Director                    | Jun/04 to present  Director, Angiotech;
Jun/04 to present   Managing Director and Co-founder of Healthcare Acquisition Investment Partners (Equity buyout fund focused on healthcare);
2000 to 2004  Managing Director, Health Care Investment Banking, Credit Suisse First Boston                                                     
|                                                |                             |                                                                                                                                                                                                                                                                                                                                           
|Greg Peet (1) (2)
British Columbia, Canada      | Director                    | Oct/05 to present  Director, Angiotech;
Jul/04 to present  Independent Corporate Director;
Jul/02 to Jul/04  Vice President and General Manager of McKesson Medical Imaging Group (medical imaging management);
Sep/92 to Jul/02  President, Chief Executive Officer and Chairman, A.L.I. Technologies Inc. (medical image management)
|                                                |                             |                                                                                                                                                                                                                                                                                                                                           
|Hartley T. Richardson
Manitoba, Canada          | Director                    | July/02 to present  Director, Angiotech;
1998 to present  President & CEO, James Richardson & Sons, Limited (investment and holding company whose subsidiaries carry on business in grain, oil & gas, financial services and real estate industries)                                                                                    
|                                                |                             |                                                                                                                                                                                                                                                                                                                                           
|Arthur Willms(1)(2)
British Columbia, Canada    | Director                    | Jun/04 to present  Director, Angiotech;
1983 to present  Director, Westcoast Energy Inc. (energy provider)                                                                                                                                                                                                                              



Page 54



---







|                                                                                                                                                                                                                                                                                                                            |                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                               
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|Executive Officers:                                                                                                                                                                                                                                                                                                         |                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                               
|                                                                                                                                                                                                                                                                                                                            |                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                               
|William L. Hunter, MD
British Columbia, Canada                                                                                                                                                                                                                                                                              | President, Chief Executive Officer,
  and Director  | Sept/02 to present  President & CEO, Angiotech;
Aug/98 to Sept/02  Chairman & CEO, Angiotech;
Nov/92 to present  Director, Angiotech                                                                                                                                                                                                                                                                                       
|                                                                                                                                                                                                                                                                                                                            |                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                               
|David M. Hall
British Columbia, Canada                                                                                                                                                                                                                                                                                      | Chief Compliance Officer                            | Dec/05 to present  Chief Compliance Officer, Angiotech;
Mar/02 to Dec/05  Chief Financial Officer, Corporate Secretary & Treasurer, Angiotech;
Jan/99 to Mar/02  Senior Vice President, Finance, Corporate Secretary & Treasurer, Angiotech                                                                                                                                                                                
|                                                                                                                                                                                                                                                                                                                            |                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                               
|K. Thomas Bailey
Washington, U.S.A.                                                                                                                                                                                                                                                                                         | Chief Financial Officer                             | Dec/05 to present  Chief Financial Officer, Angiotech;
Jan/04 to Dec/05  Vice President, Business Development, Angiotech;
Jan/03 to Jan/04  Independent Consultant
Aug 97 to Dec/02  Investment Banker, Credit Suisse First Boston and Donaldson, Lufkin & Jenrette                                                                                                                                                       
|                                                                                                                                                                                                                                                                                                                            |                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                               
|David D. McMasters, ESQ
Washington, U.S.A.                                                                                                                                                                                                                                                                                  | Senior Vice President,
  Legal and General Counsel  | Jan/04 to present Senior Vice President, Legal and General Counsel, Angiotech;
Dec/00 to Jan/04  Vice President Intellectual Property & General Counsel, Angiotech                                                                                                                                                                                                                                                          
|                                                                                                                                                                                                                                                                                                                            |                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                               
|Gary Ingenito, MD, PhD(4)
British Columbia, Canada                                                                                                                                                                                                                                                                          | Chief Clinical and
  Regulatory Affairs Officer     | Dec/05 to Feb/08  Chief Clinical and Regulatory Affairs Officer, Senior Vice President, Product Development, Angiotech;
Feb/05 to Dec/05  Senior Vice President, Clinical and Regulatory Affairs, Angiotech;
Oct/03 to Jan/05  Senior Vice President, SFBC International (drug development company);
1995 to 2003  Chief Operating Officer, Otsuka Maryland Research Institute (clinical research and development company)
|                                                                                                                                                                                                                                                                                                                            |                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                               
|Rui Avelar, MD, CCFP, DIP SPORT MED
British Columbia, Canada                                                                                                                                                                                                                                                                | Chief Medical Officer                               | Dec/05 to present  Chief Medical Officer, Angiotech
Jan/04 to Dec/05  Senior Vice President, Medical Affairs and Communications, Angiotech;
Jan/03 to Jan/04  Vice President, Medical Affairs and Communications, Angiotech;
Dec/01 to Jan/03  Vice President, Investor Relations, Angiotech;
Sept/00 to Dec/01  Biotechnology Analyst, Haywood Securities                                                               
|                                                                                                                                                                                                                                                                                                                            |                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                               
|Jeffrey P. Walker, MD(5)
    British Columbia, Canada                                                                                                                                                                                                                                                                       | Senior Vice President,
    Research and Development | May/06 to present  Senior Vice President of Research and Development, Angiotech;
    2003 to May/06 - Vice President, Advanced Technology/New Ventures, Medtronic Vascular, Inc.
    1996 to 2002, Vice President, Medical Research Department, Mirvant Pharmaceuticals                                                                                                                                                      
|                                                                                                                                                                                                                                                                                                                            |                                                     |                                                                                                                                                                                                                                                                                                                                                                                                                               
|Notes:
    (1)
    Member of the Audit Committee
    (2)
  Member of the Compensation Committee.  Mr. Peet was appointed in March 2006.
  (3)
  Member of the Governance and Nominating Committee.
  (4)
  Ceased employment on February 29, 2008
  (5)
  Dr. Walker became Chief Scientific Officer effective January 2008





Page 55



---





Directors and executive officers of our company beneficially owned, directly or indirectly, 1,298,188 common shares representing approximately 1.53% of the outstanding common shares as at December 31, 2007.



For each of the past ten years, none of our directors or executive officers has been a director, chief executive officer or chief financial officer of an issuer that was subject to an order that was issued while that person was acting in that capacity or was subject to an order that was issued after that person ceased to be acting in that capacity and which resulted from an event that occurred while that person was acting in that capacity.



For each of the past ten years, none of our directors or executive officers has been a director or executive officer of an issuer which, while that person was acting in that capacity or within one year of that person ceasing to act in that capacity, became bankrupt or made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangements or compromises with creditors or had a receiver, manager or trustee appointed to hold its assets.



None of our directors or executive officers have been subject to any penalties or sanctions imposed by a court relating to securities legislation or by a securities regulatory authority or has entered into a settlement agreement with a securities regulatory authority or any other penalties or sanctions imposed by a court or regulatory body that would likely be considered important to a reasonable investor in making an investment decision.





CORPORATE GOVERNANCE



Good governance is an important factor in the effective operation of the Company. Shareholders expect, and are entitled to, a Board that capably represents their interests in overseeing management.  The Companys Board of Directors currently consists of six independent members and one executive member. The role of chair is assumed by an independent director and is separate from the role of chief executive officer. Independent directors also chair the three committees of the Board.  Each Director brings unique experiences and skills in providing oversight and governance.  All committees consist of independent directors.



The Companys Board is strongly committed to the corporate governance requirements of the Canadian and U.S. securities commissions and stock exchanges, including the U.S. Sarbanes-Oxley Act of 2002 and Canadas National Instrument 58-101.  The Company considers these sources in reviewing and revising, where necessary, its corporate governance practices.



The Company believes that it meets or exceeds all applicable corporate governance requirements and will continue to be proactive in complying with new or evolving corporate governance standards. In 2005, the Company created the senior position of Chief Compliance Officer. The Chief Compliance Officer oversees the Companys efforts to ensure that it continues to meet or exceed all regulatory and corporate governance requirements.



The Board has overall responsibility for conduct of the business and affairs of the Company and discharges this responsibility both directly and through delegating certain authority to committees of the Board and to senior management of the Company.



The Audit Committee assists the Board in fulfilling its oversight responsibility to shareholders, potential shareholders, the investment community and others with respect to the Companys financial statements, financial reporting process, systems of internal accounting and disclosure controls, performance of the external auditors and risk assessment and management. The Committee has the power to conduct or authorize investigations into any matters within its scope of responsibilities, with full access to all books, records, facilities and personnel of the Company, its auditors and its legal advisors. In connection with such investigations or otherwise in the course of fulfilling its responsibilities under this charter, the Committee has the authority to independently retain special legal, accounting, or other consultants to advise it.





Page 56



---





The Company's independent auditor is accountable to the Board of Directors and to the Audit Committee.  The Board of Directors, through the Audit Committee, has the ultimate responsibility to evaluate the performance of the independent auditors, and through the shareholders, to appoint, replace and compensate the independent auditors. The Audit Committee pre-approves all services provided by the Companys independent auditor.



In 2002 we adopted codes of ethics for our Chief Executive Officer, Chief Financial Officer, directors and officers. These codes are available on our website at www.angiotech.com. During 2004 we also adopted codes of ethics for our employees.



More details on our corporate governance can be found at www.angiotech.com.





Audit Committee



The Audit Committee Charter is attached as Schedule A to this Annual Information Form and can also be found on our website at www.angiotech.com under the Corporate Governance section.



Our Audit Committee is comprised of the following independent and financially literate Directors:





Arthur Willms, Chairperson



David T. Howard



Greg Peet



Our board of directors has determined that it has at least one audit committee financial expert serving on its audit committee. Mr. Arthur Willms has been determined by the board to meet the audit committee financial expert criteria prescribed by the Securities and Exchange Commission (SEC) and is independent, as that term is defined by the NASDAQs listing standards applicable to the Registrant. The SEC has indicated that the designation of Mr. Willms as an audit committee financial expert does not make him an expert for any purpose, impose any duties, obligations or liability on him that are greater than those imposed on members of the Audit Committee and Board who do not carry this designation, or affect the duties, obligations or liability of any other member of the audit committee.



Relevant Education and Experience of Audit Committee Members



In addition to each members general business experience, the education and experience of each audit committee member that is relevant to the performance of his responsibilities as an audit committee member is described below:



Arthur Willms (Chair) is a retired President and Chief Operating Officer of Westcoast Energy Inc. where he held senior executive positions for 24 years.  Prior to his tenure with Westcoast Energy, Mr. Willms was a public school teacher in Alberta in Wheatland County and for the Calgary Public School Board from 1961 to 1967. In 1969, Mr. Willms became a lecturer in Economics at the University of Calgary. He holds a Bachelor of Education, a Bachelor of Arts, and a Masters in Economics from the University of Calgary. In addition to Mr. Willms' Board experience at Angiotech, he is also Chairman of the Board for the Vancouver Symphony Orchestra. His other numerous directorships include: Pacific Northern Gas, BC Lotteries Corp. and Pristine Power, Inc., and is Trustee of the 2010 Games Operating Trust. Mr. Willms was born in Namaka, Alberta.



David T. Howard is Chairman of our Board of Directors. From August 2003 to July 2005, Mr. Howard was Chairman of the Board of SCOLR, Inc., a biopharmaceutical company located in Redmond, WA. From May 2000 to August 2003, Mr. Howard was President and CEO of SCOLR. Mr. Howard is a Director at Sembiosys Genetics Inc. in Calgary, AB and James Richardson International in Winnipeg, MB. Prior to this, he has served as President & Chief Operating Officer of Novopharm International of Toronto, Ontario and President of Novopharm USA, Inc. Mr. Howards industry experience includes operational and strategic positions with Boehringer Mannheim Canada, where he was Vice President Pharmaceuticals, and Rhône-Poulenc Pharma in Montreal and Paris.





Page 57



---





Greg Peet was, most recently, the head of the McKesson Medical Imaging Group in 2002 after serving with A.L.I. Technologies Inc, since 1993, most recently as the President, CEO. At McKesson, Mr. Peet grew annual revenues 200% over two years to $100 million entirely through internally generated growth. At A.L.I. Mr. Peet led the transformation of the business from a primarily R&D facility to a viable commercial enterprise with a compounded 10 year revenue rate of 67% and over 400 employees. In 2002, McKesson purchased A.L.I. Technologies Inc. for C$526 million in cash which is widely regarded as the seminal transaction in the image management market space and was the largest cash purchase of a British Columbia technology company on record. Prior to McKesson and A.L.I, in 1993, Mr. Peet served as President and CEO of Enterprise Technologies Corp, a cable-television head-end equipment manufacturer. Mr. Peet serves as an independent director for public and private technology companies and is also Co-Chair of the Premiers Technology Council of BC







Pre-approval Policies and Procedures



It is within the mandate of the Audit Committee to approve all audit and non-audit related fees. The Audit Committee has pre-approved specifically identified non-audit tax related services, including tax compliance; the review of tax returns; and tax planning and advisory services relating to common forms of domestic and international taxation (i.e. income tax, capital tax, goods and services tax, value added tax and payroll tax).  The Audit Committee will be informed routinely as to the non-audit services actually provided by the independent auditor pursuant to this pre-approval process. The independent auditors also present the estimate for the annual audit related services to the Committee for approval prior to undertaking the annual audit of the financial statements. All of the fees presented in the table under Principal Accountant Fees and Service were pre-approved by the Audit Committee.



The Audit Committee has considered whether the provision of services other than audit services is compatible with maintaining the auditors independence. The Audit Committee has adopted a policy that prohibits the Company from engaging auditors for prohibited categories of non-audit services and requires pre-approval by the Audit Committee, or its Chair, of audit services and other services within permissible categories of non-audit services.



Principal Accountant Fees and Service



The aggregate fees for professional services rendered by the independent auditors, PricewaterhouseCoopers LLP, for Angiotech for the years ending December 31, 2007 and December 31, 2006 totalled $1,643,561 and $1,031,473, respectively, as detailed in the following table. All amounts are in U.S. dollars and have been converted from Canadian dollars using an average foreign exchange rate for the period indicated:



|                     |   | Year Ended        |  |   | Year Ended       
|-------------------- | - | ----------------- |  | - | -----------------
|(in U.S. dollars)    |   | December 31, 2007 |  |   | December 31, 2006
|Audit Fees           | $ | 1,422,125         |  | $ | 602,050          
|Audit - Related Fees | $ | 202,828           |  | $ | 65,123           
|Tax Fees             | $ | -                 |  | $ | 146,384          
|All Other Fees       | $ | 18,608            |  | $ | 217,914          
|TOTAL                | $ | 1,643,561         |  | $ | 1,031,473        



The nature of the services provided by PricewaterhouseCoopers LLP under each of the categories indicated in the table is described below.



Audit Fees



Audit fees were for professional services rendered for the audit of the Registrants annual financial statements (including SOX section 404 internal control over financial reporting requirements), quarterly reviews of interim financial statements and services provided in connection with statutory and regulatory filings or engagements.



Audit - Related Fees



Page 58



---







Audit related fees were for assurance and related services reasonably related to the performance of the audit or review of the annual statements and are not reported under Audit Fees above.  For each of 2007 and 2006, these services consisted of statutory audits of foreign subsidiaries.



Tax Fees



Tax fees were for tax compliance, tax advice and tax planning professional services. These services consisted of: tax compliance including the review of tax returns and tax planning and advisory services relating to common forms of domestic and international taxation (i.e. income tax, capital tax, goods and services tax, value added tax and payroll tax).



All Other Fees



In 2007, All Other Fees relates to services in regards to a registration statement which was not completed. In 2006, All Other Fees relates to services in regards to the senior notes registration statement and floating rate notes offering circular.



Governance and Nominating Committee



The Governance and Nominating Committee enhances corporate performance by assessing and making recommendations regarding board effectiveness and by establishing a process for identifying, recruiting, appointing and re-appointing directors.  The Committee reviews and monitors our corporate governance policies and procedures and, where necessary, makes recommendations on improvements to senior management.



The Governance and Nominating Committee Charter can be found on our website at www.angiotech.com under the Corporate Governance section.





Compensation Committee



The Compensation Committee plans for the continuity of executive officers and other key employees.  The Committee also is responsible for our overall executive compensation plan to ensure it is competitive and motivating in order to attract, retain and inspire excellence in the performance of executive officers and other key employees, while taking into account the cost of executive compensation and interests of shareholders.



The Charter of the Compensation Committee can be found on our website at www.angiotech.com under the Corporate Governance section.







DESCRIPTION OF CAPITAL STRUCTURE



Shares



Our authorized share capital consists of 250,000,000 shares, divided into 200,000,000 common shares without par value, of which, as of March 28, 2008, 85,073,983 are issued and outstanding, and 50,000,000 Class I Preference shares without par value, issuable in series, of which none is issued and outstanding.  Our Board of Directors is authorized to determine the rights and restrictions to be attached to each series of the Class I Preference shares upon issuance.  Certain conditions attached to financing indebtedness and the issuance of notes limit our ability to issue preference shares.





Page 59



---





Holders of common shares are entitled to receive notice of any meeting of shareholders and to attend and vote at those meetings, except those meetings at which only the holders of shares of another class or of a particular series are entitled to vote. Each common share entitles its holder to one vote. Subject to the rights of the holders of Class I Preference shares, the holders of common shares are entitled to receive on a proportionate basis such dividends as our Board of Directors may declare out of funds legally available for such dividends. In the event of the dissolution, liquidation, winding up or other distribution of our assets, the holders of the common shares are entitled to receive on a proportionate basis all of our assets remaining after payment of all of our liabilities, subject to the rights of holders Class I Preference shares.



The common shares carry no pre-emptive or conversion rights other than rights granted to holders of common shares under the Shareholders Rights Plan implemented effective February 10, 1999 and ratified by the shareholders on March 16, 1999, re-adopted by our shareholders on March 5, 2002, and again on June 9, 2005. The Shareholder Rights Plan is designed to encourage the fair treatment of our shareholders in connection with any take-over offer for our outstanding common shares. The Shareholder Rights Plan provides our Board of Directors and shareholders with 60 days, which is longer than provided by applicable laws, to fully consider any unsolicited take-over bid without undue pressure, to allow our Board of Directors, if appropriate, to consider other alternatives to maximize shareholder value and to allow additional time for competing bids to emerge. If a bid is made to all shareholders, which is held open for at least 60 days and is accepted by shareholders holding more than 50% of the outstanding common shares, or is otherwise permitted by our Board of Directors, then the Shareholder Rights Plan will not affect the rights of shareholders. Otherwise, all shareholders, except the parties making a take-over bid, will be able to acquire a number of additional common shares equal to 100% of their existing outstanding holdings at half the market price. Thus, any party making a take-over bid not permitted by the Shareholder Rights Plan could suffer significant dilution. The Plan has a term of nine years, subject to reconfirmation by the shareholders at the annual general meeting in 2008 and 2011.



Page 60



---







INDEBTEDNESS



The following is a summary of provisions relating to our indebtedness.



(a)

Senior Floating Rate Notes



On December 11, 2006, the Company issued Floating Rate Notes due December 1, 2013 in the aggregate principal amount of $325 million.  The net proceeds from the issuance of the Floating Rate Notes and approximately $2.9 million in cash were used to repay the outstanding principal amount under our Senior Secured Term Loan Facility. The Floating Rate Notes bear interest at an annual rate of LIBOR (London Interbank Offered Rate) which is reset quarterly, plus 3.75%.  Interest is payable quarterly in arrears on March 1, June 1, September 1, and December 1 of each year through to maturity.  The Floating Rate Notes are unsecured senior obligations, are guaranteed by certain of the Companys subsidiaries and rank equally in right of payment to all of the Companys existing and future senior unsubordinated indebtedness.  The guarantees of its guarantor subsidiaries are unconditional, joint and several.  The Company has provided condensed consolidating guarantor financial information in its consolidated financial statements as at December 31, 2007 and 2006 and for the years ended December 31, 2007, 2006 and 2005 (see note 26 of our 2007 audited consolidated financial statements).



At any time prior to June 1, 2008, the Company may redeem up to 35% of the aggregate principal amount of the Floating Rate Notes at 100% of the principal amount plus a premium equal to the interest rate per annum applicable on the date the notice of redemption is given plus accrued and unpaid interest with the net cash proceeds of one or more public offerings of the Companys equity securities. The Company may also choose to redeem the notes at any time prior to June 1, 2008 in whole or in part by paying a redemption price equal to the sum of:



(1)

100% of the principal amount of the Floating Rate Notes to be redeemed; plus

(2)

the applicable premium, being the greater of:

a.

1.0% of the principal amount of a note at such time; or

b.

the excess of the present value at such time of the redemption price of such note at June 1, 2008 plus any required interest payments due on such note through June 1, 2008 over the principal amount of the note.



On or after June 1, 2008, the Company may redeem all or a part of the Floating Rate Notes at the redemption prices (expressed as percentages of principal amount) set forth below plus accrued and unpaid interest, if any, on the notes redeemed, to the applicable redemption date, if redeemed during the period beginning on the dates indicated below:



|                                |             
|------------------------------- | ------------
|Year                            | Percentage
%
|June 1, 2008                    | 104         
|December 1, 2008                | 103         
|December 1, 2009                | 102         
|December 1, 2010                | 101         
|December 1, 2011 and thereafter | 100         



In certain change of control situations, the Company is required to make an offer to purchase the then-outstanding Floating Rate Notes at a price equal to 101% of their stated principal amount, plus accrued and unpaid interest to the applicable repurchase date, if any.













Page 61



---





(b)   Senior Subordinated Notes



On March 23, 2006, the Company issued 7.75% Senior Subordinated Notes due April 1, 2014 in the aggregate principal amount of $250 million.  The Senior Subordinated Notes were used to fund the Company's acquisition of AMI.  The Senior Subordinated Notes and related Note guarantees provided by the Company and certain of its subsidiaries are subordinated to other senior indebtedness.The Company has provided condensed consolidating guarantor financial information as of December 31, 2007 and 2006 and for the years ended December 31, 2007, 2006 and 2005 (see note 26 of our 2007 audited consolidated financial statements).



At any time prior to April 1, 2009, the Company may redeem up to 35% of the aggregate principal amount of the Subordinated Notes at 107.75% of the principal amount plus accrued and unpaid interest with the net cash proceeds of one or more offerings of the Companys equity securities or convertible debt. The Company may also choose to redeem the Notes at any time prior to April 1, 2009, in whole or in part by paying a redemption price equal to the sum of:



(1)

100% of the principal amount of the Subordinated Notes to be redeemed; plus

(2)

the applicable premium, being the greater of:

a.

1.0% of the principal amount of a note at such time; or

b.

the excess of the present value at such time of the redemption price of such note at April 1, 2009 plus any required interest payments due on such note through April 1, 2009 over the principal amount of the Note.



On or after April 1, 2009, the Company may redeem all or a part of the Subordinated Notes at the redemption prices (expressed as percentages of principal amount) set forth below plus accrued and unpaid interest, if any, on the notes redeemed, to the applicable redemption date, if redeemed during the twelve-month period beginning on April 1 of the years indicated below:



|                    |             
|------------------- | ------------
|Year                | Percentage
%
|2009                | 105.813     
|2010                | 103.875     
|2011                | 101.938     
|2012 and thereafter | 100.000     



In certain change of control situations, the Company is required to make an offer to purchase the then-outstanding Subordinated Notes at a price equal to 101% of their stated principal amount, plus accrued and unpaid interest to the applicable repurchase date, if any.





(c)

Credit Facility



On March 23, 2006, the Company entered into a $425 million senior secured facility (the Credit Facility) which included a $350 million senior secured term loan (the Term Loan) maturing March 23, 2013 and a $75 million revolving senior secured credit facility maturing March 23, 2011. Borrowings under the Credit Facility were comprised of Eurodollar loans and Base Rate loans.  Eurodollar loans bore interest at an applicable rate based on the leverage ratio plus an adjusted LIBOR rate payable on the last day of the one, two or three month interest periods applicable to the borrowing.  Base Rate loans bore interest at an applicable rate based on the leverage ratio plus the greater of (a) the Prime Rate and (b) the Federal Funds Effective Rate plus 0.5% payable on the last business day of each calendar quarter.  The applicable rate for term loans ranged from 0.25% to 1.5% and the applicable rate for revolving loans ranged from 0% to 2%.



On December 11, 2006, the Company repaid the outstanding principal amount of the Term Loan of $319.9 million with the net proceeds from the Floating Rate Notes offering plus cash on hand and terminated the revolving credit commitment.



Page 62



---







(d)

Covenants



Material covenants in the indentures governing the Subordinated Notes and Floating Rate Notes (the Indentures) specify maximum or permitted amounts for certain types of capital transactions and restrict, and under specified circumstances prohibit, the payment of dividends by the Company.  If the Subordinated Notes or Floating Rate Notes are rated investment grade and no event of default exists, certain covenants will no longer apply. Outstanding principal amounts and interest accrued and unpaid may become immediately due and payable upon the occurrence of events of default specified in the Indentures.  There are also certain limitations on asset sales and subsequent use of proceeds pursuant to the Indentures.  As of December 31, 2007, the Company was in compliance with all covenants and was not in breach of any provision of the Indentures governing the Subordinated Notes and Floating Rate Notes that would cause an event of default to occur.



(e)

Deferred Financing Costs



In 2007, the Company incurred debt issuance costs of $1,000,000 (2006 - $26,200,000) in connection with the issuance of long-term debt.  Deferred financing costs are capitalized and amortized on a straight-line basis, which approximates the effective interest rate method, to interest expense over the life of the debt instruments.



RATINGS



The ratings on our Senior Floating Rate Notes and Senior Subordinated Notes by each of Moodys Investors Service, Inc. (Moodys) and Standard & Poors Corporation (S&P, together with Moody, the Rating Agencies) are presented in the table below:



|                           |           |    
|-------------------------- | --------- | ---
|                           | Moodys   | S&P
|Senior Floating Rate Notes | B2/LGD3   | B- 
|Senior Subordinated Notes  | Caa1/LGD6 | CCC



Such ratings are not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time by the Rating Agencies.  In addition, a rating does not comment on the suitability of an investment for a particular investor.  Credit ratings are intended to provide investors with an independent measure of credit quality of an issue of securities.  In addition, the review of the characteristics of the issue of securities as part of a rating encompasses a wide range of quantifiable and non-quantifiable factors related to the issuer and the guarantor.  The Rating Agencies have issued reports providing background information relating to the basis for their respective ratings of the Senior Floating Rate Notes and the Senior Subordinated Notes and we encourage you to review these reports.



Moodys ratings for debt instruments range from Aaa to C, which represents the range from highest to lowest quality of such securities rated.  According to the Moodys rating system, debt securities rated B2, with a negative outlook, are considered speculative and are subject to high credit risk.  The addition of a 1, 2 or 3 modifier after the rating indicates the relative standing within a particular category.  The modifier 1 indicates that the obligation ranks in the higher end of its generic rating category and the modifier 3 indicates that the obligation ranks in the lower end of its generic rating category. Debt securities rated Caa are judged to be of poor standing and are subject to very high credit risk.

Moody's LGD assessments are opinions about expected loss given default on fixed income obligations expressed as a percent of principal and accrued interest at the resolution of the default. LGD assessments are assigned to individual loan, bond, and preferred stock issues. The firm-wide or enterprise expected LGD rate is a weighted average of the expected LGD rates on all constituent liabilities (excluding preferred stock), where the weights equal each obligation's expected share of the total liabilities at default.



Page 63



---





The following scale is used in the assignment of LGD assessments:

|       |               
|------ | --------------
|Rating | Loss range    
|LGD1   | ≥0% and < 10% 
|LGD2   | ≥10% and < 30%
|LGD3   | ≥30% and < 50%
|LGD4   | ≥50% and < 70%
|LGD5   | ≥70% and < 90%
|LGD6   | ≥90% and ≤100%

S&Ps ratings for debt instruments range from AAA to D, which represents the range from highest to lowest quality of such securities rated.  According to the S&P rating system, debt securities rated B- are considered to be more vulnerable to non-payment and have significant speculative characteristics, but the obligor currently has the capacity to meet its financial commitment on the obligation.  Adverse business, financial or economic conditions likely will impair the obligors capacity or willingness to meet its financial commitment on the obligation.  A + or - grade indicate the relative standing within a rating category.  Debt securities rated CCC is currently vulnerable to non-payment, and is dependent upon favorable business, financial, and economic conditions for the obligor to meet its financial commitment on the obligation. In the event of adverse business, financial, or economic conditions, the obligor is not likely to have the capacity to meet its financial commitment on the obligation.



MARKET FOR SECURITIES



Trading Price and Volume



Our common shares are publicly traded on the Toronto Stock Exchange under the trading symbol ANP and on the NASDAQ National Market under the trading symbol ANPI. The following table summarizes the high and low prices and trading volume for our common shares during 2007 and 2006 on a monthly and quarterly basis. The prices listed below are in Canadian dollars for trading on the Toronto Stock Exchange and in U.S dollars for trading on the NASDAQ National Market.



Page 64



---







|2007      |   |                  |   |              |              |          |   |      |         | Trading  
|--------- | - | ---------------- | - | ------------ | ------------ | -------- | - | ---- | ------- | ---------
|          |   | Canadian Dollars |   | U.S. Dollars | Trading      | Volume  
|Month     |   | (TSX)            |   | (NASDAQ)     | Volume (TSX) | (NASDAQ)
|          |   | High             |   | Low          |              | High     |   | Low  |         |          
|January   | $ | 11.15            | $ | 9.09         | $            | 9.47     | $ | 7.73 | 379,400 | 467,500  
|February  |   | 10.58            |   | 7.66         |              | 9.02     |   | 6.60 | 701,600 | 1,133,300
|March     |   | 7.88             |   | 6.16         |              | 6.75     |   | 5.33 | 417,300 | 874,700  
|April     |   | 7.10             |   | 6.02         |              | 6.29     |   | 5.28 | 352,800 | 887,800  
|May       |   | 8.00             |   | 6.09         |              | 7.31     |   | 5.47 | 633,800 | 1,357,500
|June      |   | 7.91             |   | 7.13         |              | 7.40     |   | 6.72 | 231,000 | 644,100  
|July      |   | 7.89             |   | 7.22         |              | 7.56     |   | 6.85 | 368,400 | 794,200  
|August    |   | 7.72             |   | 5.75         |              | 7.34     |   | 5.40 | 278,900 | 726,800  
|September |   | 6.85             |   | 6.16         |              | 6.54     |   | 5.85 | 171,200 | 321,000  
|October   |   | 7.69             |   | 4.00         |              | 7.90     |   | 4.13 | 482,100 | 1,193,000
|November  |   | 4.50             |   | 3.50         |              | 4.75     |   | 3.55 | 321,700 | 751,800  
|December  |   | 4.00             |   | 3.05         |              | 4.00     |   | 3.10 | 310,000 | 774,700  





|        |   |                  |   |              |              |          |   |      |         | Trading
|------- | - | ---------------- | - | ------------ | ------------ | -------- | - | ---- | ------- | -------
|        |   | Canadian Dollars |   | U.S. Dollars | Trading      | Volume  
|Quarter |   | (TSX)            |   | (NASDAQ)     | Volume (TSX) | (NASDAQ)
|        |   | High             |   | Low          |              | High     |   | Low  |         |        
|Q1      | $ | 11.15            | $ | 6.16         | $            | 9.47     | $ | 5.33 | 479,520 | 794,938
|Q2      |   | 8.00             |   | 6.02         |              | 7.40     |   | 5.28 | 378,274 | 924,211
|Q3      |   | 7.89             |   | 5.75         |              | 7.56     |   | 5.40 | 268,421 | 608,280
|Q4      |   | 7.69             |   | 3.05         |              | 7.90     |   | 3.10 | 371,870 | 870,091







Page 65



---







|2006      |   |                  |   |              |              |          |   |       |         | Trading
|--------- | - | ---------------- | - | ------------ | ------------ | -------- | - | ----- | ------- | -------
|          |   | Canadian Dollars |   | U.S. Dollars | Trading      | Volume  
|Month     |   | (TSX)            |   | (NASDAQ)     | Volume (TSX) | (NASDAQ)
|          |   | High             |   | Low          |              | High     |   | Low   |         |        
|January   | $ | 16.68            | $ | 13.57        | $            | 14.20    | $ | 11.86 | 181,800 | 623,800
|February  |   | 19.29            |   | 15.40        |              | 16.80    |   | 13.24 | 312,900 | 980,600
|March     |   | 19.00            |   | 16.95        |              | 16.48    |   | 14.62 | 225,400 | 619,800
|April     |   | 17.53            |   | 15.87        |              | 15.39    |   | 13.76 | 156,600 | 424,500
|May       |   | 16.87            |   | 15.19        |              | 15.37    |   | 13.60 | 178,500 | 342,400
|June      |   | 15.62            |   | 12.78        |              | 14.19    |   | 11.34 | 264,400 | 516,300
|July      |   | 13.90            |   | 12.45        |              | 12.32    |   | 10.99 | 192,700 | 337,800
|August    |   | 13.95            |   | 11.56        |              | 12.39    |   | 10.25 | 298,700 | 360,200
|September |   | 13.54            |   | 9.50         |              | 12.22    |   | 8.47  | 217,800 | 474,700
|October   |   | 10.97            |   | 9.45         |              | 9.81     |   | 8.36  | 498,000 | 563,900
|November  |   | 10.80            |   | 9.00         |              | 9.45     |   | 8.00  | 656,000 | 531,100
|December  |   | 10.12            |   | 9.15         |              | 8.80     |   | 7.98  | 518,800 | 455,000





|        |   |                  |   |              |              |          |   |       |         | Trading
|------- | - | ---------------- | - | ------------ | ------------ | -------- | - | ----- | ------- | -------
|        |   | Canadian Dollars |   | U.S. Dollars | Trading      | Volume  
|Quarter |   | (TSX)            |   | (NASDAQ)     | Volume (TSX) | (NASDAQ)
|        |   | High             |   | Low          |              | High     |   | Low   |         |        
|Q1      | $ | 19.29            | $ | 13.57        | $            | 16.80    | $ | 11.86 | 230,069 | 707,303
|Q2      |   | 17.53            |   | 12.78        | $            | 15.39    | $ | 11.34 | 196,862 | 415,950
|Q3      |   | 13.95            |   | 9.50         | $            | 12.39    | $ | 8.47  | 233,042 | 375,577
|Q4      |   | 10.97            |   | 9.00         | $            | 9.81     | $ | 7.98  | 554,155 | 500,222







Page 66



---





Comparative Shareholder Return Performance Graph



The following graph compares cumulative total Shareholder return on $100 invested in Common shares of the Company on September 30, 2002 with the cumulative total return of the S&P/TSX Composite Index (S&P/TSX) and the NASDAQ Biotechnology Index, assuming the re-investment of dividends.  The Common shares began trading on the TSX on December 18, 1997. The Company changed its financial year end to December 31 effective December 31, 2003.



[exhibit991003.jpg]

The following numerical values were used to generate the Share Price Performance Graph.



|                           |             |            |            |            |            |           
|-------------------------- | ----------- | ---------- | ---------- | ---------- | ---------- | ----------
|                           | Sept. 30/02 | Dec. 31/03 | Dec. 31/04 | Dec. 31/05 | Dec. 31/06 | Dec. 31/07
|Companys Total Return     | 100         | 189        | 141        | 97         | 61         | 22        
|S&P/TSX                    | 100         | 133        | 150        | 182        | 209        | 224       
|NASDAQ Biotechnology Index | 100         | 156        | 165        | 170        | 172        | 180       





Based on information provided by our transfer agent, as of April 16, 2007, we had 569 shareholders of record. We believe we have approximately 19,687 beneficial owners of our common shares in total. This belief is based on the registered shareholder list as of April 2007 and the number of proxy statements and annual reports required by intermediaries, for our Annual General Meeting held on June 7, 2007.





QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK



The primary objective of our investment activities is to preserve our capital to fund operations. We also seek to maximize income from our investments without assuming significant risk. To achieve our objectives, we maintain a portfolio of cash equivalents and investments in a variety of securities of high credit quality. As of December 31, 2007 we had cash and cash equivalents of $91.3 million.



Page 67



---





Interest Rate Risk

As the issuer of the Floating Rate Notes, we are exposed to interest rate risk. The interest rate on the Floating Rate Notes is reset quarterly to 3-month LIBOR plus 3.75%. The Floating Rate Notes currently bear interest at a rate of approximately 6.8% (December 31, 2007  8.9%). Based upon the average floating rate debt levels of the Company during the year ended December 31, 2007, a 100 basis point increase in interest rates would have impacted our interest expense by approximately $3.3 million. We do not use derivatives to hedge against interest rate risk.

Foreign Currency Risk

We operate internationally and enter into transactions denominated in foreign currencies. As such, our financial results are subject to the variability that arises from exchange rate movements in relation to the U.S. dollar. Our foreign currency exposures are primarily limited to the Canadian dollar, the Swiss franc, the Danish kroner, the Euro and the U.K. pound sterling. We incurred transaction losses of $2.8 million for the year ended December 31, 2007 primarily as a result of changes in the relationship of the U.S. to Canadian dollar and other foreign currency exchange rates when translating our foreign currency-denominated cash, cash equivalents and short-term investments to U.S. dollars for reporting purposes at period end. We have not entered into any forward currency contracts or other financial derivatives to hedge foreign exchange risk, and therefore we are subject to foreign currency transaction and translation gains and losses. We purchase goods and services in U.S. and Canadian dollars, Swiss francs, Danish kroner, and U.K. pound sterling, and earn a significant portion of our license and milestone revenues in U.S. dollars. Foreign exchange risk is managed primarily by satisfying foreign denominated expenditures with cash flows or assets denominated in the same currency.

Since we operate internationally and approximately 16.9% of our net revenue for the year ended December 31, 2007 was generated in other than the United States dollar, foreign currency exchange rate fluctuations could significantly impact our financial position, results of operations, cash flows and competitive position.

For purposes of specific risk analysis, we used a sensitivity analysis to measure the potential impact to our consolidated financial statements for a hypothetical 10% strengthening of the U.S. dollar compared with the Canadian dollar, the Swiss franc, the Danish kroner, the Euro and the U.K. pound sterling for the year ended December 31, 2007. Assuming a 10% strengthening of the U.S. dollar, our product net revenue would have been negatively impacted by approximately $2.7 million. We occasionally enter into forward contracts and have currently entered into a currency swap whereby we have swapped Euro 3.1 million for US$4.5 million. Other than these contracts, to date, we have not hedged our exposure to changes in foreign currency exchange rates, and as a result, we could incur unanticipated translation gains and losses.





LEGAL PROCEEDINGS



In connection with maintaining the value of our various intellectual property and exclusivity rights, we regularly evaluate the activities of others worldwide. Our success will depend, in part, on our ability to obtain patents, or licenses to patents, maintain trade secret protection and enforce our rights against others. Should it become necessary to protect those rights, we will pursue all cost-efficient strategies, including when appropriate negotiation or litigation in any relevant jurisdiction.



i)

The Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business.  Such matters are subject to many uncertainties.  Management believes that adequate provisions have been made in the accounts where required and the ultimate resolution of such contingencies will not have a material adverse effect on the financial position of the Company. However, we are not able to predict the outcome of the pending legal proceedings listed below, or other legal proceedings, to which we may become subject in the normal course of business or estimate the amount or range of any possible loss we might incur if we do not prevail in the final, non-appealable determinations of such matters. Therefore, the Company has no current accruals for these potential contingencies. The Company cannot provide assurance that the legal proceedings listed here, or other legal proceedings not listed here, will not have a material adverse impact on our financial condition or results of operations.





Page 68



---





ii)

BSC, a licensee, is often involved in legal proceedings (to which the Company is not a party) concerning challenges to its stent business. If a party opposing BSC is successful, royalty revenue would likely be significantly reduced. The ultimate outcome of any such proceedings is uncertain at this time.



iii)

At the EPO, various patents either owned or licensed by or to the Company are in opposition proceedings. In EP0809515 (which the Company licenses from (and to) BSC), the EPO held an oral hearing on January 30, 2008, and thereafter revoked this patent.  This decision of the opposition board may be appealed.  Oppositions against European Patent Nos. EP0876165 (which relates to our Co-Seal product), EP1429664 (which relates to our Quill SRS products), EP0975340, EP1118325, EP1155689 and EP1407786 are in progress, with briefs being exchanged. The grant of European Patent No. EP0830100, which relates to our ePTFE vascular graft products, was opposed with an oral hearing conducted on September 28, 2006. At the end of the hearing, the EPO determined that an amended form of the patent was valid. The opponent appealed this decision.



iv)

On March 1, 2006, the Board of Appeals of the Japanese Patent Office issued a final order of revocation regarding certain claims of our Japanese Patent No. 3423317, directed to a stent coated with paclitaxel. Angiotech appealed this decision to Japans Intellectual Property High Court, however in November 2007, the Intellectual Property High Court ruled in favour of the Japanese Patent Office.  In January 2008, Angiotech appealled this decision to Japans Supreme Court, and we are waiting to hear whether the Supreme Court will agree to hear our appeal.



v)

In February 2005, a claim was filed by Conor in a court in the United Kingdom alleging that one of the Company's U.K. stent patents is invalid and seeking to have that patent revoked.  On February 24, 2006, a U.K. court ruled in favor of Conor, finding that the Companys UK Hunter Patent was invalid.  Angiotech launched an appeal at the Court of Appeals, however that appeal was dismissed.  The Company subsequently filed a Petition with the House of Lords to request that the House of Lords overrule the lower court decision, and this Petition was accepted.  A date for a hearing before the House of Lords has been set for May 6  8, 2008.  Conor will not be participating in this hearing.



vi)

In April 2005, the Company together with BSC commenced a legal action in the Netherlands against Sahajanand Medical Technologies Pvt. Ltd. for patent infringement.  The hearing was held in March 2006.  In May 2006, the Dutch court ruled in favor of Angiotech, finding that Angiotechs EP (NL) Hunter patent was valid, and that SMTs Infinnium stent was infringing that patent.  SMT has filed an appeal, and is currently enjoined from selling their stent in the Netherlands pending resolution of that appeal.  The court held a hearing on March 13, 2008, and a decision is expected to issue on May 29, 2008.



vii)

In December 2005, the Company together with BSC commenced a Preliminary Injunction Proceeding in the Netherlands against Biosensors International Group Ltd. and six related companies including Occam International BV, requesting a preliminary injunction.  In March 2006, a Dutch court ruled against Angiotechs request for a preliminary injunction against Occam and its distributor.  An appeal was filed by Angiotech and may be heard late in 2008.



viii)

In July 2004, Dr. Gregory Baran initiated legal action, alleging infringement by Medical Device Technologies (“MDT”) of two U.S. patents owned by Dr. Braun.  These patents allegedly cover MDT’s BioPinceTM automated biopsy device, which had 2005 sales of $3.6 million.  On September 25, 2007, the judge issued her decision pursuant to the Markman hearing of December 2005.  We consider the decision to be largely favorable to Angiotech.  We are now in the discovery phase of this litigation.  No hearing date has yet been set by the court.



ix)

On March 23, 2006, RoundTable Healthcare Partners, LP as Seller Representative, Angiotech as Buyer, and LaSalle Bank as Escrow Agent, executed an Escrow Agreement under which Angiotech deposited $20 million with LaSalle.  On April 4, 2007, LaSalle Bank received an Escrow Claim Notice issued by Angiotech, which directed LaSalle to remit the $20 million to Angiotech as Buyer.  On or about Apri1 16, 2007, LaSalle received from RoundTable a Notice of Objection to Angiotech's Escrow Claim Notice.  On July 3, 2007, LaSalle filed an action in the Circuit Court of Cook County, Illinois, asking the court to resolve this dispute.   This litigation is ongoing.



Page 69



---







We intend to pursue and to defend vigorously any and all actions of third parties related to our extensive patent portfolio and pioneering technology. Any failure to obtain and protect intellectual property could adversely affect our business and our ability to operate could be hindered by the proprietary rights of others. The ultimate outcome of these oppositions and legal proceedings, including possible appeals, are uncertain at this time.







MATERIAL CONTRACTS



The following is a list of material contracts that we have entered into since January 1, 2002 outside of the ordinary course of business or are otherwise required to be disclosed by applicable securities laws:



(1)

Distribution and License Agreement with Baxter Healthcare Corporation dated April 1, 2003, as amended, as described in the section titled General Development of the Business  Acquisitions and Collaboration, License and Sales and Distribution Agreements.



(2)

Manufacturing and Supply Agreement with Baxter Healthcare Corporation dated April 1, 2003, as amended, as described in the section titled General Development of the Business  Acquisitions and Collaboration, License and Sales and Distribution Agreements.



(3)

Amendment dated September 24, 2004 between Angiotech Pharmaceuticals, Inc. and Cook Incorporated Modifying the July 9, 1997 License Agreement among Angiotech Pharmaceuticals, Inc., Boston Scientific Corporation and Cook Incorporated dated July 9, 1997, as amended, as described in the section titled General Development of the Business  Acquisitions and Collaboration, License and Sales and Distribution Agreements.



(4)

Amendment dated November 23, 2004 between Angiotech Pharmaceuticals, Inc. and Boston Scientific Corporation Modifying the July 9, 1997 License Agreement among Angiotech Pharmaceuticals, Inc., Boston Scientific Corporation and Cook Incorporated dated July 9, 1997, as amended, as described in the section titled General Development of the Business  Acquisitions and Collaboration, License and Sales and Distribution Agreements.



(5)

Research and License Agreement dated October 3, 2005 between Angiotech Pharmaceuticals, Inc. and CombinatoRx, Incorporated, as described in the section titled General Development of the Business  Acquisitions and Collaboration, License and Sales and Distribution Agreements.



(6)

Series E Convertible Preferred Stock Purchase Agreement dated October 3, 2005 between Angiotech Pharmaceuticals, Inc. and CombinatoRx, Inc.



(7)

Stock Purchase Agreement dated January 31, 2006, as amended March 23, 2006, between Angiotech Pharmaceuticals (US), Inc., Roundtable Healthcare Partners, LP, Roundtable Healthcare Investors, LP, Marmon Medical Companies, LLC, certain named sellers, American Medical Instruments Holdings, Inc. and Angiotech Pharmaceuticals, Inc., as described in the section titled General Development of the Business  Acquisitions and Collaboration, License and Sales and Distribution Agreements.



(8)

Purchase Agreement dated March 16, 2006 among Angiotech Pharmaceuticals, Inc., Credit Suisse Securities (USA) LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, pursuant to which the purchasers acquired the Subordinated Notes.



(9)

Indenture dated March 23, 2006 among Angiotech Pharmaceuticals, Inc., certain of its subsidiaries and Wells Fargo Bank, N.A. as described in the section titled Indebtedness.





Page 70



---





(10)

Registration Rights Agreement dated March 23, 2006 among Angiotech Pharmaceuticals, Inc., Credit Suisse Securities (USA) LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, as described in the section titled Indebtedness.



(11)

Indenture dated December 11, 2006 among Angiotech Pharmaceuticals, Inc., certain of its subsidiaries and Wells Fargo Bank, N.A. as described in the section titled Indebtedness.



(12)

Registration Rights Agreement dated December 11, 2006 among Angiotech Pharmaceuticals, Inc., Credit Suisse Securities (USA) LLC, Banc Of America Securities LLC and BMO Capital Markets Corp., as described in the section titled Indebtedness.



(13)

Purchase Agreement dated November 30, 2006 among Angiotech Pharmaceuticals, Inc., Credit Suisse Securities (USA) LLC, Banc of America Securities LLC and BMO Capital Markets Corp., pursuant to which the purchasers acquired the Floating Rate Notes.



TRANSFER AGENT & REGISTRAR



The registrar and transfer agent for the common shares in Canada is Computershare Investor Services Inc., 510 Burrard Street, Vancouver, British Columbia and in the U.S. is Computershare Trust Company, Inc. 12039 West Alameda Parkway, Suite Z-2, Lakewood, Colorado. These offices and the principal offices of Computershare Investor Services Inc. in the city of Toronto can effect transfers and make deliveries of certificates for common shares.



EXPERTS



The Company's independent auditors are PricewaterhouseCoopers LLP, Chartered Accountants, who have issued an independent auditors' report dated March 12, 2008 in respect of the Company's consolidated financial statements as at December 31, 2006 and 2007 and for each of the two years ended December 31, 2007 and the Company's internal control over financial reporting as at December 31, 2007.



PricewaterhouseCoopers LLP has advised us that they are independent with respect to the Company within the meaning of the rules of the U.S. Securities and Exchange Commission and the Rules of Professional Conduct of the Institute of Chartered Accountants of British Columbia.



FORWARD-LOOKING STATEMENTS



Statements contained in this Annual Information Form that are not based on historical fact, including without limitation statements containing the words believes, may, plans, will, estimates, continues, anticipates, intends, expects and similar expressions, constitute forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and constitute forward-looking information within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the safe harbor provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for 2008 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research development and product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements.



Known risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; availability of financial reimbursement coverage from governmental and third-party payers for products and related treatments; adverse results or unexpected delays in drug discovery and clinical development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development and to expand commercialization activities or consummate acquisitions; and any other factors that may affect our performance.



Page 71



---







In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this Annual Information Form to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete preclinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third-party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; our ability to continue to service our debt obligations; our ability to achieve the financial benefits expected as a result of our acquisition of AMI; and any other factors referenced in our other filings with the applicable Canadian securities regulatory authorities or the SEC.



For a more thorough discussion of the risks associated with our business, see the section entitled Risk Factors in this Annual Information Form.



Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward looking statements contained in this Annual Information Form to reflect future results, events or developments.







ADDITIONAL INFORMATION



Additional information relating to us may be found on SEDAR at www.sedar.com and additional financial information is provided in our Consolidated Financial Statements and Managements Discussion and Analysis dated March 10, 2008 for the year ended December 31, 2007 and the Auditors Report to the Shareholders, which are hereby incorporated by reference.  In accordance with National Instrument 51-102 Continuous Disclosure Requirements, our shareholders may elect annually to receive annual or interim corporate mailings, including annual or interim financial statements of the Corporation and related Managements Discussion and Analysis, if they so request.  Shareholders wishing to receive these mailings should complete the appropriate request form included with their annual shareholders meeting materials.  Additional information, including directors and officers remuneration and indebtedness, principal holders of our issued shares and options to purchase our shares, if applicable, is contained in our information circular issued in connection with the annual general meeting of shareholders held June 7, 2007.  Copies of all of those documents are available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov and may be obtained upon request from the Corporate Secretary, Angiotech Pharmaceuticals, Inc., 1618 Station Street, Vancouver, British Columbia, V6A 1B6 (telephone (604) 221-7676; facsimile: (604) 221-2330).







Page 72



---





SCHEDULE A



Audit Committee Charter



ANGIOTECH PHARMACEUTICALS, INC.





PURPOSE AND AUTHORITY



The purpose of the Audit Committee (the Committee) is to oversee the accounting and financial reporting processes of the Company and the audits of its financial statements, and thereby assist the Board of Directors (the Board) in monitoring (1) the integrity of the financial statements of the Company, (2) compliance by the Company with legal and regulatory requirements related to financial reporting, (3) the performance and independence of the Company's independent auditors, and (4) performance of the Companys internal controls and financial reporting process. The Committee performs such functions as may be assigned by law, by the Company's certificate of incorporation, memorandum, articles or similar documents, or by the Board.

The Committee has the power to conduct or authorize investigations into any matters within its scope of responsibilities, with full access to all books, records, facilities and personnel of the Company, its auditors and its legal advisors.  In connection with such investigations or otherwise in the course of fulfilling its responsibilities under this charter, the Committee has the authority to independently retain special legal, accounting, or other consultants to advise it, and may request any officer or employee of the Company, its independent legal counsel or independent auditor to attend a meeting of the Committee or to meet with any members of, or consultants to, the Committee.  The Committee has the power to create specific sub-committees with all of the power to conduct or authorize investigations into any matters within the scope of the mandate of the sub-committee, with full access to all books, records, facilities and personnel of the Company, its auditors and its legal advisors.  In particular, the Committee may delegate to one or more independent Committee members the authority to pre-approve non-audit services provided that the pre-approval is presented to the Committee at the first scheduled meeting following such pre-approval.

The Company's independent auditor is ultimately accountable to the Board of Directors and to the Committee, who, as representatives of the Company's shareholders, have the ultimate authority and responsibility to evaluate the independent auditor, appoint and replace the independent auditor, and to determine appropriate compensation for the independent auditor.  In the course of fulfilling its specific responsibilities hereunder, the Committee must maintain free and open communication between the Company's independent auditors, Board of Directors and Company management.  The responsibilities of a member of the Committee are in addition to such member's duties as a member of the Board.

While the Committee has the responsibilities and powers set forth in this charter, it is not the duty of the Committee to plan or conduct audits or to determine that the Company's financial statements are complete, accurate, and in accordance with generally accepted accounting principles.



MEMBERSHIP AND ORGANIZATION

Membership

1.

The Committee shall consist of a minimum of three members of the Board, appointed annually, each of whom is affirmatively confirmed as independent by the Board, with such affirmation disclosed in the Companys annual Information Circular.

2.

A member of the Committee may be replaced at any time by the Board and will cease to be a member upon ceasing to be a Director of the Company.

3.

The Board will elect, by a majority vote, one member as chairperson of the Committee.



i-



---





4.

The Committee will appoint its own secretary who need not be a Director of the board.

5.

Each member of the Committee will meet all independence and financial literacy requirements of The Toronto Stock Exchange, the independence requirements of the NASDAQ Stock Market (which includes meeting the definition of independent director under the NASDAQ Rules), and the independence criteria of the U.S. Security and Exchange Commissions (the SEC) Rules.

6.

Each member of the Committee shall be able to read and understand fundamental financial statements, including balance sheets, income statements, and cash flow statements.

7.

At least one member of the Committee will be an audit committee financial expert as defined by the applicable rules set out by the SEC or any other applicable regulatory authority.

8.

No director who has participated in the preparation of the financial statements of the Company or any current subsidiary of the Company at any time during the past three years will be eligible for membership on the Committee.

9.

Any member of the Committee who serves on more than three public company audit committees must inform the Chairman of the Board who will consider and assess that members ability to be effective on the Committee.

10.

A member of the Audit Committee may not, other than in his or her capacity as a member of the Audit Committee, the Board of Directors, or any other Board committee, accept any consulting, advisory, or other compensatory fee from the Company, and may not be an affiliated person of the Company or any subsidiary thereof.

Committee Meetings

1.

The Committee will meet at least quarterly or more often as may be deemed necessary or appropriate in its judgment, either in person or telephonically.

2.

The Committee will meet with the independent auditor and the internal auditor at least quarterly, either in person or telephonically.

3.

Meetings may be requested by any member of the Committee, Chief Executive Officer (CEO), Chief Compliance Officer (CCO), Chief Financial Officer (CFO), VP, Finance & Accounting, Corporate Controller, the independent auditors or the internal auditors.

4.

The independent auditor will be notified of every Committee meeting and be permitted to appear and speak at those meetings.

5.

The Committee will keep minutes of its meetings which will be provided to the Board.

6.

The Committee will report its actions to the Board along with such recommendations as the Committee may deem appropriate.

7.

A majority of the members of the Committee shall constitute a quorum.



DUTIES & RESPONSIBILITIES

Independent Auditor

The independent auditor reports directly to the Committee and the Committee and the Board have the authority to replace the independent auditor.  With respect to its oversight of the independent auditor, the Committee shall:

1.

Annually appoint the independent auditor to be proposed for shareholder approval.

2.

Approve the compensation of the independent auditor.

3.

Review with the independent auditor, the audit scope and plan of the independent auditor.

4.

Evaluate the performance of the independent auditor and, if so determined by the Committee, replace the independent auditor.



ii-



---





5.

Approve permissible non-audit services of the independent auditor and establish policies and procedures for their engagement for such services and to ensure that the independent auditor is not engaged to perform any activities prohibited by any of the Canadian provincial securities commissions, the SEC or any securities exchange on which the Companys shares are traded, including:

a.

Bookkeeping or other services related to accounting records or financial statements of the Company;

b.

Financial information systems design and implementation consulting services;

c.

Appraisal or valuation services, fairness opinions, or contributions-in-kind reports;

d.

Actuarial services;

e.

Internal audit outsourcing services;

f.

Any management or human resources function;

g.

Broker, dealer, investment advisor, or investment banking services;

h.

Legal services;

i.

Expert services unrelated to the auditing service; and

j.

Any other service the Board determines is not permitted.

6.

Ensure that no individual who is, or in the past 3 years has been, affiliated with or employed by a present or former auditor of the Company or an affiliate, is hired by the Company as a senior officer, including Corporate Controller, until at least 3 years after the end of either the affiliation or the auditing relationship.

7.

Take reasonable steps to confirm the independence of the independent auditor, which shall include:

a.

Ensuring receipt from the independent auditor of a formal written statement delineating all relationships between the independent auditor and the Company, consistent with the Independence Standards Board Standard No. 1 and related Canadian regulatory body standards;

b.

Reviewing with the independent auditor any relationships or services provided to the Company, including non-audit services, that may impact the objectivity and independence of the independent auditor; and

c.

As necessary, taking, or recommending that the Board take, other appropriate actions to oversee the independence of the independent auditor.

8.

Ensure that the audit partner rotation requirements are met.

9.

Confirm with management and the independent auditor that no restrictions are placed on the scope of the auditors review and examination of the Companys accounts.

10.

Discuss in private with the independent auditor matters affecting the conduct of their audit and other corporate matters.

11.

Review and discuss with management and the independent auditor at the completion of its examination, any serious difficulties or disputes with management encountered during the course of the audit or review.



Financial Information Review Process

In connection with the review of the annual audited financial statements, interim financial statements, MD&A, press releases or other financial disclosure, the Committee, as applicable, shall:

1.

Review and discuss with management and the independent auditor at the completion of its annual audit and interim reviews:

a)

The Company's audited annual or reviewed interim financial statements and related notes and the Companys accompanying MD&A;



iii-



---





b)

Review the independent auditor's report concerning the matters required to be discussed by Statement on Auditing Standards No. 61, CICA Handbook Section 5751 or SEC Rule 2-07, as the same may be modified or supplemented from time to time;

c)

The appropriateness of the presentation of any non-GAAP related financial information;

d)

The adequacy of the Company's internal accounting and financial controls that management and the Board have established and the effectiveness of those systems;

e)

Financial statement effects of significant transactions and other complex accounting issues;

f)

The accounting policies which may be viewed as critical, including all alternative treatments for financial information within generally accepted accounting principles that have been discussed with management, and review and discuss any significant changes in the accounting policies of the Company and industry accounting and regulatory financial reporting proposals that may have a significant impact on the Company's financial reports;

g)

Any correspondence with regulators or governmental agencies and any employee complaints or published reports which raise material issues regarding the Company's financial statements or accounting policies;

h)

The management letter delivered by the independent auditor in connection with the audit;

2.

Approve and recommend to the Board that the audited annual financial statements and MD&A be approved by the Board prior to public disclosure;

3.

Approve interim financial statements and MD&A prior to public disclosure;

4.

Review with the Company's General Counsel, litigation and other legal matters that may have a material impact on the financial statements, the Company's financial compliance policies and any material reports or inquiries received from regulators or governmental agencies related to financial matters;

5.

Review financial press releases and earnings guidance;

6.

Review and approve all financial disclosure contained in filings with the Canadian provincial securities commissions and the SEC;

7.

Review representation letters provided by management to the independent auditor;

8.

Review minutes of all Disclosure Committee meetings of the Company; and

9.

Review the process for certification of the interim and annual financial statements by the CEO and the CFO and the certifications made by the CEO and CFO.



Corporate Compliance, Internal Controls & Internal Audit

With respect to the oversight of the financial compliance, internal controls and internal audit activities, the Committee shall:

1.

Annually review the activities, resources and scope of the Corporate Compliance function and its internal audit and other compliance activities;

2.

Ensure that the Corporate Compliance function has unrestricted access to all functions, records, property and personnel within the Company;

3.

Review significant internal audit findings and recommendations and monitor managements progress against action plans for remediation;

4.

Meet separately with the Chief Compliance Officer or Manager, Financial Compliance (or individuals performing the internal audit function) to discuss matters the Committee or the Corporate Compliance function believes should be discussed in private;



iv-



---





5.

Review any reportable conditions, material weakness in internal controls and any fraud and illegal acts involving management or other  employees who have a significant role in the companys internal control and significant deficiencies affecting internal control; and

6.

Review any issues including any difficulties encountered during any internal audit activities.

7.

Review, monitor and report on the companys adherence to SOX legislation and Canadian Multilateral Instruments 52-109 and 52-111.

8.

Quarterly, or as necessary, review key financial ratio and risk factors provided to the Board of Directors at the regular quarterly Board meetings and where appropriate, recommend changes to measured ratios and risks factors.

Accountability

1.

At least annually, the Committee will review and evaluate the performance of the Committee and its members and report its findings to the Board.

2.

The Committee will annually review and reassess the adequacy of the Committees Charter and recommend any proposed changes to the Board for approval.

3.

The Committee shall review and approve any Audit Committee disclosures required by securities regulators contained in the Companys disclosure documents.



Other Duties & Responsibilities

The Committee shall:

1.

Annually review a procedure through which employees and others can inform the Committee regarding any concerns about the Companys accounting, internal accounting controls or auditing matters.  The procedure shall include responding to and keeping of records of, any such complaints;

2.

Review at least annually, the program established by management to monitor compliance with the Companys code of ethics policy;

3.

Review and approve all related party transactions in excess of $60,000;

4.

Arrange and review results of an annual audit of the expense reports of the Chairman of the Board and the CEOs expense accounts;

5.

Meet periodically with management to review the Company's major financial risk exposures and the steps management has taken to monitor and control such exposures;

6.

Assess risk areas and policies to manage risk including, without limitation, environmental risk, insurance coverage and other areas as determined by the Board from time to time;

7.

Review the appointment of the Chief Financial Officer, Chief Compliance Officer and any other senior financial executives involved in the financial reporting process; and

8.

Review and discuss with management, and approve changes to, the Company's Corporate Treasury Policy.



v-



---





Committee Timetable



|                                                                                                                               |             |     |     |     |     |     |     |     |     |     |     |    
|------------------------------------------------------------------------------------------------------------------------------ | ----------- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
|DUTIDUTIES & RESPONSIBILITIES                                                                                                  | Jan         | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
|Independent Auditor                                                                                                           
|1 Appoint Independent Auditor for Shareholder Approval                                                                         |             |     | ü   |     |     |     |     |     |     |     |     |    
|2 Approve Independent Auditor Compensation                                                                                     |             |     |     |     |     |     |     |     |     |     |     | ü  
|3 Review Audit Scope & Plan                                                                                                    |             |     |     |     |     |     |     |     |     |     |     | ü  
|4 Review Performance of Independent Auditor                                                                                    |             | ü   |     |     |     |     |     |     |     |     |     |    
|5 Approve Non-audit Services of Independent Auditor                                                                            | As Required
|6 Confirm New Senior Officers Not Affiliated with Independent Auditor Prior to Hiring                                          | As Required
|7 Confirm Independence of Independent Auditor                                                                                  |             |     |     |     |     |     |     |     |     |     |     | ü  
|8 Ensure Audit Partner Rotation Requirements are Met                                                                           |             |     |     |     |     |     |     |     |     |     |     | ü  
|9 Confirm Unrestricted Scope of Independent Auditors Review                                                                   |             | ü   |     | ü   |     |     | ü   |     |     | ü   |     |    
|10 Discuss Matters Affecting the Conduct of the Independent Auditor, Audit and other Corporate Matters Privately               |             | ü   |     | ü   |     |     | ü   |     |     | ü   |     |    
|11 Review and Discuss Difficulties or Disputes Between Independent Auditor & Management                                        |             | ü   |     | ü   |     |     | ü   |     |     | ü   |     |    
|Financial Information Review Process                                                                                          
|1 Review and Discuss with Management and the Independent Auditor at the Completion of Annual Audit or Interim Review:          |             |     |     |     |     |     |     |     |     |     |     |    
|a)  Financial Statements and MD&A                                                                                              |             | ü   |     | ü   |     |     | ü   |     |     | ü   |     |    
|b)  Independent Auditors Report                                                                                               |             | ü   |     | ü   |     |     | ü   |     |     | ü   |     |    
|c)  Non-GAAP Related Financial Information                                                                                     |             | ü   |     | ü   |     |     | ü   |     |     | ü   |     |    
|d)  Adequacy and Effectives of Internal Controls                                                                               |             | ü   |     |     |     |     |     |     |     |     |     |    
|e)  Significant Transaction/Complex Accounting Issues                                                                          |             | ü   |     | ü   |     |     | ü   |     |     | ü   |     |    
|f)  Critical Accounting Policies and Significant Changes                                                                       |             | ü   |     | ü   |     |     | ü   |     |     | ü   |     |    
|g)  Material Issues Raised by Regulators/Gov Agencies or Employees                                                             |             | ü   |     | ü   |     |     | ü   |     |     | ü   |     |    
|h)  Management Letter                                                                                                          |             | ü   |     |     |     |     |     |     |     |     |     |    
|2  Approve Audited Financial Statements and MD&A; Recommend to Board for Approval                                              |             | ü   |     |     |     |     |     |     |     |     |     |    
|3  Approve Interim Financial Statements and MD&A prior to Disclosure                                                           |             |     |     | ü   |     |     | ü   |     |     | ü   |     |    
|4  Review Litigation and Other Legal Matters with Companys General Counsel                                                    |             | ü   |     | ü   |     |     | ü   |     |     | ü   |     |    
|5  Review Financial Press Releases and Earnings Guidance                                                                       |             | ü   |     | ü   |     |     | ü   |     |     | ü   |     |    
|6  Review Financial Disclosure in Filings; Recommend that Board Approve Disclosure                                             |             |     | ü   |     |     |     |     |     |     |     |     |    
|7  Review Independent Auditors Representation Letter                                                                          |             |     |     |     |     |     |     |     |     |     |     | ü  
|8  Review Disclosure Committee Minutes                                                                                         |             | ü   |     | ü   |     |     | ü   |     |     | ü   |     |    
|9  Review Certification Process and Financial Statements Certifications of CEO & CFO                                           |             | ü   |     |     |     |     |     |     |     |     |     |    
|Internal Audit Function                                                                                                       
|1  Review Activities, Resources and Scope of Internal Audit Function                                                           |             |     |     |     |     |     |     |     |     |     |     | ü  
|2  Ensure Internal Audit Function has Unrestricted Access to All Functions, Records, Property and Personnel Within the Company |             | ü   |     | ü   |     |     | ü   |     |     | ü   |     |    
|3  Review Significant Audit Findings and Recommendations and Monitor Managements Progress with Remediation                    |             | ü   |     | ü   |     |     | ü   |     |     | ü   |     |    
|4  Meet with Internal Auditor Separately                                                                                       |             | ü   |     | ü   |     |     | ü   |     |     | ü   |     |    





vi-





---

|                                                                                                                                    |             |   |   |   |  |  |   |  |  |   |  |  
|----------------------------------------------------------------------------------------------------------------------------------- | ----------- | - | - | - |  |  | - |  |  | - |  | -
|5  Review Reportable Conditions, Material Weakness and Fraud                                                                        |             | ü |   | ü |  |  | ü |  |  | ü |  |  
|6  Review Any Issues Including any Difficulties Encountered by the Internal Audit Function                                          |             | ü |   | ü |  |  | ü |  |  | ü |  |  
|7  Review, monitor and report on the companys adherence to SOX legislation and Canadian Multilateral Instruments 52-109 and 52-111 |             | ü |   | ü |  |  | ü |  |  | ü |  |  
|Accountability                                                                                                                     
|1  Review Committee Performance and Report to Board                                                                                 |             |   |   |   |  |  |   |  |  |   |  | ü
|2  Review of Committee Charter                                                                                                      |             |   |   |   |  |  |   |  |  |   |  | ü
|3  Review and Approve Required Committee Regulatory Disclosures                                                                     |             |   | ü |   |  |  |   |  |  |   |  |  
|Other Duties & Responsibilities                                                                                                    
|1  Adopt and Review Procedure for Whistleblower Policy                                                                              |             |   |   |   |  |  |   |  |  |   |  | ü
|2  Review Program for Monitoring Compliance to Companys Code of Ethics                                                             |             |   |   |   |  |  |   |  |  |   |  | ü
|3  Review and Approve Related Party Transactions over $60,000                                                                       | As Required
|4  Review Audit of Expense Reports for Board Chair and CEO                                                                          |             |   |   |   |  |  |   |  |  |   |  | ü
|5  Review Companys Major Financial Risk Exposures                                                                                  |             |   |   |   |  |  |   |  |  | ü |  |  
|6  Assess Risk Areas and Risk Management Policies                                                                                   |             |   |   |   |  |  |   |  |  | ü |  |  
|7  Review Appointment of Senior Financial Management                                                                                | As Required
|8  Review and Approve Changes to Companys Corporate Treasury Policy                                                                |             | ü |   | ü |  |  | ü |  |  | ü |  |  





vii-



---